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 The thesis entitled ‘Experiences of Psychological Distress, Uncertainty, and Coping 
Amongst People with Cancer’ explores the psychological experiences of individuals affected 
by cancer.  
 A systematic literature review of the of the relationship between psychological 
distress and uncertainty amongst younger adults with cancer is presented in section one. 
Fifteen eligible studies were identified via database and hand searches. Risk of bias 
assessments were carried out. Findings demonstrated a highly significant relationship 
between uncertainty and psychological distress, with a number of studies indicating that 
uncertainty predicts psychological distress. Inconsistency in findings, however, suggests that 
other variables may influence this relationship. Risks of bias were identified across studies.  
 A research study exploring patients’ experiences of coping longer-term with cancer of 
unknown primary (CUP) is presented in section two. Interviews were carried out with ten 
participants and data was analysed using interpretative phenomenological analysis. Three 
superordinate themes were identified: (1) ‘“Fuss and Bother”: The Upheaval of Everyday 
Life’, with subordinate themes of ‘Appointment threats’, and ‘Symptoms and side-effects’; 
(2) ‘“It’s the Unknowing”: The Enduring Uncertainty of CUP’ with subordinate themes of  
‘“What the bloody hell’s that?!”’, ‘An uncertain future’, and ‘Hope’; and (3) ‘“Just Get on 
With It”: Managing and Moving Forwards’ with subordinate themes of ‘Maintaining 
normality’, ‘Acceptance’, and ‘Support’. Findings highlighted that the experiences of people 
living longer-term with CUP are comparable to those of other cancer patient populations, 
however, they also face a number of distinct challenges.  
 A critical appraisal of the research paper is presented in section three. Within the 
critical appraisal, consideration is given to the epistemological and ontological assumptions 
made within the thesis, the position of the researcher and the importance of researcher 
reflexivity, and the research process. 
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Abstract  
Introduction: Experiences of psychological distress and uncertainty are prevalent amongst 
cancer survivors. This systematic review aimed to collate and evaluate the available 
quantitative evidence regarding the relationship between these experiences amongst younger 
adults with cancer.  
Methods: Studies were identified through academic database searches and hand searches. 
Inclusion criteria were: (1) published in English (2) quantitative methodology (3) published 
in a peer reviewed journal (4) mean sample age of 55 or younger (5) sample with confirmed 
diagnosis of any cancer (6) and analysis of the association between psychological distress and 
uncertainty. Studies were assessed for risk of bias.  
Results: Fifteen studies were identified which demonstrated a statistically significant 
relationship between psychological distress and uncertainty amongst younger adults with 
cancer. Several studies suggested that uncertainty is a predictor of psychological distress. 
Findings indicated that a number of other variables may mediate and influence this 
relationship.  
Conclusion: There is a significant association between uncertainty and distress across a range 
of different cancer survivor populations. However, variability in findings suggested that these 
experiences were also influenced by other factors which merit further investigation. 
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Introduction 
 The effects of cancer and its treatments on the physical, social, and emotional 
wellbeing of individuals following diagnosis has been widely established (Cleeland, 2007; 
Fan, Filipczak, & Chow, 2007; Mor, Allen & Malin, 1994; van't Spijker, Trijsburg, & 
Duivenvoorden, 1997). Guidelines for supportive care for adults with cancer from the 
National Institute for Health and Care Excellence (NICE, 2004) recommend that 
psychological assessment and support are embedded throughout the care pathway to facilitate 
the management of cancer-related psychological distress.   
Psychological distress in relation to cancer has been defined by The National 
Comprehensive Cancer Network (NCCN, 2010) as “a multifactorial unpleasant emotional 
experience of a psychological (cognitive, behavioural, emotional), social, and/or spiritual 
nature that may interfere with the ability to cope effectively with cancer, its physical 
symptoms and its treatments”. This definition incorporates a spectrum of experiences ranging 
from foreseeable reactions, including feelings of fear or sadness, to emotional difficulties 
meeting criteria for psychiatric diagnoses such as depression or generalised anxiety disorder 
(NCCN, 2010; NICE 2004). Such experiences are common for people with cancer (NICE, 
2004). The shortened term ‘distress’ is used throughout the remainder of the review in 
reference to psychological distress.  
The experience of distress amongst individuals with cancer has been widely 
researched and reported prevalence rates of diagnosable mental health difficulties vary from 
0-49% (Massie, 2004; van't Spijker et al. 1997). It has been suggested that this wide 
variability of prevalence rates may be attributable to the discrepant conceptualisations and 
measurements of distress across studies. They may also reflect the divergent experiences of 
individuals with different diagnoses, stages of disease progression, and treatment pathways. 
The majority of studies indicate clinical levels of depression or anxiety to impact between 
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one-in-five and one-in-three people with cancer (Brintzenhofe-Szoc, Levin, Li, Kissane, & 
Zabora, 2009; Linden, Vodermaier, MacKenzie, & Greig, 2012.; Singer, Das-Munshi, & 
Brähler, 2009; Zabora, Brintzenhofe-Szoc, Curbow, Hooker, & Piantadosi, 2001) compared 
with approximately one in six people in the general population (House of Commons Library, 
2018).  
Evidence suggests that prevalence of distress may differ depending upon the cancer 
diagnosis. Systematic literature reviews investigating distress within different cancer 
populations report prevalence rates of 15-27% for prostate cancer (Watts et al., 2014), 13-
27% for ovarian cancer (Watts, Prescott, Mason, McLeod, Lewith, 2015), 9-66% for breast 
cancer (Maass, Roorda, Berendsen, Verhaak, & de Bock, 2015), and 1-57% for colorectal 
cancer (Peng, Huang, & Kao, 2019).  Several studies comparing rates of distress between 
cancer populations have found patients with lung cancer to experience greater levels of 
distress relative to those with other cancers (Carlson et al., 2004; Linden et al., 2012; Zabora 
et al., 2001). Reasons for this include self-blame, poorer prognosis, later detection, and 
respiratory symptoms (Akin, Can, Aydiner, Ozdilli, & Durna, 2010; Cataldo & Brodsky, 
2013). Gynaecological, haematological, and brain cancers have also been found to lead to 
greater levels of anxiety when compared with other cancers (Linden et al., 2012). 
Additionally, cancer of unknown primary is associated with high levels of distress as 
increased uncertainty in the condition has been shown to amplify difficulties encountered 
across other cancers (Richardson et al., 2015).  
A range of different factors have been associated with cancer-related distress. Disease 
characteristics, including longer duration of disease presence (Mitchell, Ferguson, Gill, Paul, 
& Symonds, 2013) and more advanced stage of illness (Couper et al., 2010) may increase 
distress. Cancer recurrence has also been shown to elicit greater distress than initial diagnosis 
(Munkres, Oberst, Hughes, 1992).  Demographic variables including female gender, lower 
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socio-economic status, younger age, and being single have been demonstrated to increase the 
likelihood of experiencing anxiety or depression in cancer patients (Linden et al., 2012; 
Montel, Clark, & Loscalzo, 2018; Smith et al., 2018; Watson, Davolls, Mohammed, & 
Shepherd, 2015). Being younger at the time of diagnosis has also been associated with higher 
levels of distress (Watson et al., 2015). Possible reasons for this difference may include the 
greater effects of cancer and treatment side-effects for young people on fertility, social roles, 
future expectations, and financial stability (Mor, Allen & Malin, 1994; Rosen, Rodriguez-
Wallberg, & Rosenzweig, 2009). Treatment factors found to elevate distress include surgical 
or invasive treatments (Lim, Devi, &Ang, 2011), receiving multiple treatments (Admiraal, 
Reyners, & Hoekstra-Weebers, 2013), and perceived passive role in treatment decision 
making (Hack et al., 2010). Frequency of physical symptoms has also been found to be 
positively correlated with distress (Delgado-Guay, Parsons, Li, Palmer, & Bruera, 2009).  
Other predictors of increased distress include personality traits and styles of thinking 
and coping. Arras et al. (2002) reported individuals employing avoidant coping experience 
greater anxiety and depression, however, a ‘blunting’ approach to coping, involving 
avoidance of disease-salient information, may also serve a protective function against distress 
(Miller 1995). Those described as possessing more ‘neurotic’ personality traits have also 
been found to experience greater levels of distress (Paika et al., 2010), as well as those of less 
optimistic disposition (Gustavsson-Lilius, Julkunen, Keskivaara, Lipsanen, & Hietanen, 
2012).  
Uncertainty  
 Uncertainty amongst those with acute or chronic illness has been defined as “the 
inability to determine the meaning of illness-related events” (Mishel, 1988, p. 225). Lazarus 
and Folkman’s (1984) theoretical model of the relationship between stress, appraisal, and 
coping posits that uncertainty impacts on appraisal, with high uncertainty theoretically 
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causing greater stress and reducing coping capacity. Based on this, Mishel (1988; 1990) 
developed the theory of uncertainty in illness which postulates that uncertainty occurs in 
response to illness factors which are ambiguous, vague, unpredictable, unfamiliar, 
inconsistent, or unknown (McCormick, 2002; Mishel, 1984). The theory provides a four-part 
framework for understanding the experience of uncertainty. Firstly, interpretation of illness-
related experiences (the stimuli frame) is moderated by information and support received 
(structure providers) and ability make sense of available information (cognitive capacities). 
These factors are described as antecedents, based on which uncertainty is perceived. 
Secondly, uncertainty is appraised via a process of either inference or illusion. Inference 
refers to the process of comparing present experiences to related situations (for example, 
recalling one’s grandmother to have died as a result of cancer), while illusion denotes the 
construction of usually positive beliefs whereby the absence of information is interpreted as 
the potential for a positive outcome. This appraisal process leads to the interpretation of 
uncertainty as either dangerous or a positive opportunity. Thirdly, based upon the nature of 
this appraisal, different coping strategies are mobilised. Where uncertainty is interpreted as a 
‘danger’, individuals seek to reduce uncertainty (e.g. through seeking information) or use 
affect regulation strategies to manage the distress which is associated by the uncertainty. 
Where uncertainty is framed as an opportunity, ‘buffering strategies’ such as avoidance or 
minimisation of threatening stimuli are employed to sustain the favoured uncertain state. 
Finally, where these coping strategies are effective, they facilitate adjustment to the initial 
illness-related experiences (Mishel, 1988, 1990; Zhang, 2017).    
Uncertainty and Distress in Cancer 
 A literature review by Shaha, Cox, Talman, and Kelly (2008) identified uncertainty as 
a prevailing experience affecting cancer patients. Sources of uncertainty identified were lack 
of information, the course of the disease and treatment choices, and everyday life and coping 
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with the disease. Given the prevalence of uncertainty across cancer populations, the 
uncertainty in illness model has been widely applied and tested by studies involving patients 
with cancer (Zhang, 2017). While distress is not a distinct component of the model, the 
relationship between uncertainty and distress (generated via the appraisal of danger or threat) 
is inferred (Mishel, Padilla, Grant, & Sorenson, 1991). A 2017 scoping review by Jabloo et 
al. investigated antecedents and outcomes associated with uncertainty amongst older adults 
(≥65years) with cancer. Results showed that uncertainty was positively correlated at a 
statistically significant level with psychological distress (measured as anxiety and depression) 
in two studies (Galfin & Watkins, 2012; Lien et al., 2009).  
Review Rationale and Objectives 
 As summarised above, the prevalence of distress and uncertainty are elevated amongst 
people living with cancer. A scoping review investigating the relationship between these 
factors reported that amongst older adults with cancer, uncertainty and distress are related at 
the level of statistical significance (Jabloo et al., 2017). This evidence may suggest that, in 
accordance with Mishel’s uncertainty in illness model, uncertainty is perceived as a potential 
danger which may lead to distress. No existing review of the literature has assessed how the 
relationship between uncertainty and distress manifests in younger adults who are prone to 
greater levels of distress than older cancer patients (Cancer research UK, n.d.; Watson et al., 
2015). Therefore, the aim of this review was to collate and appraise the existing quantitative 
evidence regarding the relationship between distress and uncertainty amongst younger adults 
with cancer. Reviewing the research in this way can provide a better understanding of the 
existing data and the scope for subsequent meta-analysis. Qualitative data was not included as 
the remit of the review was to examine the relationship between uncertainty and 
psychological distress in as tightly controlled and defined a way as possible.  This was 
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intended to facilitate consistency with the theoretical and conceptual definitions outlined in 
the introduction, rather than including subjective experiences and interpretations.  
Method 
This review follows Preferred Reporting Items for Systematic Reviews and Meta 
Analyses (PRISMA) statement guidelines where applicable (Moher, Liberati, Tetzlaff, 
Altman, & The PRISMA Group, 2009) to maximise transparency of reporting. Adherence to 
reporting guidelines is recommended when conducting systematic reviews as inadequate 
reporting can prevent accurate interpretation of findings and the corresponding weight carried 
by the conclusions of the review (Fleming, Koletsi, & Pandis, 2014). Use of PRISMA 
guidelines have been recommended for the reporting of systematic reviews in clinical and 
health psychology (Perestelo-Pérez, 2013).  
Objective 
The PICO (Population, Intervention, Comparison, Outcome[s]) Framework 
(Richardson, Wilson, Nishikawa, & Hayward, 1995) was employed to frame the review 
question. This approach is recommended to formulate a specific research question according 
to systematic criteria which determine the scope of the review (Higgins & Green, 2011; 
Perestelo-Pérez, 2013). Use of the PICO framework can also optimise the balance between 
sensitivity and specificity of search results retrieved via electronic database searching 
(Perestelo-Pérez, 2013; Schardt, Adams, Owens, Keitz, Fontelo, 2007). PICO items are 
outlined in Table 1-A (p.1-48).  
TABLE 1-A HERE 
 
Search Strategy 
 Searches of relevant electronic databases (PsycINFO, MEDLINE, the Cumulative 
Index to Nursing and Allied Health Literature [CINAHL], and Web of Science) were 
conducted on 20
th
 January 2019. Prior to this, guidance was sought from a specialist librarian 
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regarding the search strategy to optimise retrieval of relevant search results. In each data base 
the following free text terms, and Boolean operators were searched in study titles and 
abstracts: (“cancer” OR “neoplasm*” OR “onco*” OR “tumour” OR “malign*”) AND 
(“uncertainty”) AND (“distress” OR “anx*” OR “worr*” OR “depress*” OR “mood” OR 
“affect*” OR “wellbeing” OR “well-being” OR “well being” OR “emotion*” OR “mental 
health”). Searches were also trialled with additional cancer type-specific terminology (e.g. 
carcinoma, melanoma), however, the number of results retrieved was not significantly 
greater, and as such, on the advice of the specialist librarian, these terms were omitted. The 
number of results retrieved by these trials are presented in Appendix 1-A (p.1-59). The 
decision was taken to exclude ‘trauma’ from the searches, as although post-traumatic stress 
responses to cancer and cancer treatment are widely recognised, diagnosable post-traumatic 
stress disorder has been shown to impact a relatively small number of patients (approximately 
4%). It is acknowledged, however, that there may be overlap in the experiences of post-
traumatic stress and broader distress (Palmer, Kagee, Coyne, & DeMichele, 2004). The 
truncation function (*) was applied to a number of terms in order to capture relevant terms 
with variant endings or spellings. Related thesaurus terms for each database were also 
searched. Age limiters were applied in PsychINFO and CINAHL to exclude papers focusing 
on populations below the age of eighteen. Equivalent limiters were not available for Web of 
Science or MEDLINE. Additional filters were also employed on the advice of the specialist 
librarian where searches retrieved more than 2000 results from a single multi-disciplinary 
database. This decision was made due to the practical limitations inherent in screening a high 
volume of search results with potentially decreased relevancy. This applied only to searches 
in Web of Science where 2472 results were retrieved prior to additional limiters being 
applied. The ‘web of science categories’ used to refine the search are listed in the full search 
strategy which is detailed in Appendix 1-B (p.1-60). No date limits were applied to the 
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search, allowing papers to be retrieved from any point within each database’s temporal range. 
It was anticipated, however, that relevant papers would have been published from the 1980s 
onwards following the publication Mishel’s uncertainty in illness theory. 
 Search results were imported using Mendelay referencing software and duplicate 
results were removed. Results were then screened against inclusion and exclusion criteria as 
described by Booth, Sutton, and Papaioannou (2016); the title and abstract of each paper was 
screened initially, followed by the full text. Additional hand searches of references from each 
eligible study and from key literature reviews (Jabloo et al., 2017; Shaha et al., 2008) were 
also undertaken. These additional searches are recommended to decrease the probability of 
relevant studies being omitted from the review (Greenhalgh & Peacock, 2005). A flow 
diagram of the screening and selection process is presented in Figure 1-A (p.1-58).   
FIGURE 1-A HERE 
Inclusion Criteria 
 Studies meeting the following criteria were eligible for inclusion in the review: (1) 
published in the English language (2) quantitative methodology (3) published in a peer 
reviewed journal (4) sample population of working age adults (with a mean age of 55 or 
below) (5) sample with confirmed diagnosis of any cancer, including individuals pre-, during, 
and post-treatment (6) measure(s) of distress and measure(s) of uncertainty (7) and analysis 
of the association between distress and uncertainty.  
Quantitative observational studies of cross-sectional, correlational, prospective, and 
case-control design were eligible for inclusion. Intervention trials or studies of experimental 
design where either distress or uncertainty were manipulated were eligible for inclusion only 
if data were available for a control group meeting inclusion and exclusion criteria. Studies 
reporting on samples with multiple life-limiting conditions were eligible for inclusion only 
where results for the cancer sub-sample were reported separately. 
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‘Psychological distress’ was conceptualised broadly, incorporating experience of 
anxiety and/or depression; measures looking at these individual constructs were eligible for 
inclusion as well as any measures looking at global distress. This decision was made based on 
the interchangeable use of these concepts across the relevant literature, and tendency for 
constructs of anxiety, and depression to overlap and be interpreted generically as distress 
(Linden et al., 2012; Osman et al., 2012). Previous research has shown that anxiety, 
depression, and distress are inter-related constructs which are strongly correlated in people 
with cancer (Pandey et al., 2007). The concept of ‘stress’ was also included as it is 
understood to be a distress-related construct, with a tendency to co-occur with anxiety and 
depression, that is widely applied within related literature on coping (Osman et al., 2012). For 
the sake of this review, ‘stress’ was conceptualised in line with Lazarus and Folkman’s 
(1984) definition of psychological stress, as opposed to physiological stress responses 
(Lazarus, 1974). Any quantitative measure of distress and uncertainty was deemed acceptable 
(e.g. standardised measures, unvalidated Likert scales), as were results of sub-scales forming 
part of a larger related measure (e.g. quality of life or adjustment) where results for distress or 
uncertainty were reported and analysed discretely. The decision was made to include studies 
using the Profile of Mood States (POMS) or short form (POMS-SF) to assess distress as, 
although described as a measure of transient mood states (McNair, Lorr, & Droppleman, 
1989), it has been frequently employed for research purposes as a proxy for distress (Curran, 
Andrykowski, & Studts, 1995). Measures assessing symptom distress were not included as, 
although a related concept, the physical symptoms of distress are conceptualised differently 
to the psychological (Wu et al., 2015).  
In the UK, ‘older’ adults are generally conceptualised as people aged 65 and above 
based on this being the previously recognised state pension age (Banks & Smith, 2006). 
Although this has now legally altered, this age cut-off continues to represent a significant 
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socially recognised transition from mid-life to old age (“Retirement Age”, 2013). While it is 
acknowledged that this definition is relatively arbitrary, Eurocentric, and not necessarily 
reflective of the perceptions individuals aged 65 years and older hold about themselves 
(Westerhof, 2009; World Health Organisation, 2002), for pragmatic purposes it has been used 
to differentiate ‘older’ and ‘younger’ cancer patients. This also acknowledges that cancer is 
increasingly likely to affect people from the age of 65 onwards (Cancer Research UK, n.d.). 
Due to this, the likelihood of mean sample age being skewed towards the upper end of this 
spectrum was recognised. Accordingly, studies where the mean age of sample participants 
exceeded 55 years were excluded in order to differentiate the sample from the population 
reviewed previously by Jabloo et al. (2017), where studies with a mean sample age of 65 and 
above were included.  
Exclusion Criteria 
 Studies were excluded where they (1) included individuals aged 17 or younger (2) did 
not report a mean sample age (3) used a qualitative methodology (4) were of single case or 
case study design (5) contained a sample of over 50% long-term cancer survivors (6) focused 
exclusively on young adults diagnosed with cancer in childhood or adolescence.   
Studies of single-case design and case studies were excluded based on inherent 
limitations in generalisability (Thomas, 2011) and an absence of group mean data that was of 
interest in this review. Studies focusing on young adults who had been diagnosed with cancer 
in childhood and adolescence were excluded based on evidence that their needs and 
experiences are quite distinct from those of individuals diagnosed with cancer in adulthood 
(Hudson et al., 2003). For the sake of this study, long-term survivorship was defined as being 
in remission/cancer free five years post-cancer treatment. This was based on the 5-year point 
being a significant, widely used clinical marker for survival rates, beyond the period when 
cancer is most likely to recur (National Cancer Institute, 2019). Again, the needs and 
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experiences of this group may be quite different to those of individuals with more recent 
experiences of diagnosis and treatment (Chambers et al., 2012; Dunn et al., 2012; Helgeson 
& Tomich, 2005).    
Data Extraction and Assessment 
 Data from studies was compiled using a template based on Booth et al.’s (2016, 
p.176) data extraction form which is presented in Appendix 1-C (p.1-63). Assessments of 
reporting quality and methodological quality were undertaken by the author. A second 
independent reviewer assessed risk of bias in 20% of the studies (n=4), with any 
discrepancies being discussed to reach consensus, in order to minimise individual reviewer 
bias, as recommended in the Cochrane Handbook (Boutron et al., 2011). The ratings of the 
second reviewer are presented in Appendix 1-D (p.1-64) along with a description of 
discrepancies and resolutions. Due to the range of different statistical analyses employed 
across studies, it was not possible or within the scope of this review to conduct a meta-
analysis of all the findings. However, a meta-analysis was carried out to combine the effects 
of correlations between uncertainty and distress. The meta-analysis and results are reported in 
Appendix 1-E (p.1-68).  
 Risk of bias assessment.  
 The AXIS quality appraisal tool was used to assess the risk of bias in the included 
studies (Downes, Brennan, Williams, & Dean, 2016). This tool was selected as it was 
designed for assessment of cross-sectional studies which were predicted to be the 
predominant design of included correlational studies. A particular strength of the tool is its 
inclusion of items to appraise both methodological and reporting quality. A copy of the tool 
and guidance can be found in Appendix 1-F (p.1-71). The tool uses ‘yes’, ‘no’, and ‘don’t 
know’ ratings. For the purpose of this review, an additional rating of ‘partial’ was used where 
criteria were met to some degree, as used in similar assessment tools (Williams, Plassman, 
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Burke, Holsinger, & Benjamin, 2010). A rating of ‘not applicable’ was also used where items 
were irrelevant to the study design. An alternative quality assessment tool developed by the 
Agency for Health Research and Quality (AHRQ, Plassman, Williams, Burke, Holsinger, & 
Benjamin, 2010) was also considered. This tool is designed for use with observational 
studies; however, a number of the criteria were not found to apply for any of the included 
studies, therefore it was felt that the AXIS was a more appropriate choice. Two items, 
however, were adopted from the AHRQ tool to supplement the AXIS for assessment of 
controlled or longitudinal studies.  
Results 
A total of 18 studies were eligible for inclusion in the review. Of these, three studies 
were identified through reference list hand searches
3, 10, 11
. An overview of study 
characteristics, methods, and results is presented in Table 1-B (p.1-49). Additional study 
information is outlined in Appendix 1-G (p.1-72). Superscript numerical references 
throughout the results section correspond to the study number in Tables 1-B and 1-G. Where 
multiple studies were published by the same author(s) within 5 years, the authors were 
contacted to clarify whether the same data had been used (if not explicit in the text). Studies 
where it was confirmed that the same sample had been used have been treated as a single 
study where data were the same, with results from each paper reported successively in Table 
1-B. This applied to two studies, one of which was reported on by two papers
14, 15
 and one of 
which was reported on in three papers
1, 2, 3
. The number of distinct studies included in the 
review is therefore 15.  









 All included studies were descriptive in nature with 11 employing a cross-sectional 
design
1,4,5,6,7,11,12,13,14,16,17
 and the remaining four using a longitudinal approach
8,9,10,18
. The 




Context and sample. 










. All studies employed convenience sampling with participants recruited from 




            A total of 2158 cancer patients took part in the included studies along with 116 
comparison or control participants from two studies
13,17
. Participants were aged between 19 
and 89 years, with reported mean age of the samples ranging from 44 to 55 years. Many of 
the studies focused exclusively on female cancer patients (n=12), while the remaining studies 
reported 30-47% of their sample to be female
1,5,17
. Between 42 and 100% of participants were 
reported to be married or to have a partner. Where reported, the ethnicity of participants from 
North America was predominantly White Caucasian (64-97%), whilst studies carried out in 
Southeast Asia reported principally on samples of Thai, Chinese, and Malay patients. The 
level of education received by participants was variable across studies. Where reported as 
means, the number of years of education ranged from 8-16 years. Where reported, the 
proportion of participants having received tertiary level education was 28-100% for North 
American studies, 10-36% from studies in Hong Kong and Malaysia, and 7% for the study 
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conducted in Spain. The percentage of participants reported to be in current employment 
ranged from 39% to 77%.  





, brain tumour (n=1)
1





, and colorectal cancer (n=1)
6
. Samples in all studies contained 
patients diagnosed with different stages of cancer: across studies 22-75% of patients were 
described as having stage I or stage II cancer whilst 8-77% had a stage III or IV diagnosis. 
Three studies reported some participants as having stage 0 breast cancer (7-24%)
7,8,9
 where 
the abnormal cancer cells are classified as non-invasive (American Cancer Society, 2017). 
Where reported, all or most participants were experiencing a first diagnosis of cancer; one 
study included only patients experiencing their first cancer recurrence
13
. Participants were 
recruited from across the trajectory from pre- to post-treatment and treatments received by 
patients included surgery (including stem cell transplantation and cosmetic reconstruction), 
radiotherapy, chemotherapy, neoadjuvant therapy (including hormonal therapy), and 
experimental drugs.  
Measures 
 A selection of different self-report measures was used across studies to assess distress. 
Measures employed were the Hospital Anxiety and Depression Scale (n=3, HADS, Zigmond 
& Snaith, 1983), the POMS or POMS-SF (n=2, McNair, Lorr, & Droppleman, 1989), the 
State-Trait Anxiety Inventory (n=2, STAI, Spielberger, Sydeman, Owen, & Marsh, 1999), 
the ‘psychological distress’ subscale of the Psychosocial Adjustment to Illness Scale (n=2, 
PAIS, Shahid, Wilkinson, Marcu, & Shapiro, 2011), the Center for Epidemiological Studies-
Depression (n=2, CES-D, Radloff, 1977), the Cancer Worry Scale (n=1, CWS, Custers et al., 
2014), the Short Health Anxiety Inventory (n=1, SHAI, Salkovskis, Rimes, Warwick, & 
Clark, 2002), the Brief Symptom Inventory (n=1, BSI, Derogatis & Melisaratos, 1983), and 
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the Beck Depression Inventory (n=1, BDI, Beck, Ward, Mendelson, Mock, & Erbaugh, 
1961). 
 A smaller number of self-report measures was used to measure uncertainty. The 
majority of studies used the Mishel Uncertainty in Illness Scale (n=6, MUIS, Mishel & 
Epstein, 1990) or a modified condition- or context-specific version (n=3). These adaptations 
were the community form (MUIS-C, Mishel, 1999) and brain tumour form (MUIS-BT, Lin et 
al., 2012). Measures used in the remaining studies were the Intolerance of Uncertainty Scale 
(n= 2, IUS, Buhr & Dugas, 2002) or IUS short form (n=1, IUS-12, Carleton, Norton, & 
Asmundson, 2007), a single item about uncertainty from the Quality of Life Scale-Patient 
Version (n=1, QOL-PV, Padilla et al., 1983), the Uncertainty domain of the Decisional 
Conflict Scale, question format (n=1, DCS, O’Connor, 1993), and the Uncertainty sub-scale 
of the Cancer and Treatment Distress (CTDX) measure (n=1, Syrjala, Yi, & Langer, 2016). 
Risk of Bias Assessment 
 A full assessment of the risk of bias for each study is presented in Appendix 1-H (p.1-
77). All studies met AXIS criteria for reduced risk of bias in a number of areas including: 
presenting clear aims and objectives and selecting appropriate designs; offering a clear 
description of the target population; and assessing appropriate variables for study aims. Most 
studies also provided an adequate report of basic data in the results; only two studies were 
assessed as ‘partial’ on this item due to the description of sample characteristics lacking 
detail
5,6
. Reporting standards were met by most studies on items regarding internal 
consistency, with only three out of the eighteen studies having identified discrepancies in the 
reported figures
1,2,7
. The majority of studies also received a rating of ‘yes’ in relation to 
reporting of all analyses; where this was not the case the analyses had not been reported 
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 Mixed outcomes were found across studies in relation to a number of items. While ten 
studies reported on the use of reliable, previously published measures
1,3,4,6,7,12,13,14,15,18 
the 
remaining studies received a rating of ‘partial’ for this item where variable measures had 
been newly developed or where variables were measured using unvalidated single-item 
questions
2,5,8,9,10,11,16,17
. For the most part, authors’ discussions and conclusions were 
comprehensive and justified by the results, although a minority of studies (n=4)
1,6,10,12
 failed 
to offer a full overview of findings or consider confounding variables. A number of studies 
also failed to adequately acknowledge study limitations
3,6,9,10,11,12,13
. Only one study explicitly 
identified a potential conflict of interest (COI)
1 
while twelve studies provided some 
information confirming there to be no conflictual funding sources or other 
COIs
2,3,6,8,9,11,12,13,14,15,16,17
. In the remaining studies no information was provided. Eight 
studies provided explicit information regarding processes for gaining ethical approval and 
informed consent
4,5,6,8,9,14,15,16. 
A further five studies provided information regarding one of 
these processes
3,7,11,17,18
, while the remaining five studies did not report on either
1,2,10,12,13
.  
 There were several areas where risk of bias was found to affect most or all of the 
included studies. Firstly, risks of sampling bias were identified. The majority of the studies 
reported on a convenience sample recruited from a single site or otherwise narrow pool of 
potential participants
1,2,3,4,5,6,7,9,10,11,12,14,15,17,18
, such as hospitals from one metropolitan area. 
Exclusion criteria in ten studies
1,2,3,4,6,8,15,16,17,18 
(such as geographical area, treatment type, 
functional ability, and previous psychiatric treatment) were also identified as reducing the 
overall representativeness of the sample. Secondly, reporting and methodological biases were 
identified in relation to study non-responders. Ten studies omitted any description from the 
methods of how participant non-response would be managed
1,2,3,4,5,6,7,12,15,17
. Eight studies did 
not state the rate of non-response
1,3,5,7,10,12,15,17 
while three studies reported response rates of 
less than 80%
8,3,16
. Of those reporting on participant non-response, only two provided partial 
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information on reasons for non-response
8,10
; no demographic data regarding non-responders 
were available. Thirdly, risks of bias in relation to study results and interpretation were 





regarding determination of statistical significance or other effects. Additionally, only two 
studies provided a justification of sample size based on a power analysis
6,14
.  
 Ratings on the additional items from the AHRQ applied to only a small number of 
studies (n=4) incorporating either a control condition
17
 or longitudinal design
8,9,10
. The one 
study employing a control condition was awarded a rating of ‘partial’ as samples were 
matched for age but had differences in other demographic variables including ethnicity, 
education, and marital status
17
. Of the longitudinal studies, one provided a clear rationale for 
follow-up duration
9
, reducing risk of bias, while the remaining two were rated as ‘partial’ 




 Relationship between uncertainty and distress. 
 All of the included studies reported a statistically significant relationship between 
uncertainty or intolerance of uncertainty and distress. Correlation analysis was used in 10 
studies to assess the strength of the relationship
2,6,9,10,11,13,14,15,16,18
. The findings from these 
studies demonstrated statistically significant positive correlations explaining between 16% 
and 62% of the variance between variables. Where distress was measured using an overall 
distress measure (POMS, PAIS, or BSI)
2,6,10,11,13,16
, 27-54% of the variance was found to be 
shared with uncertainty. When distress was measured using scales more specifically assessing 





 respectively. Intolerance of uncertainty was demonstrated to share 64% 
variance with depression in one study
17
 and 50% variance with health anxiety in another
7
. 
Two studies found only the ambiguity sub-scale of the MUIS to be statistically significantly 
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. When interpreted in accordance with Cohen’s (1988) guidance, 
the magnitudes of the reported correlation effect sizes were small in five studies
9,11,14,15
, 
medium in four studies
10,13,15,18
, and large in three studies
7,16,17
. It is acknowledged that, as per 
Cohen’s guidance, these effect sizes can only offer a rough rule-of-thumb and must be 
interpreted with caution. All studies where a large effect size was found focused on pre-
treatment samples, although other studies reporting smaller effects also involved patients at 
this point in their cancer journey.   
 A number of studies conducted further analyses to investigate the nature of the 
association between uncertainty and distress, including analyses testing a number of 
theoretical models aiming to explain the psychological experiences of cancer patients. Most 
of these analyses suggested uncertainty to be a statistically significant predictor of distress, 
including both depression and anxiety
3,8,10,14,15
. One study demonstrated that intolerance of 
uncertainty was also a significant predictor for depression
4
. A further study, however, 
provided evidence that increased distress was predictive of greater levels of uncertainty
1
. 
Non-significant effects were reported for the impact of intolerance of uncertainty on health 
anxiety
7
 and uncertainty on depression in two of the studies
9,17
.  
 Mediation effects.  
 Several studies incorporated mediation analyses investigating the relationship of other 
related variables, particularly coping strategies, to both distress and uncertainty. Mishel et 
al.’s (1991)
12
 regression analysis demonstrated the relationship between uncertainty and 
distress to be mediated by mastery, danger appraisal, and the emotion-focused coping 
strategy of wishful thinking. Emotion-focused coping was also found to be a mediating 
variable between intolerance of uncertainty and depression by Taha, Matheson, & Anisman 
(2012)
17
. Coping strategies more broadly were found to mediate the relationship between 
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This study also demonstrated distress to mediate the relationship of uncertainty and coping 
strategies with quality of life. Findings from Cahill et al. (2014)
1
 and Lin et al. (2013)
3
 
showed distress mediated the effect of uncertainty on symptom severity, while Detprapon et 
al. (2009)
5
 and Mishel and Braden (1987)
10
 found uncertainty to mediate the effect of 
symptom experience and physical function on distress.   
 Analyses of the mediating relationships of other variables were not statistically 
significant. These included the impact of uncertainty in the relationship between locus of 
control and anxiety and depression, and of daily hassle intensity in the relationship between 
intolerance of uncertainty and depression.  
 Effects of time.  
 Three studies employed a longitudinal design to assess the relationship between 
distress and uncertainty at two time points across the cancer treatment trajectory
8,10,18
. 
Increases in the association between variables over time were see in two studies. Results 
reported by Mishel and Braden (1987)
10
 showed that during the diagnostic period for women 
with gynaecological cancer there was no statistically significant relationship between the two 
uncertainty and distress, rather distress was shown to be predicted by lower levels of social 
affirmation. However, when followed up during treatment, a statistically significant 
relationship between distress and uncertainty was observed. Similarly, Wong and Bramwell 
(1992)
18 
reported a non-significant relationship between distress and uncertainty in women 
with breast cancer when assessed prior to hospital discharge following mastectomy when re-
assessed post-discharge was found to reach the level of statistical significance. Conversely, 
Lam et al. (2012)
8
 reported a decrease in the strength of the relationship between distress and 
uncertainty over time. When assessed in their sample of breast cancer patients, the 
relationship was found to be statistically significant prior to surgery but to have weakened to 
a level of non-significance one-month post-surgery.   
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Discussion 
The primary aim of this systematic literature review was to synthesise the current 
evidence pertaining to the relationship between uncertainty and distress for younger adults 
with cancer. Overall, the findings of the included studies suggest that the relationship 
between uncertainty and distress is noteworthy, as demonstrated by the small to large 
correlational effect sizes reported. In several studies, uncertainty and intolerance of 
uncertainty were shown to be predictive, offering support to Mishel’s uncertainty in illness 
theory and the inferred impact of uncertainty upon distress via increased danger appraisal. 
However, the limitations identified within the included studies and inherent within the review 
design mean that these findings must be interpreted with caution.   
 The consistently reported findings of a statistically significant positive correlation 
between uncertainty and distress are comparable with the results presented by Jabloo et al. 
(2017) in their review of uncertainty amongst older adults with cancer. As in Jabloo et al.’s 
review, the relationship was seen to be significant for patients with various cancer diagnoses 
and stages of progression, at different stages in the treatment trajectory, suggesting the 
experience of both uncertainty and distress to perhaps unsurprisingly characterise the entire 
cancer experience. Supporting this are a large number of qualitative studies exploring 
patients’ lived experiences of cancer where the interlinked themes of distress and uncertainty 
repeatedly emerge (Bailey, Wallace, & Mishel, 2007; Drageset, Lindstrøm, Giske, & 
Underlid, 2011; Halldórsdóttir & Hamrin, 1996; Hansen et al., 2012; Thomas 2008).  
Despite the majority of findings suggesting a significant relationship between 
variables, some variation in findings was reported, suggesting that the relationship between 
uncertainty and distress cannot be assumed to be static or ubiquitous. Findings from Wong 
and Bramwell (1992) demonstrated the relationship between uncertainty and distress was not 
significant for breast cancer patients having undergone surgery whilst they remained in 
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hospital, but was statistically significant post discharge. Conversely, Lam et al. (2012) found 
that the strength of the relationship decreased over time, being statistically significant prior to 
breast cancer operation and falling to non-significant levels one-month post-operation. These 
findings may be demonstrative of the rapid changeability of psychological variables for 
individuals with cancer. Times when the relationship is weaker between distress and 
uncertainty may reflect the role of other factors such as physician communication (Zachariae 
et al., 2003), social support (Kornblith et al., 2001; Pinar, Okdem, Buyukgonenc, & Ayhan, 
2012), or physical symptoms (Liao et al., 2011). 
Of those studies using predictive modelling techniques, the majority suggested 
uncertainty or intolerance of uncertainty to predict distress. These findings can be considered 
consistent with Mishel’s uncertainty in illness theory (1988), according to which, uncertainty 
is potentially appraised as dangerous which may lead to increased distress. The findings in 
several studies indicating the relationship between uncertainty and distress to be mediated by 
emotion-focused coping strategies also lends support to the model whereby affect-control 
strategies are employed in response to danger appraisals and postulated to facilitate more 
effective adaptation to illness.  
A minority of analyses did not find uncertainty or intolerance of uncertainty to have a 
statistically significant predictive effect on distress (Kryanou et al., 2014; Northouse, Dorris, 
& Charron-Moore, 1995). A further study demonstrated conflicting findings, with results 
showing distress to be a significant predictor of uncertainty (Cahill et al., 2014). These 
findings suggest that the relationship between distress and uncertainty is complex and is not 
necessarily linear or monodirectional. The variability in the nature of the relationship 
presented in these findings may also give an indication that there are other factors and 
variables impacting upon distress and uncertainty which may not have been considered 
within the analyses. The findings also omitted any analysis in relation to non-distressing 
1-24 
UNCERTAINTY AND DISTRESS IN CANCER 
 
uncertainty, i.e. where uncertainty may be framed as opportunity (Mishel, 1988) which could 
partially explain outcomes where uncertainty and distress were not significantly related 
(McCormack et al, 2011).  
Limitations of the Included Studies 
 Although the results demonstrated a compelling case for the importance of the 
relationship between uncertainty and distress in younger cancer patients, the findings must be 
interpreted in light of the quality of the research. A number of limitations were identified 
across the included studies, potentially increasing the risk of bias. The descriptive 
methodological designs of the included studies are limited by a lack of control for potential 
confounding variables or inclusion of control subjects (with the exclusion of one study), 
meaning that results cannot be interpreted definitively.  
 The quality assessment of studies using the AXIS tool highlighted several 
methodological limitations. Risk of bias was incurred in most studies through the use of 
convenience sampling. Representativeness of the samples was also potentially affected by the 
relatively high proportion of white Caucasian, highly educated participants in the North 
American studies. A number of studies focused solely on female cancer patients; however, 
the mixed gender studies contained a greater proportion of male participants. This may 
impact upon the interpretation of results as previous research has demonstrated that female 
cancer patients tend to exhibit greater levels of distress (Keller & Henrick, 1999; Linden et 
al., 2012). While the focus of this review was on younger adults with cancer, the mean age of 
all studies was over 44, likely representing the increased likelihood of developing cancer with 
increased age (Cancer Research UK, n.d.), meaning that results may not necessarily be fully 
generalisable to young adults with cancer given the evinced inverse relationship between age 
and distress in cancer (Mosher & Danoff-Burg, 2006). Several studies excluded patients with 
greater levels of functional ability who are likely to be those with increased levels distress 
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(Banks et al., 2010). Measures used across studies were generally appropriate, although a 
minority of studies employed unvalidated or single-item measurement tools. The potential for 
bias inherent within self-report measurement must also be considered (Van de Mortel, 2008).  
 Additional potential biases were identified in relation to quality of reporting and 
methodology. The omission of power analyses from all but two studies means that there is a 
possibility that analyses may have under- or over-estimated findings. The lack of information 
in all studies regarding non-responders also means it is impossible to know whose data has 
not been included in the study.  
 Another consideration is the inclusion within the review of two studies authored by 
Mishel and the potential for a vested interest in the publication of results providing evidence 
for her proposed uncertainty in illness theory.  
Limitations of the Systematic Literature Review 
 It is important to acknowledge the constraints inherent in the methodological 
approach of this systematic literature review and their impact upon the interpretation of 
findings. Firstly, while a great deal of attention was given to developing a comprehensive 
search strategy, it cannot be guaranteed that all relevant research has been retrieved. The 
process of hand-searching the reference lists of included studies and key reviews led to the 
retrieval of three studies meeting the inclusion criteria which were not found in the initial 
database searches. While the process of handsearching aims to increase the robustness of the 
search strategy, the number of additional relevant papers found during this process suggests 
that it is possible that further relevant papers have been missed. It is possible that additional 
trialling of search terms or searching of additional multi-disciplinary databases may have 
resulted in additional relevant findings. Secondly, while a second reviewer assessed the risk 
of bias in a sub-sample of papers, due to practical constraints it was not possible for all 
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included papers to be reviewed independently in this manner as would be ideal to reduce the 
risk of bias.  
 A further limitation of this review relates to the conceptualisation of distress. While 
the review aimed to take a broad definition of distress, incorporating experiences of 
depression and anxiety, in order to maximise the incorporation of relevant findings, there is 
ongoing debate and conflictual findings regarding conceptualisation of these aspects of 
experience and whether they are overlapping or distinct but related experiences (Drapeau, 
Marchand, & Beaulieu-Prévost, 2011; Ridner, 2004).  
 As psychological distress was broadly defined within this review, a range of different 
measures was employed across studies to assess relevant and subsumed constructs including 
depression and anxiety. So too were various measures of uncertainty and intolerance of 
uncertainty used. This necessarily raises questions regarding the validity and sensitivity of the 
different measures used to assess the variables of interest, especially given the disparity 
amongst findings in different studies. It is possible that lack of convergence between 
measurement tools arising from the measurement of related but distinct phenomena (e.g. 
aspects of depression or anxiety) may have influenced individual study results. The presence 
of this kind of divergence between constructs assessed by measures purporting to evaluate the 
same psychological phenomena is a persistent challenge (Ro & Lawrence, 2007). This may 
be partially attributable to the variety of semantic, epistemological, and conceptual 
perspectives that exist in relation to psychological concepts, and the resulting inevitable 
presence of fallibility in psychological measurement (Hathcoat, 2013).  
 Whilst the aim of the review was to investigate the relationship between distress and 
uncertainty in cancer as a broad, super-ordinate phenomenon, it is acknowledged that the 
experience of cancer is very individual and impacted by a wide range of factors. 
Interpretation of results may be impacted by the inclusion within the review of studies 
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relating to multiple types of cancer, cancers of all stages of progression, and patients at 
different temporal points in the treatment journey. Additionally, the definition of ‘younger’ 
cancer survivors included participants of a wide range of ages, and it is possible that the 
experiences associated with cancer may be very different for those at the polarities of this 
range.  
Research Recommendations 
 Although the majority of the included findings suggest that distress and uncertainty 
are related, and that uncertainty predicts distress, the shared variance for which findings are 
able to account is mixed, suggesting that there are possibly multiple other factors contributing 
to and interacting with the experience of distress for cancer patients. While some studies did 
consider other variables, including symptom distress and coping, research which generates a 
clearer understanding of the relationship between uncertainty, distress, and related factors 
would be beneficial. Therefore, controlled studies and methodological approaches allowing 
confounding variables to be controlled would be advantageous. Studies comparing the nature 
of the relationship between uncertainty and distress in different cancer populations at 
different points in the treatment journey would also be helpful to establish patterns in 
relationship intensity which could meaningfully inform when clinical interventions may be 
most useful. Studies investigating any differences in the relationship for patients with 
different stages of cancer would also be beneficial as in all studies patients with differing 
stages of cancer were grouped together.  
Additionally, issues raised through quality appraisal should be considered as 
important steps in improving the methodological rigour of future research. As a priority, 
power analyses and non-response data should be reported to allow for more accurate 
interpretation of findings. More longitudinal data would also be advantageous to increase 
understanding of the relationship between uncertainty and distress over time.   
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Clinical Implications 
 The indication from a number of studies that uncertainty and intolerance of 
uncertainty are predictive of distress highlights the potential for interventions which enable 
management of uncertainty as a means of reducing distress. A number of studies have been 
published evaluating the outcomes from uncertainty management interventions demonstrating 
positive outcomes including enhanced coping skills and self-efficacy (Germino et al., 2013). 
While these interventions may be beneficial for cancer survivors faced with uncertainty 
following completion of treatment, they have less utility for patients at diagnosis and 
undergoing treatment due to the necessary prioritisation of medical treatments and time 
constraints which may get in the way of formalised interventions at this time. Therefore, 
opportunities to reduce uncertainty and enhance tolerance of uncertainty and adaptive coping 
during routine medical contact may be more effective and pragmatic for individuals newly 
diagnosed and undergoing treatment. As findings from this review demonstrated a strong 
relationship between uncertainty and distress pre-treatment, this may be an important time at 
which support with tolerating and reducing uncertainty may have a substantial impact on 
reducing associated distress. Therefore, although communicating uncertainty may be an 
essential aspect of medical practitioners’ duties, it is possible that the way in which this is 
communicated can serve to alleviate uncertainty associated-distress (Kruijver, Kerkstra, 
Bensing, & van de Wiel, 2000). Identified aspects of effective nurse to patient 
communication may support this, including empathy and ongoing training in communication 
skills. Additionally, interventive communication could be facilitated through use of the 
patient-centred communication model which highlights the management of uncertainty 
(including attention to coping strategies) as a key function of the communication (Epstein & 
Street, 2007; McCormack et al., 2011). The findings from Mishel et al. (1984) and Mishel 
and Braden (1987) also highlight that ambiguity as a specific sub-component of uncertainty 
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has a particularly strong relationship with distress which could be an important area for 
intervention. This is consistent with evidence that uncertainty can increase ambiguity 
aversion which leads to elevated cancer worry (Han et al., 2011).  As ambiguity is defined as 
“unclear or ever-changing bodily cues about the state of the illness that may be confused with 
other illness concerns” (Mishel, 1997), it is possible that greater focus on education and 
information relating to interpretation of bodily cues could help to reduce ambiguity and 
associated distress.  
Conclusion 
 Findings from the 15 included studies provided evidence that uncertainty and distress 
are significantly associated for patients with different types and grades of cancer and at 
different points in the treatment journey. The majority of results also suggested that 
uncertainty is predictive of distress, supporting Mishel’s uncertainty in illness model which 
posits that uncertainty may be appraised as threatening and which may raise distress. 
Emotion-focused coping strategies were shown in several studies to mediate between 
uncertainty or intolerance of uncertainty and distress. The relationship between variables, 
however, is not necessarily static or ubiquitous and may vary over time and in relation to 
other factors which were not elucidated within the research. Results must be interpreted 
cautiously in light of the identified methodological weaknesses across studies, including an 
absence of power analyses and recurrent sampling biases. Future research should focus upon 
addressing these identified limitations and providing a clearer picture of the impact of 
associated variables and cancer stage. Findings highlight the potential for effective 
communication as an intervention to support tolerance and reduction of uncertainty, 
particularly areas of ambiguity, which may in turn reduce the experience of distress for 
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Tables and Figures 
 















PICO Item Criteria for this review 
Population Younger adults (aged ≤55)  
Living with cancer (any kind of cancer; any stage of cancer (I-IV), including curative and palliative 
patients; pre-, during-, or up to 5 years post-treatment) 
Intervention Not applicable (although intervention studies reporting data for control groups meeting inclusion 
criteria will be eligible for inclusion)  
Comparison Not applicable (although groups where a comparison condition is employed may be eligible for 
inclusion) 
Outcomes Measure of uncertainty; measure of psychological distress 
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Table 1-B: Overview of Study Characteristics  
Study  Country 



























































































































Analysis: Key Outcomes 
1 
Cahill et al. 
(2014) 




















































Path analysis: Statistically significant 
(p<0.001) effect found for mood on 
uncertainty (unstandardized/standardized 
coefficient = 5.35/0.54). Mood state found 
to mediate the relationship between 
uncertainty and symptoms.  
 
More frequent use of personal health 
records found to decrease uncertainty.  
 
2 
Lin et al. 
(2012) 
            Correlation: significant positive correlation 
(p<0.01) between uncertainty and mood 
state as measured by the five negative mood 
subscales of the POMS-SF. Uncertainty was 
negatively correlated (p<0.01) with the 
vigour sub-scale. 
3 
Lin et al. 
(2013) 
            Structural equation modelling: Uncertainty 
had a significant (p<0.05) direct impact on 
all negative mood states (tension, anger, 
depression, fatigue & confusion).  
 
Uncertainty had a significant (p<0.05) 
indirect impact (via mood state) on 
symptom severity for all mood states except 
confusion. 
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Multivariate analysis: No significant 
association between intolerance of 
uncertainty and distress or cancer worry.  
 
Post-hoc univariate ANOVA: Significant 
effect found for intolerance of uncertainty 
on HADS-Depression (F=6.86, p=0.02) and 
cancer worry (F=7.15, p=0.02). Association 
between intolerance of uncertainty and 








et al.  
(2009) 






















CES-D Linear Structural Relationship analysis: 
Modified model demonstrated a statistically 
significant direct effect of uncertainty on 
depression (0.82, p<0.001). Uncertainty was 
seen in the model to mediate the 
relationships between symptom experience, 
and depression and quality of life.  
 
Buddhist practices had a non-significant 





er et al.  
(2002) 






























Spearman’s rank order correlation: 
statistically significant relationship found 
between uncertainty and distress (rs=0.5, 
p=0.001).  
 
No significance difference in variables 
between women opting in and out of 
clinical trial. Evidence provided (in part) for 
the King's framework and relationship of 
uncertainty with emotional wellbeing and 
impact on decision making.  
 
7 
Jones et al. 
(2014) 





























Pearson’s correlations: statistically 
significant relationship between health 
anxiety and intolerance of uncertainty 
(r=0.50, p<0.001).  
 
Multiple regression: intolerance of 
uncertainty was not a significant unique 
predictor of health anxiety, however other 
unique predictors identified were younger 
age, more advanced cancer stage, increased 
body vigilance, and cognitive anxiety 
sensitivity.  
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STAI Hierarchical linear modelling: Uncertainty 
about the future was a significant predictor 
of pre-operative anxiety (coefficient= -.426, 
standard error.130, p<0.01). Six months 
post-surgery this association was not 
significant. 
 
Pre-operative anxiety was also predicted by 
higher levels of depression, lower levels of 
life satisfaction, less sense of control, and 
difficulty coping. Higher anxiety across 
time following surgery was predicted by 
higher pre-operative anxiety, poorer 
physical health, lower sense of control, and 
increased feelings of isolation.   
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Pearson’s correlation: Pre surgery there was 
a significant positive relationship between 
uncertainty and anxiety (r=0.16, p<0.001) 
and depression (r=0.20, p<0.001). One 
month post-surgery both of these 






USA 44 20-83 
(53) 

















Pearson’s correlation: Significant positive 
correlation between psychological distress 
and ambiguity about illness (MUIS sub-
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scale) during treatment (r=0.46, p<.001). 
The relationship between psychological 
distress and other sub-scales of uncertainty 
were not reported to be significant.  
 
Regression analysis: During treatment 
ambiguity about illness (MUIS sub-scale) 
significantly predicts psychological distress.  
Ambiguity about illness was found to 
mediate the relationship of social 
affirmation and control over physical 






























Pearson’s correlation: Significant positive 
correlation between psychological distress 
and ambiguity about illness (MUIS sub-
scale) (r=0.27, p<0.05). Correlation 
between total MUIS score and 
psychological distress was non-significant 
(p>0.05).  
 
Hierarchical multiple regression: A strong 
relationship was found between uncertainty 
and pessimism; women with more 
uncertainty and pessimism had greater 






USA 100 20-81 
(53) 



























POMS Regression analysis: Testing of model 
found the relationship between uncertainty 
and psychological distress to be mediated 
by statistically significant (p<0.05) 
relationships between mastery, danger 
appraisal, and wishful thinking (a sub-
category of emotion-focused coping).  
 
Mastery was found to mediate the 
1-53 
UNCERTAINTY AND DISTRESS IN CANCER 
 
relationship between uncertainty and danger 
appraisal, accounting for 17% of the 
variance (2% variance explained by 
uncertainty). Danger appraisal was found to 
have a highly significant relationship with 
uncertainty (p<0.001). The mediating effect 
of coping strategy of wishful thinking 
between danger appraisal and emotional 
distress was found to was found to 
contribute 2% of the variance, while danger 

































BSI Pearson’s correlation: Statistically 
significant relationship found between 
psychological distress and uncertainty 
(r=0.42, p<0.01). 
 
Multiple regression: Uncertainty found to 
have a non-significant contribution to 
regression equation of emotional distress. 
Symptom distress, personal support and 
hopelessness all significantly contributed to 
the model, (total variance R2=0.43).  
 
Husbands' distress levels were found to 



























HADS Pearson’s correlation: Significant 
relationship found between uncertainty and 
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anxiety (r= 0.287, p<0.01) and uncertainty 
and depression (r=0.321, p<0.01).  
 
Partial least squares-structural equation 
modelling: Direct effect found for 
uncertainty on anxiety (standardized path 
coefficient 0.24, p<0.05, t=2.490) Direct 
effect found for uncertainty on depression 
(standardized path coefficient 0.25, p<0.05, 
t=2.548).  
 
Analyses of the mediation effect of 
uncertainty between locus of control and 
psychological distress were not statistically 
significant (p≤0.1).  
 
Uncertainty did significantly mediate the 
effect of uncertainty on quality of life 




Sharif et al. 
(2017) 





















  Pearson’s correlation: Significant 
relationship found between uncertainty and 
anxiety (r= 0.274, p<0.01) and uncertainty 
and depression (r=0.319, p<0.01). 
 
Partial least squares-structural equation 
modelling: Direct effect found for 
uncertainty on depression and anxiety 
(standardized path coefficient 0.253, 
p<0.01, t=2.885). 
 
BC patients experiencing greater 
uncertainty are more likely to use avoidant 
rather than emotional coping strategies 
which amplifies anxiety and depression and 
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Pearson’s correlation: Statistically 
significant relationships found between 
uncertainty and mood state (r=0.54, 
p<0.001), and uncertainty and depression 
(r=0.62, p<0.001).  
 
17 































BDI Pearson's r correlation: Statistically 
significant relationships found between 
intolerance of uncertainty (IU) and 
depression (r=.64, p<0.01).  
 
Hierarchical regression analysis: Daily 
hassle intensity mediates the relationship 
between IU and depressive symptoms for 
controls but not BC survivors. Emotion-
focused coping mediated the relationship 
between IU and depressive symptoms for 
patients (F(4, 37)=10.94,  p<0.001, R2= .54)  
 
Additional findings: Depression levels and 
experience of daily hassles for patients was 
similar to controls’, patients had lower IU 
than controls. Women with greater IU were 
more likely to use emotion-focused coping 
and have depressive symptoms. IU and 
depressive symptoms decrease over time 

















STAI Pearson's r correlations: Pre-discharge 
following surgery the relationship between 
uncertainty and anxiety was not significant 
(r= 0.09, p=0.34). One to two weeks post-
hospital discharge the relationship was 
found to be significant (r= 0.42, p=0.02) 
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T-tests (time 1- 1-2 days pre-discharge, time 
2-1-2 weeks post-discharge): Time 1 to time 
2- no significant change in anxiety or 
uncertainty.  
 
Note. Abbreviations in alphabetical order: A- Asian; A/P- Asian/Pacific Islander; ANOVA- analysis of variance; B- Black; BC- breast cancer; BDI- Beck 
depression inventory; Br- brachytherapy; BSI- brief symptom inventory; BT- brain tumour; C- chemotherapy; CES-D- centre for epidemiological studies- 
depression scale; Ch- Chinese; CR- colorectal; CT- clinical trial; CTXD- cancer and treatment distress measure; CWS- cancer worry scale; DCS- decisional conflict 
scale; G- gynaecological; H- hormonal treatment; Ha- haematological; HADS- hospital anxiety and depression scale; HCT- hematopoietic cell transplantation; HN- 
head and neck; Ind- Indian; IUS- intolerance of uncertainty scale; IUS-12- intolerance of uncertainty scale- short form; L- Latin/South American; M- Malay; MUIS-
BT- Mishel uncertainty in illness scale- brain tumour form; MUIS-C- Mishel uncertainty in illness scale- community form; N- neoadjuvant therapy; NA- Native 
American/Alaskan; O- other; PAIS- psychological adjustment to illness scale; POMS- profile of mood states; POMS-SF- profile of mood states- short form; QOL-
PV- quality of life scale- patient version; R= radiotherapy; S- surgery; SD- standard deviation; SHAI- short health anxiety inventory; STAI- state-trait anxiety 
inventory; TB- Thai Buddhist. 
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list hand searches 
(n=3) 




Reasons listed in Appendix 1-I 
(p.1-81) 




Records excluded (n=304) 
with reasons: 
Participants under 18 years or sample 
mean age >65 years 
(n=53) 




No measure of distress 
(n=55) 
No measure of uncertainty 
(n=22) 
Not available in English 
(n=26) 
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Appendices 
Appendix 1-A: Search Term Trial Results 
 











Psychinfo Final search strategy 78329 31171 1320771 667 440 
Strategy with additional cancer 
terms 79451 " " 678 448 
Medline Final search strategy 3422994 87506 3360102 2073 n/a 
Strategy with additional cancer 
terms 3551583 " " 2097 n/a 
CINAHL Final search strategy 572455 19329 682156 1012 n/a 
Strategy with additional cancer 
terms 590164 " " 1029 n/a 
Web of 
science Final search strategy 3709786 444964 5364510 2555 661 
 
Strategy with additional cancer 
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Appendix 1-B: Full Search Strategy 
 
Database Concept 1: 
Cancer 
 Concept 2:  
Uncertainty 
 Concept 3: 
Distress 










“Uncertainty”   
AND  Thesaurus term (DE)  
“Emotional states” or “stress” or “well being” 









OR OR OR 
Free text in Abstract  
cancer or neoplasm* or onco* 
or tumour or malign*  
Free text in 
Abstract  
Uncertainty 
Free text in Abstract  
distress or anx* or worr* or depress* or mood 
or affect* or wellbeing or well-being or well 
being or emotion* or mental health or stress 
OR OR OR 
Free text in Title  
cancer or neoplasm* or onco* 
or tumour or malign*  
Free text in 
Title  
Uncertainty 
Free text in Title  
distress or anx* or worr* or depress* or mood 
or affect* or wellbeing or well-being or well 





MeSH heading (MH) 
“neoplasms”  
AND Mesh Heading 
(MH) 
“Uncertainty” 
AND Mesh Heading (MH) 
“Anxiety” or “anxiety disorders” or 
“depression” or “depressive disorder” or 





OR OR OR 
Free text in Abstract 
cancer or neoplasm* or onco* 
or tumour or malign*  
Free text in 
Abstract  
Uncertainty 
Free text in Abstract  
distress or anx* or worr* or depress* or mood 
or affect* or wellbeing or well-being or well 
being or emotion* or mental health or stress 
OR OR OR  
Free text in Title Free text in Free text in Title distress or anx* or worr* or 
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cancer or neoplasm* or onco* 





depress* or mood or affect* or wellbeing or 
well-being or well being or emotion* or 




MeSH Heading (MH) 
“Neoplasms” 









AND Mesh Heading (MH) 
“symptom distress” or “anxiety” or “anxiety 
disorders” or “generalized anxiety disorder” or 
“depression” or “depression, reactive” or 
“psychological well-being” or “psychological 




Free text in Abstract 
cancer or neoplasm* or onco* 
or tumour or malign*  
OR OR OR 
Free text in Title  
cancer or neoplasm* or onco* 
or tumour or malign* 
Free text in 
Abstract  
Uncertainty 
Free text in Abstract  
distress or anx* or worr* or depress* or mood 
or affect* or wellbeing or well-being or well 
being or emotion* or mental health or stress 
OR  
Free text in 
Title  
Uncertainty 
Free text in Title 
distress or anx* or worr* or depress* or mood 
or affect* or wellbeing or well-being or well 











cancer or neoplasm* or onco* 
or tumour or malign*  
AND TITLE:  
Uncertainty 
AND TOPIC:  
distress or anx* or worr* or depress* or mood 
or affect* or wellbeing or well-being or well 




OR OR OR 
TITLE:  




distress or anx* or worr* or depress* or mood 
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or tumour or malign*  or affect* or wellbeing or well-being or well 
being or emotion* or mental health or stress 
1
 Additional Web of Science Limiters Applied: psychology, psychology multidisciplinary, psychology clinical, social sciences interdisciplinary, 
psychiatry, psychology social, psychology developmental, social work, sociology, social sciences biomedical, nursing 
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Sample (n)  
Sampling /Recruitment  
Sample Characteristics  
Study date/duration  









Author Conclusions  
Comments  
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Appendix 1-D: Second Reviewer Quality Appraisal Ratings 
 
Section # Question (yes/no/partial/don't know/not applicable [n/a]) 
Ehrenberg
er et al. 
2002 








1 Were the aims/objectives of the study clear? yes yes yes yes 
Methods 2 Was the study design appropriate for the stated aim(s)? yes yes yes yes 
 3 Was the sample size justified? yes partial no partial 
 4 Was the target/reference population clearly described? yes yes yes yes 
 5 Was the sample frame taken from an appropriate population 
base so that it closely represented the target/reference 
population under investigation? 
partial partial partial yes 
 6 Was the selection process likely to select subjects/ 
participants that were representative of the target/reference 
population under investigation? 
partial partial yes partial 
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 8 Were the risk factor and outcome variables measured 
 appropriate to the aims of the study? (validity) 
yes yes yes yes 
 9 Were the risk factor and outcome variables measured  
correctly using instruments that had been trialled, piloted, or 
published previously? (reliability) 
yes partial yes partial 
 10 Is it clear what was used to determine statistical significance 
 and/or precision estimates? (e.g. p-values, confidence  
intervals) 
yes partial partial yes 
 11 Were the methods (including statistical methods)  
sufficiently described to enable them to be repeated? 
yes yes yes yes† 
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A Selection minimizes baseline differences in prognostic 
factors? (For controlled studies only) 
Factors to consider: 
• Was selection of the comparison group appropriate? 
o Consider whether these two sources are likely to differ on 
factors related to the outcome (besides cancer status).  
 
• Did the study investigators do other things to ensure that 
exposed/unexposed groups were comparable, e.g., by using 
stratification, matching, or propensity scores? 
n/a n/a n/a n/a 
 B Adequate follow-up period (longitudinal studies only)? 
Factors to consider: 
• A justification of the follow-up period length is preferable. 
n/a n/a n/a n/a 
Results 12 Were the basic data adequately described? partial yes yes yes 
 13 Does the response rate raise concerns about non-response 
bias? 
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 14 If appropriate, was information about non-responders  
described? 
no no no no 
 15 Were the results internally consistent? yes no yes yes 
 16 Were the results presented for all the analyses described in 
the methods? 
yes yes yes yes 
Discussion 17 Were the authors' discussions and conclusions justified by 
 the results? 
partial yes partial yes 
 18 Were the limitations of the study discussed? partial yes partial yes 
 19 Were there any funding sources or conflicts of interest that  












†- On reviewing Syrjala et al. (2016), discrepant ratings were given on item 11 by the first and second reviewer. A partial rating was given by 
the first reviewer and a yes rating was given by the second reviewer. Based on discussion and reappraisal of the paper, the reviewers agreed upon 
a rating of ‘yes’ for this criterion as adequate information was provided about the study methodology for the study to be replicated. This was the 
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Appendix 1-E: Meta-Analysis  
A meta-analysis can be used to synthesise the findings of multiple studies to provide a 
weighted average of the combined study effect sizes (Borenstein, Hedges, Higgins, & 
Rothstein, 2009). While many criticisms of meta-analytic techniques have been made, 
asserting that an entire research field cannot be distilled meaningfully into one number 
(Bailar, 1997), the technique can provide a convenient way to summarise large amounts of 
data. 
Due to the different statistical techniques used across the studies included in this 
review, a meta-analysis combining all of the findings was not possible. As such, a meta-
analysis was conducted only upon findings of the correlational relationship between 
uncertainty and distress to establish the combined effect size of the reported correlation 
coefficients. Pearson’s r was extracted from seven of the included studies. Where studies 
reported distinct correlations for both depression and uncertainty and anxiety and uncertainty, 
these effects were combined to form an overall effect for the relationship between 
psychological distress and uncertainty prior to inclusion of data in the meta-analysis. The 
study by Syrjala et al. (2016) reported on the relationship between an uncertainty measure 
and both the POMS and CES-D. The effect size from the analysis including the POMS was 
selected as this is widely used as an overall measure of distress, rather than just the 
depressive symptoms captured by the CES-D. The two reported effect sizes from different 
time points in Wong et al.’s paper were combined prior to meta-analysis to give an overall 
effect for the sample. Of the two papers authored by Sharif (2017) and Sharif et al. (2017) 
which were based upon the same study, the analysis with the larger sample was chosen for 
inclusion.  
Analysis was carried out using ‘MedCalc’ online software. The software calculates 
meta-analyses using both a fixed effects and random effects model (MedCalc, n.d.): 
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MedCalc uses the Hedges-Olkin (1985) method for calculating the weighted summary 
Correlation coefficient under the fixed effects model, using a Fisher Z transformation 
of the correlation coefficients. Next the heterogeneity statistic is incorporated to 
calculate the summary Correlation coefficient under the random effects model 
(DerSimonian and Laird, 1986).  
For the purposes of this meta-analysis, the random-effects model is likely to be the 
more appropriate approach due to the level of heterogeneity in study variables such as cancer 
type, stage, and treatment (Borenstein et al., 2009).  
The extracted data and results of the meta-analysis are presented in figure 1-E-1. A 
forest plot of the included effects and meta-analysis is presented as a forest plot in figure 1-E-
2. The random effects meta-analysis suggested a combined effect of r=0.35 (95% CI 0.21-
0.48), indicating a highly statistically significant relationship between uncertainty and distress 
in younger adults with cancer (p<.001). Interpreted in light of guidance from Cohen (1988), 
the magnitude of the effect size is within the medium range.  
Figure 1-E-1: Meta-analysis results 
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Figure 1-E-2: Forest plot of the meta-analysis of the relationship between uncertainty and 
psychological distress in younger adults with cancer 
 
 The meta-analysis adds to the findings presented in the main body of the systematic 
review that there is a clear and significant relationship between uncertainty and psychological 
distress for younger adults with caners. As highlighted in the review discussion, this may be 
an important factor when considering communication and psychological interventions for this 
particular population. However, other factors that contribute to the remaining variance 
between these two variables merit further investigation. Of course, the limitations associated 
with the systematic review as a whole, which are highlighted in the discussion section, must 
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Appendix 1-F: AXIS Quality Appraisal Tool 
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n/a 18% high school 
53% college  
29% postgraduate  
60% first 
occurrence; 















n/a 55%primary  
39% high school 














70% married n/a Range=0-21 years 
Mean: 8 years 
n/a n/a 
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75% married/common law 
partner 
24% other (e.g. single, 
divorced, widowed) 
unemployed 39% 






certificate or less 














24% single   

















7% pt  
20% retired  
31% housewife  
6% no formal 
education 
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centres 7% unemployed before 
diagnosis  











75% married; 10% 
divorced, widowed, 
separated; 15% single 
52% employed  
13% employed on sick 
leave  
10% retired 
17% unemployed due 
to diagnosis 
7% unemployed prior 
to diagnosis/student  
 
18% high school 
53% college  
29% postgraduate  
60% first 
occurrence 
















75% married; 10% 
divorced, widowed, 
separated; 15% single 





























63% married  
11% single seven  
13% widowed 
n/a 59% high school 
28% college  
0% n/a 
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15% single  
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22% 4yrs+  
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93% married/partner   
7% single/divorced 
n/a 69% more than 














17% pt  
60% ft  
10% retired  
12% unemployed  
17%, high school 














40% employed n/a n/a n/a 
Note. Studies in italics/grouped by single braces indicate where multiple studies were based on data from the same sample. Abbreviations: n/a= 
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Introduction 1) Were the aims/objectives of the study 
clear? 
Y  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
Methods 2) Was the study design appropriate for the 
stated aim(s)? 
Y  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
 
3) Was the sample size justified? 
N N N Y N N N Y P  N N N N Y N Y  N N 
 4) Was the target/reference population 
clearly described? 
Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
 5) Was the sample frame taken from an 
appropriate population base so that it 
closely represented the target/reference 














P P P 
 








 6) Was the selection process likely to 
select subjects/ 
participants that were representative of the 
target/reference population under 
investigation? 
P P Y P Y P Y P P Y Y Y Y Y P P P P 
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P P N N P P D P P D P D P 
 8) Were the risk factor and outcome 
variables measured 
 appropriate to the aims of the study? 
(validity) 
Y  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
 9) Were the risk factor and outcome 
variables measured  
correctly using instruments that had been 
trialled, piloted,  
or published previously? (reliability) 
Y  Y P Y Y P P P Y P P Y Y Y Y P P Y 
 10) Is it clear what was used to determine 
statistical significance 
 and/or precision estimates? (e.g. p-values, 
confidence  
intervals) 
Y  P Y Y P Y P P Y P P P P Y P Y P P 
 11) Were the methods sufficiently 
described to enable them to be repeated? 









 A) Selection minimizes baseline 
differences in prognostic factors? (For 
controlled studies only) 
Factors to consider: 
• Was selection of the comparison group 
appropriate? 
o Consider whether these two sources are 
likely to differ on factors related to the 
outcome (besides cancer status).  
 
• Did the study investigators do other 
things to ensure that exposed/unexposed 
groups were comparable, e.g., by using 




































 B) Adequate follow-up period 
(longitudinal studies only)? 
Factors to consider: 
• A justification of the follow-up period 































Results 12) Were the basic data adequately 
described? 
Y  Y P P Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
 13) Does the response rate raise concerns 





















 14) If appropriate, was information about 
non-responders  
described? 
N N N N N P N N N N N N N N N N N N 
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 15) Were the results internally consistent? P Y Y Y P Y Y N Y Y Y Y Y Y Y Y Y Y 
 16) Were the results presented for all the 
analyses described in 
 the methods? 








Discussion 17) Were the authors' discussions and 
conclusions justified by 
 the results? 
P Y Y P Y Y Y Y Y P Y P Y Y Y Y Y Y 
 18) Were the limitations of the study 
discussed? 
Y  Y Y P Y Y P Y P N N P N Y Y Y Y Y 
Other 19) Were there any funding sources or 
conflicts of interest that  


























 20) Was ethical approval or consent of 
participants attained?  
D
K 








Y Y Y P P 
Note. † Amended to Y following discussion with second reviewer (see Appendix 1-D [p.1-64] for rationale). Abbreviations: Y= yes, N= no, P= 
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Reason for exclusion Number of studies excluded at 
title screening (n=2305) 
Participants under 18 years or 
sample mean age >65 years 
 
66 






No measure of distress 
 
837 
No measure of uncertainty 
 
87 
Not available in English 
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EuropeanoJournaloofoCanceroCare Author Guidelines 
 
1. SUBMISSION 
2. AIMS ANB SCOPE 
3. MANUSCRIPT CATEGORIES ANB REQUIREMENTS 
4. PREPARING THE SUBMISSION 
5. EBITORIAL POLICIES ANB ETHICAL CONSIBERATIONS 
6. AUTHOR LICENSING 
7. PUBLICATION PROCESS AFTER ACCEPTANCE 
8. POST PUBLICATION 




Authors should kindly note that submission implies that the content has not been published or 
submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific 
meeting or symposium. 
 
Once the submission materials have been prepared in accordance with the Author 




The submission system will prompt authors to use an ORCID iD (a unique author identifier) to 
help distinguish their work from that of other researchers. Click here to find out more. 
 
Click here for more details on how to use ScholarOne. 
 




By submitting a manuscript to or reviewing for this publication, your name, email address, and 
affiliation, and other contact details the publication might require, will be used for the regular 
operations of the publication, including, when necessary, sharing with the publisher (Wiley) and 
partners for production and publication. The publication and the publisher recognize the 
importance of protecting the personal information collected from users in the operation of these 
services, and have practices in place to ensure that steps are taken to maintain the security, 




The European Journal of Cancer Care will consider for review articles previously available as preprints. 
Authors may also post the submitted version of a manuscript to a preprint server at any time. Authors are 
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2. AIMS ANB SCOPE 
The EuropeanoJournaloofoCanceroCare aims to encourage comprehensive, multiprofessional 
cancer care across Europe and internationally. It publishes original research reports, literature 
reviews, commentaries, guest editorials, letters to the Editor and special features on current 
issues affecting the care of cancer patients. The Editor welcomes contributions which result from 
team working or collaboration between different health and social care providers, service users, 
patient groups and the voluntary sector in the areas of: 
 
• Primary, secondary and tertiary care for cancer patients 
• Multidisciplinary and service-user involvement in cancer care 
• Rehabilitation, supportive, palliative and end of life care for cancer patients 
• Policy, service development and healthcare evaluation in cancer care 
• Psychosocial interventions for patients and family members 
• International perspectives on cancer care 
 
The journal provides a forum for multiprofessional and service-user dialogue, and the reporting of 
original research or rigorous reviews within the field of cancer care both in Europe and 
internationally. The journal welcomes original research, reviews and correspondence from 
individuals whose first language is not English, but places great weight in its published papers on 
accuracy, fluency and clarity of expression as befits any journal published for an international 
and multiprofessional audience. 
 
 
3. MANUSCRIPT CATEGORIES ANB REQUIREMENTS 
 
Original Papers 
Original articles, which report on new research findings or conceptual analyses that make a 
significant contribution to knowledge will be considered for publication. 
WORD LIMIT: 4000 word limit, excluding references, figures, and tables). 
ABSTRACT: A structured abstract is required (200 words maximum) under the following sub-
headings: Objective; Methods; Results and Conclusion. The abstract should describe the 
purpose, study population, methodology, setting and details of the variables under study. It 
should also highlight the main results and conclusions of the study. 
MAIN TEXT: Should be structured under the following sub-headings: introduction, methods, 
results, and discussion. 




WORD LIMIT: 5000 
ABSTRACT: A structured abstract is required (200 words maximum) under the following sub-
headings: Introduction, Methods, Results, Conclusion. 
MAIN TEXT: Reviews must contain a clear exposition of the background, search strategy, 
databases, keywords and any selection/evaluation criteria used in the review where appropriate. 
It should also highlight the main results and conclusions of the study. 
RESEARCH REPORTING CHECKLIST: Please see section 5 Research Reporting Guidelines. 
 
Letters to the Editor 
WORD LIMIT: 600 
ABSTRACT: N/A 
MAIN TEXT: Letters should be succinct and must relate to an article that has been published in 
the Journal. The Editor reserves the right to shorten letters if necessary, but will be sent to the 
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authors for approval. 
RESEARCH REPORTING CHECKLIST: N/A 
 
Commentaries 
WORD LIMIT: 1500 
ABSTRACT: N/A 
MAIN TEXT: evidence-based opinion pieces involving areas of broad interest. 
RESEARCH REPORTING CHECKLIST: N/A 
 
Registered Reports 
EuropeanoJournaloofoCanceroCare welcomes Registered Reports. This is a new article type 
designed to increase the transparency and reproducibility of hypothesis-driven science. 
Registered Reports differ from the conventional research article as part of the review process is 
conducted before authors collect and analyse data. The cornerstone of the Registered Reports 
format is that a significant part of the manuscript will be assessed prior to data collection, with the 
highest quality submissions accepted in advance. Please view the full Registered Reports author 
guidelines here to help prepare your submission. 
 
 
4. PREPARING THE SUBMISSION 
 
Cover Letters 
Cover letters are not mandatory; however, they may be supplied at the author’s discretion. 
 
Parts of the Manuscript 
The manuscript should be submitted in separate files: title page; main text file; figures. 
 
Title page 
The title page should contain: 
  
i. A short informative title containing the major key words. The title should not contain 
abbreviations (see Wiley's best practice SEO tips); 
ii. A short running title of less than 40 characters; 
iii. The full names of the authors and email address and telephone number of corresponding 
author; 
iv. The author's institutional affiliations where the work was conducted, with a footnote for 
the author’s present address if different from where the work was conducted; 
v. Acknowledgments. 
vi. Conflict of Interest statement for all authors; 
vii. Funding statements 
  
Authorship 
Please refer to the journal’s authorship policy the Editorial Policies and Ethical 
Considerations section for details on eligibility for author listing. 
 
Acknowledgments 
Contributions from anyone who does not meet the criteria for authorship should be listed, with 
permission from the contributor, in an Acknowledgments section. Financial and material support 
should also be mentioned. Thanks to anonymous reviewers are not appropriate. 
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Conflict of Interest Statement 
Authors will be asked to provide a conflict of interest statement during the submission process. 
For details on what to include in this section, see the section ‘Conflict of Interest’ in the Editorial 
Policies and Ethical Considerations section below. Submitting authors should ensure they 
liaise with all co-authors to confirm agreement with the final statement. 
 
Main Text File 
As papers are double-blind peer reviewed the main text file should not include any information 
that might identify the authors. 
 
The main text file should be presented in the following order: 
  
i. Title, abstract and key words; 
ii. Main text; 
iii. References; 
iv. Tables (each table complete with title and footnotes); 
v. Figure legends; 
vi. Appendices (if relevant). 
  
Figures and supporting information should be supplied as separate files. 
 
Title 
Should be clear, descriptive, and avoid the use of metaphor, elaborate language or respondent 
quotations which are less likely to be discovered by the electronic algorithms of modern search 
engines. Titles should include words pertaining to population or sample, the method of inquiry, 
any tools or measures used and its key findings as appropriate. These words should be 
reiterated at least once in the abstract. 
 
Keywords 
Please provide six keywords. When selecting keywords, Authors should consider how readers 
will search for their articles. These words should be reiterated at least once in the abstract and or 
title. Keywords should be taken from those recommended by the US National Library of 
Medicine's Medical Subject Headings (MeSH) browser list at www.nlm.nih.gov/mesh. 
 
Main Text General Style Points 
 
• Anonymity: As papers are double-blind peer reviewed, the main text file should not 
include any information that might identify the authors. 
• Spelling: The journal uses British UK spelling; however, authors may submit using either 
UK or US spelling, as this is converted to UK spelling by the production team. 
• Footnotes: to the text are not allowed and any such material should be incorporated into 
the text as parenthetical matter. 
• Abbreviations: In general, terms should not be abbreviated unless they are used 
repeatedly and the abbreviation is helpful to the reader. Initially, use the word in full, 
followed by the abbreviation in parentheses. Thereafter use the abbreviation only. 
• Units of measurement: Measurements should be given in SI or SI-derived units. Visit 
the Bureau International des Poids et Mesures (BIPM) website at www.bipm.fr for more 
information about SI units. 
• Numbers: numbers under 10 are spelt out, except for: measurements with a unit 
(8mmol/l); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils). 
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• Trade Names: Chemical substances should be referred to by the generic name only. 
Trade names should not be used. Drugs should be referred to by their generic names. If 
proprietary drugs have been used in the study, refer to these by their generic name, 




References should be prepared according to the PublicationoManualoofotheoAmericano
PsychologicaloAssociation (6th edition). This means in text citations should follow the author-date 
method whereby the author's last name and the year of publication for the source should appear 
in the text, for example, (Jones, 1998). The complete reference list should appear alphabetically 
by name at the end of the paper. 
 
A sample of the most common entries in reference lists appears below. For more information 
about APA referencing style, please refer to the APA FAQ. Note that for journal articles, issue 
numbers are not included unless each issue in the volume begins with page one, and a DOI 
should be provided for all references where available. 
 
Journaloarticle 
Beers, S. R. , & De Bellis, M. D. (2002). Neuropsychological function in children with 





Bradley-Johnson, S. (1994). Psychoeducationaloassessmentoofostudentsowhooareovisuallyo
impairedooroblind:oInfancyothroughohighoschool (2nd ed.). Austin, TX: Pro-ed. 
 
InternetoDocument 





Tables should be self-contained and complement, not duplicate, information contained in the 
text. They should be supplied as editable files, not pasted as images. Legends should be concise 
but comprehensive – the table, legend, and footnotes must be understandable without reference 
to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, , §, ¶, should be 
used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as 
SD or SEM should be identified in the headings. 
 
Figure Legends 
Legends should be concise but comprehensive – the figure and its legend must be 
understandable without reference to the text. Include definitions of any symbols used and 
define/explain all abbreviations and units of measurement. 
 
Figures 
Although authors are encouraged to send the highest-quality figures possible, for peer-review 
purposes, a wide variety of formats, sizes, and resolutions are accepted. Click here for the basic 
figure requirements for figures submitted with manuscripts for initial peer review, as well as the 
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more detailed post-acceptance figure requirements. 
 
Figures may be reproduced in colour online free of charge. Please note, however, that it is 
preferable that line figures (e.g. graphs and charts) are supplied in black and white so that they 




Appendices will be published after the references. For submission they should be supplied as 
separate files but referred to in the text. 
 
Supporting Information 
Supporting information is information that is not essential to the article, but provides greater 
depth and background. It is hosted online and appears without editing or typesetting. It may 
include tables, figures, videos, datasets, etc. 
 
Click here for Wiley’s FAQs on supporting information. 
 
Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are 
available via a publicly available data repository, authors should include a reference to the 
location of the material within their paper. 
 
Wiley Author Resources 
Manuscript Preparation Tips: Wiley has a range of resources for authors preparing 
manuscripts for submission available here. In particular, authors may benefit from referring to 
Wiley’s best practice tips on Writing for Search Engine Optimization. 
 
Article Preparation Supports 
Wiley Editing Services offers expert help with English Language Editing, as well as translation, 
manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you 
can submit your manuscript with confidence. Also, check out our resources for Preparing Your 
Article for general guidance about writing and preparing your manuscript. 
 
5. EBITORIAL POLICIES ANB ETHICAL CONSIBERATIONS 
 
Editorial Review and Acceptance 
The acceptance criteria for all papers are the quality and originality of the research and its 
significance to journal readership. Except where otherwise stated, manuscripts are double-blind 
peer reviewed. Papers will only be sent to review if the Editor-in-Chief determines that the paper 
meets the appropriate quality and relevance requirements. 
 




An appeal against a decision on a manuscript should be filed within 28 days of notification of the 
decision. The appeal should be in the form of a letter addressed to the Editor-in-Chief and 
submitted to the EJCC editorial office. The letter should include clear and concise grounds for the 
appeal, including specific points of disagreement with the decision. The appeal will then be 
assessed by the EJCC editorial team, led by the Editor-in-Chief, and informed by the reviewer 
assessments and subsequent editorial communications. 
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Bata Storage and Bocumentation 
EuropeanoJournaloofoCanceroCare encourages authors to share the data and other artefacts 
supporting the results in the paper by archiving it in an appropriate public repository. Authors 
should include a data accessibility statement, including a link to the repository they have used, in 
order that this statement can be published alongside their paper.” If data cannot be shared for 
reasons such as ethical, privacy, or confidentiality matters, please inform the Editors in your 
cover letter on submission. 
 
Authors can consult the global registry of research data repositories re3data.org to help them 
identify registered and certified repositories relevant to their subject areas. 
 
Bata Citation 
In recognition of the significance of data as an output of research effort, Wiley has endorsed the 
FORCE11 Bata Citation Principles and is implementing a mandatory data citation policy. 
Journal policies should require data to be cited in the same way as article, book, and web 
citations and authors are required to include data citations as part of their reference list. Data 
citation is appropriate for data held within institutional, subject focused, or more general data 
repositories. It is not intended to take the place of community standards such as in-line citation of 
GenBank accession codes. 
 
When citing or making claims based on data, authors must refer to the data at the relevant place 
in the manuscript text and in addition provide a formal citation in the reference list. We 





Human Studies and Subjects 
For manuscripts reporting medical studies that involve human participants, a statement 
identifying the ethics committee that approved the study and confirmation that the study 
conforms to recognized standards is required, for example: Beclaration of Helsinki; US Federal 
Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines 
for Good Clinical Practice. It should also state clearly in the text that all persons gave their 
informed consent prior to their inclusion in the study. 
 
Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent 
human subjects being recognized (or an eye bar should be used). Images and information from 
individual participants will only be published where the authors have obtained the individual's free 
prior informed consent. Authors do not need to provide a copy of the consent form to the 
publisher; however, in signing the author license to publish, authors are required to confirm that 
consent has been obtained. Wiley has a standard patient consent form available for use. 
 
Clinical Trial Registration 
The journal requires that clinical trials are prospectively registered in a publicly accessible 
database such as http://clinicaltrials.gov/ and clinical trial registration numbers should be 
included in all papers that report their results. Clinical trials are defined as interventional studies. 
Authors are asked to include the name of the trial register and the clinical trial registration 
number at the end of the abstract. If the trial is not registered, or was registered retrospectively, 
the reasons for this should be explained. 
 
Research Reporting Guidelines 
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Accurate and complete reporting enables readers to fully appraise research, replicate it, and use 
it. Authors are encouraged to adhere to the following research reporting standards. 
 
• CONSORT checklist for reports of randomised trials and cluster randomised trials 
• TREND checklist for non-randomised controlled trials 
• PRISMA checklist for systematic reviews and meta-analyses 
• STROBE checklist for observational research 
• SRQR or CASP checklist for qualitative studies 
• SQUIRE checklist for quality improvement 
 
See the EQUATOR Network for other study types, and for guidance on selecting the 
appropriate tool for your article. 
 
Conflict of Interest 
The journal requires that all authors disclose any potential sources of conflict of interest. Any 
interest or relationship, financial or otherwise that might be perceived as influencing an author's 
objectivity is considered a potential source of conflict of interest. These must be disclosed when 
directly relevant or directly related to the work that the authors describe in their manuscript. 
Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, 
membership of a company board of directors, membership of an advisory board or committee for 
a company, and consultancy for or receipt of speaker's fees from a company. The existence of a 
conflict of interest does not preclude publication. If the authors have no conflict of interest to 
declare, they must also state this at submission. It is the responsibility of the corresponding 
author to review this policy with all authors and collectively to disclose with the submission ALL 
pertinent commercial and other relationships. 
 
Funding 
Authors should list all funding sources in the Acknowledgments section. Authors are responsible 
for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry 




The list of authors should accurately illustrate who contributed to the work and how. All those 
listed as authors should qualify for authorship according to the following criteria: 
 
1. Have made substantial contributions to conception and design, or acquisition of data, or 
analysis and interpretation of data; 
2. Been involved in drafting the manuscript or revising it critically for important intellectual 
content; 
3. Given final approval of the version to be published. Each author should have participated 
sufficiently in the work to take public responsibility for appropriate portions of the content; 
and 
4. Agreed to be accountable for all aspects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropriately investigated and 
resolved. 
  
Contributions from anyone who does not meet the criteria for authorship should be listed, with 
permission from the contributor, in an Acknowledgments section (for example, to recognize 
contributions from people who provided technical help, collation of data, writing assistance, 
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acquisition of funding, or a department chairperson who provided general support). Prior to 
submitting the article all authors should agree on the order in which their names will be listed in 
the manuscript. 
 
Additional Authorship Options. Joint first or senior authorship: In the case of joint first 
authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered 
joint first author’ or ‘X and Y should be considered joint senior author.’ 
 
ORCIB 
As part of the journal’s commitment to supporting authors at every step of the publishing process, 
the journal requires the submitting author (only) to provide an ORCID iD when submitting a 




This journal is a member of the Committee on Publication Ethics (COPE). Note this journal 
uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in 
submitted manuscripts. Read Wiley'sTop 10 Publishing Ethics Tips for Authors here. Wiley’s 
Publication Ethics Guidelines can be found here. 
 
 
6. AUTHOR LICENSING 
If your paper is accepted, the author identified as the formal corresponding author will receive an 
email prompting them to log in to Author Services, where via the Wiley Author Licensing Service 
(WALS) they will be required to complete a copyright license agreement on behalf of all authors 
of the paper. 
 
Authors may choose to publish under the terms of the journal’s standard copyright agreement, 
or OnlineOpen under the terms of a Creative Commons License. 
 
General information regarding licensing and copyright is available here. To review the Creative 
Commons License options offered under OnlineOpen, please click here. (Note that certain 
funders mandate that a particular type of CC license has to be used; to check this please 
click here.) 
 
Self-Archiving definitions and policies. Note that the journal’s standard copyright agreement 
allows for self-archiving of different versions of the article under specific conditions. Please click 
here for more detailed information about self-archiving definitions and policies. 
 
Open Access fees: If you choose to publish using OnlineOpen you will be charged a fee. A list 
of Article Publication Charges for Wiley journals is available here. 
 
Funder Open Access: Please click here for more information on Wiley’s compliance with 
specific Funder Open Access Policies. 
 
 
7. PUBLICATION PROCESS AFTER ACCEPTANCE 
 
Accepted article received in production 
When an accepted article is received by Wiley’s production team, the corresponding author will 
receive an email asking them to login or register with Wiley Author Services. The author will be 
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asked to sign a publication license at this point. 
 
Proofs 
Once the paper is typeset, the author will receive an email notification with the URL to download 
a PDF typeset page proof, as well as associated forms and full instructions on how to correct and 
return the file. 
 
Please note that the author is responsible for all statements made in their work, including 
changes made during the editorial process – authors should check proofs carefully. Note that 
proofs should be returned within 48 hours from receipt of first proof. 
 
Early View 
The journal offers rapid speed to publication via Wiley’s Early View service. Early View (Online 
Version of Record) articles are published on Wiley Online Library before inclusion in an issue. 
Note there may be a delay after corrections are received before the article appears online, as 
Editors also need to review proofs. Once the article is published on Early View, no further 
changes to the article are possible. The Early View article is fully citable and carries an online 
publication date and DOI for citations. 
 
eLocators 
This journal now uses eLocators. eLocators are unique identifies for an article that service the 
same function page numbers have traditionally served in the print world. When citing this article, 
please insert the eLocator in place of the page number. For more information, please visit the 
Author Services eLocator page here. 
 
 
8. POST PUBLICATION 
Access and sharing 
When the article is published online: 
 
• The author receives an email alert (if requested). 
• The link to the published article can be shared through social media. 
• The author will have free access to the paper (after accepting the Terms & Conditions of 
use, they can view the article). 
• The corresponding author and co-authors can nominate up to ten colleagues to receive a 
publication alert and free online access to the article. 
  
Print copies of the article can now be ordered (instructions are sent at proofing stage) or 
visit www.sheridan.com/wiley/eoc. 
 
Promoting the Article 
To find out how to best promote an article, click here. 
 
 
Article Promotion Support 
Wiley Editing Services offers professional video, design, and writing services to create 
shareable video abstracts, infographics, conference posters, lay summaries, and research news 
stories for your research – so you can help your research get the attention it deserves. 
 
Cover Image Submissions   
1-91 
UNCERTAINTY AND DISTRESS IN CANCER 
 
This journal accepts artwork submissions for Cover Images. This is an optional service you can 
use to help increase article exposure and showcase your research. For more information, 
including artwork guidelines, pricing, and submission details, please visit the Journal Cover 
Image page.   
  
Measuring the Impact of an Article 
Wiley also helps authors measure the impact of their research through specialist partnerships 
with Kudos and Altmetric. 
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Abstract 
Objective: Cancer of unknown primary (CUP) has been relatively overlooked by previous 
research investigating the psychological experiences of cancer patient populations. The 
condition is associated with elevated uncertainty which may exacerbate difficulties 
encountered in other cancers. This study aimed to explore the coping experiences of people 
living longer-term (>6 months) with CUP.  
Methods: Semi-structured interviews were conducted with 10 participants. Interpretative 
phenomenological analysis was used to identify superordinate and subordinate themes from 
patients’ accounts.  
Results: Superordinate themes were: (1) ‘“Fuss and Bother”: The Upheaval of Everyday 
Life’, with subordinate themes of ‘Appointment threats’, and ‘Symptoms and side-effects’; 
(2) ‘“It’s the Unknowing”: The Enduring Uncertainty of CUP’, with subordinate themes of  
‘“What the bloody hell’s that?!”’, ‘An uncertain future’, and ‘Hope’; and (3) ‘“Just Get on 
With It”: Managing and Moving Forwards’, with subordinate themes of ‘Maintaining 
normality’, ‘Acceptance’, and ‘Support’.   
Conclusion: Findings demonstrated that the experiences of people living longer-term with 
CUP parallel those of other cancer patient populations, however, patients with CUP face 
particular challenges with perceived loss of control, burdensome medical regimes, and 
unrelenting uncertainty which may make coping harder. Findings were synthesised with 
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Introduction 
Cancer of unknown primary (CUP) is a diagnosis given where a secondary cancer has 
been identified in the absence of an identifiable primary site (Fizazi et al., 2015; 
Varadhachary & Raber, 2014). The diagnosis can only be made once standardized 
investigations have failed to discover the primary cancer (Airoldi, 2012). Possible reasons 
that the primary cancer cannot be identified include: it being too small to register on scans or 
being obscured; the body’s immune system eradicating it; or it passing from the body (The 
Christie NHS Foundation Trust, n.d.). Where all possible investigations have not yet taken 
place or cannot take place, the secondary cancer is referred to as a malignancy of undefined 
origin, differentiating this group of patients from those with ‘confirmed’ CUP (National 
Institute for Health and Care Excellence, NICE, 2010).  
Approximately 9000 people in the UK are diagnosed with CUP annually (Cancer 
Research UK, 2017). The condition is usually associated with limited life expectancy 
(Hemminki, Bevier, Hemminki, & Sundquist, 2012). While a minority of patients (15-20%) 
belong to clinical subsets with more favourable prognoses, 80-85% of CUP patients belong to 
unfavourable subsets with a median survival time from diagnosis of six months (Airoldi, 
2012; Fizazi et al 2015). However, a sub-group of these patients are able to be stabilised with 
treatment beyond this time, with approximately 20% surviving one year or more and 13% 
surviving three years or more from diagnosis (Cancer Research UK, 2017).     
Psychological Aspects of Cancer 
Research has shown that individuals with cancer experience elevated distress (Carlson 
et al., 2004; Zabora, Brintzenhofe Szoc, Curbow, Hooker, & Piantadosi, 2001). Distress in 
relation to cancer has been defined by The National Comprehensive Cancer Network 
(NCCN, 2010) as “a multifactorial unpleasant emotional experience of a psychological 
(cognitive, behavioural, emotional), social, and/or spiritual nature that may interfere with the 
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ability to cope effectively with cancer, its physical symptoms and its treatments.” Within this 
definition, distress is conceptualised as difficulties with mood, anxiety, and adjustment 
ranging from mild reactions to clinically diagnosable psychiatric disorders, and existential 
and spiritual crises. A meta-analysis by Singer, Das-Munshi and Brähler (2009) found that 
one in three people with cancer meet criteria for diagnosis of a psychiatric disorder, 
compared with between one in four and one in six people in the general population (Mind, 
2017; Singer et al., 2009). NICE guidelines (2004) recommend that all cancer patients receive 
psychological assessment at key points in the treatment journey and have access to 
appropriate psychological support.    
Psychological Aspects of CUP  
                 Few studies have been undertaken with CUP patients. Results from a study 
comparing patients with CUP to patients with cancers of known primary sites have shown 
individuals with CUP experience greater levels of depression, anxiety, and somatization 
(Hyphantis et al., 2013). Compared with patients with other cancers, CUP patients have less 
understanding of their condition and are more likely to want written information (Wagland et 
al., 2017). Previous studies have suggested that elevated illness uncertainty associated with 
CUP amplifies difficulties encountered across other cancers (La Pushin, 2009; Richardson et 
al., 2015). Uncertainty in CUP has been linked to: numerous investigative tests (Symons, 
James & Brooks, 2009); indefinite prognosis and lack of clarity in treatment plans (Ryan, 
Lawlor & Walshe, 2013); and lack of continuity in care (Richardson et al., 2015). Therefore, 
increased uncertainty and its impact in CUP may make coping particularly challenging 
(Hyphantis et al, 2013). A small number of published qualitative studies (Boyland & Davis, 
2008; Isida, et al., 2016; Richardson et al.) support this, however, these studies have included 
predominantly individuals in the early stages following diagnosis which has been shown to 
be a time of high uncertainty across cancer patient populations (Worster & Holmes, 2008) 
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and for many people with CUP life expectancy may be limited. No research has been 
conducted which investigates the experiences of individuals living longer beyond CUP 
diagnosis.  
Coping 
Coping has been conceptualised in numerous ways. Lazarus and Folkman’s (1984) 
definition of coping as “constantly changing cognitive and behavioural efforts to manage 
external and/or internal demands that are appraised as taxing or exceeding the resources of 
the person” has been widely accepted and applied. Based on this, Folkman and Lazarus 
(1980; 1985; Lazarus & Folkman, 1984) proposed, in line with their transactional model of 
stress and coping (TMSC), that coping can be separated into two categories: emotion-focused 
coping which relates to attempts to alter emotions through strategies such as re-appraisal; and 
problem-focused coping which pertains to attempts to change external factors via strategies 
such as problem-solving (Roesch et al., 2005). A further dimension to coping is direction of 
focus. Strategies directed towards a threat are described as ‘approach coping’ (e.g. problem-
solving) and strategies directed away from a threat are labelled as ‘avoidance coping’ (e.g. 
distraction) (Moos & Schaefer, 1993). Corresponding conceptualisations of these phenomena 
in the literature include repression and sensitization (Byrne, 1964) and monitoring and 
blunting (Miller, 1987).  
Coping with Cancer 
Previous research has demonstrated that various coping strategies are used by people 
with cancer (Nipp et al., 2016). Both emotion-focused and problem-focused approach coping 
have been linked to improved psychological and physical wellbeing (Roesch et al., 2005). 
Avoidance coping, conversely, has been associated with elevated distress and poorer physical 
functioning (Roesch et al.). However, it has been suggested that avoidance coping may 
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facilitate short-term management of illness-related stress (Vos & Haes, 2007) and allow those 
with terminal illness to make the most of their time (van Laarhoven, 2012).  
Uncertainty amongst cancer patients has been demonstrated to be negatively 
correlated with coping (Germino et al., 1998). Difficulty coping with uncertainty has been 
identified amongst patients with advanced cancers (Kimbell, Murray, Macpherson & Boyd, 
2016). According to Mishel’s uncertainty in illness theory (UIT, 1988), appraisal of 
uncertainty as ‘danger’ or ‘opportunity’ leads to different styles of coping. The use of 
emotion-focused coping strategies in response to ‘danger’ appraisals, has been found to 
mediate between fear of uncertainty and distress during and after cancer treatment (Taha, 
Matheson & Anisman, 2012).  
Study Rationale 
The experience of uncertainty has been identified as a challenge to coping across 
different cancer patient populations. This is a particular issue for individuals with CUP which 
is associated with greater uncertainty than other cancers. Given the negative correlational 
relationship between uncertainty and implementation of coping strategies, this may make it 
harder for this patient group to effectively cope. Therefore, research investigating how 
individuals with CUP cope is warranted.   
Existing qualitative research has focused predominantly on CUP patients soon after 
diagnosis, possibly due to often-limited life expectancy. However, a subgroup of CUP 
patients is medically stable at six months (the median life expectancy in this population) and 
beyond diagnosis. This group of patients have had a prolonged period of coping with the 
uncertainties of CUP and potential related distress; however, no research has focused on this 
population who are living ‘longer-term’ with CUP. Research addressing this gap in the 
literature is necessary to inform clinical practice around how this population can be 
supported. 
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Aim 
The aim of the study was to explore the experiences of individuals coping longer-term 
with CUP. It was hoped that this knowledge would indicate how individuals perceived their 
capacity to cope, what factors influenced this, and what coping strategies were used.  
            Research questions. 
What are the coping experiences of people who are living longer-term with CUP? 
• How do these patients perceive their ability to cope? 
• What influences perceptions of coping? 
• What are patients’ experiences of coping over time? 
Method  
The study protocol was registered with The National Cancer Research Institute. 
Where applicable, recommendations on the standards for reporting qualitative research 
(O'Brien, Harris, Beckman, Reed, & Cook, 2014) were followed to enhance transparency and 
inform interpretation of findings. Ethical approval was granted by the Health Research 
Authority (HRA). The ethics application and associated documents are presented in Section 
Four.  
Approach 
The approach was informed by the research questions and the underlying ontological 
and epistemological assumptions made therein. A relativist ontological position and 
interpretative epistemological paradigm guided the research process. The aims of the study 
and research questions assume that we can come to understand the reality of living longer-
term with CUP through individuals’ lived experiences. Therefore, interpretative 
phenomenological analysis was selected due to the approach’s centralised focus upon the 
meaning derived from individuals’ experiences of a particular phenomenon. IPA is 
characterised as an inductive, idiographic approach embedded within the interpretivist 
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tradition (Tuffour, 2017). Distinct from other modes of qualitative analysis, IPA prioritises 
the ‘fine-grained’, detailed analysis of each individual account, the language used to convey 
the individual’s subjective reality, and the ‘psychological entailments’ therein (Murray & 
Wilde, 2020). Particular attention is given to the way in common themes “play out for 
individuals” (Smith, 2011, p.10). The analytic steps outlined by Smith and Osborn (2008) 
were followed to enhance consistency and replicability (Noble & Smith 2015). The explicit 
recognition of the researcher’s role in the interpretation of data is seen to be a strength of 
IPA. Thus, while the researcher may not always be consciously aware of biases, the approach 
emphasises reflexivity and openness in relation to the potential for researcher bias to 
influence results (Malim, Birch, & Wadeley, 1992).  
Sample 
A purposive sampling strategy was used to identify eligible participants. Ten 
participants were recruited from four NHS Trusts in the North West of England. A sample of 
this size is recommended by Smith, Flowers, and Larkin (2009) for professional doctorate 
research and publication. A further two eligible patients were identified by clinical staff but 
did not consent to be contacted by the researcher. All patients that agreed to be contacted by 
the researcher consented to participate. These 12 CUP patients represented all eligible 
candidates for the study within the six recruiting NHS Trusts during the recruitment window 
(two Trusts did not have any patients meeting inclusion criteria). The response rate for the 
study is therefore 83.3%.  
Inclusion and exclusion criteria. 
Participants were eligible for inclusion if: they had been diagnosed with CUP for six 
months or longer; they were deemed to be clinically stable by their medical team; they were 
aged 18 or over; and they were able to provide informed consent. Participants were excluded 
if: they were acutely unwell; they did not speak English; they were under 18 years of age; or 
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they lacked capacity to provide consent to participate. Smith and Osborn (2008) posit that the 
sample for IPA should be homogeneous. Therefore, the inclusion and exclusion criteria 
aimed to ensure participants had comparable experiences.  
Sample characteristics. 
Sample characteristics are presented in Table 2-A (p.2-41). The sample had a mean 
age of 72.3 years (median= 75 years), ranging from 58 to 77 years. An equal number of males 
and females were recruited, and all participants identified as white British. Time from CUP 
diagnosis ranged from six months to five years and seven months with a mean of 23.9 months 
(median=16 months). All participants had a histologically confirmed diagnosis of CUP and 
none of them were from favourable risk subsets of CUP. Four participants had nodal disease 
only while the other six patients had visceral metastases. Understandably, there was a longer 
time from diagnosis in patients without visceral metastases. All participants reported 
receiving some treatment (e.g. surgery, radiotherapy, and/or chemotherapy) since diagnosis.   
TABLE 2-A HERE 
Procedure 
 Research materials were developed in consultation with a service user group from a 
participating NHS Trust, as recommended by the HRA (2018). Two changes to the consent 
form were made based on service-users’ feedback. Firstly, the window of time given for 
participants to withdraw their data from the study following participation was extended from 
one week to two to allow more time for consideration. Secondly, the word ‘anonymously’ 
was replaced with ‘without my details’ to promote ease of understanding. The service user 
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Data collection. 
Potential participants were identified by members of their medical team and informed 
consent was sought prior to data collection. Participants were given the choice of meeting in 
their own homes or at their local hospital site. Data was collected from July to September 
2019 via audio-recorded semi-structured interviews. Interviews lasted between 27 and 101 
minutes (mean=49 minutes). Questions for the interview schedule (Appendix 2-A, p.2-43) 
were informed by the research questions and guidance from Smith and Osborn (2008). Semi-
structured interviews are deemed the ‘exemplary’ method for IPA and are widely used in 
phenomenological research (Brinkmann, 2014; Smith and Osborn, 2008). 
Analysis 
The analytic strategy followed the recommendations of Smith and Osborn (2008). 
This involved each interview being transcribed verbatim then read independently several 
times to generate initial themes which were noted in the margins. Related initial themes were 
then organised into clusters. The clusters of themes from the first case were used to orient the 
analysis of subsequent transcripts. This process was repeated for each transcript, with 
convergences and divergences attended to. Themes from across the transcripts were 
synthesised and organised hierarchically to produce ‘superordinate’ and associated 
‘subordinate’ themes. Initial annotation and coding were done manually. Microsoft Excel was 
used to organise exemplar quotations by theme. Examples of each stage of the theme 
development process are presented in Appendix 2-B (p.2-44).  
To maintain an awareness of researcher biases, a reflective journal was kept 
throughout the research process, excerpts from which are documented in Appendix 2-C (p.2-
51). Content from the journal was discussed in monthly research supervision. A reflexive 
statement acknowledging these biases has been included within Section Three.  
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Results 
Three superordinate themes were identified: (1) ‘“Fuss and Bother”: The Upheaval of 
Everyday Life’, with subordinate themes of ‘Appointment threats’, and ‘Symptoms and side-
effects’; (2) ‘“It’s the Unknowing”: The Enduring Uncertainty of CUP’, with subordinate 
themes of  ‘“What the bloody hell’s that?!”’, ‘An uncertain future’, and ‘Hope’; and (3) 
‘“Just Get on With It”: Managing and Moving Forwards’, with subordinate themes of 
‘Maintaining normality’, ‘Acceptance’, and ‘Support’.  Themes are presented 
diagrammatically in Figure 2-A (p.2-42). A table in Appendix 2-D (p.2-53) indicates which 
themes were present in which participants’ accounts.  
FIGURE 2-A HERE 
“Fuss and Bother”: The Upheaval of Everyday Life 
 The description of CUP as a disruptive presence in participants’ lives was present to 
varying degrees across the sample. Participants shared a narrative that the practical and 
mental time and attention demanded by CUP (for example, for attending appointments or 
ruminating upon concerns) led to difficulty engaging with valued activities. This was framed 
in the accounts as a significant threat to participants’ subjective sense of coping, as captured 
in this extract from Sarah:  
All my normal activities just stopped […] Fourteen months of…not easy 
examinations and all very upsetting knowing that […] there’s nothing that can be 
done […] I don’t know that I have actually coped. I haven’t had time to cope. I’ve just 
been busy [laughs] you know? Look at the calendar, what’s next? […] How do we fit 
that in? Is it possible to go away? No! […] I don’t feel I’ve dealt with it, [laughs] 
haven’t made…any decision…I’ve just gone along with everything…I’ve been told 
“you’ve got an appointment”, a PET scan here, or a CAT scan, or MRI scan…it’s 
gone on and on.  
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Sarah’s sense of not having coped seems underpinned by feelings of passivity and 
powerlessness in relation to CUP itself and associated medical procedures. Her impression 
that she had not been coping reflects an underlying assumption that coping is an active 
process, involving the deliberate employment of strategies. Sarah’s account suggests that the 
unremitting nature of her medical care, which feels outside of her control, has drained her of 
the internal resources to activate a conscious coping response.  
 Appointment threats. 
 Appointments were perceived to entail multiple threats including burden on time, 
anxiety, and loss of control. Graham’s comment, “I’m sick of going to the doctor’s, I seemed 
to be living there at one time,” demonstrates his frustration caused by the frequency of 
appointments and interruption they cause to his life.  
The threatening nature of appointments for many participants also related to 
anticipatory anxiety: 
I think the worst times for you, every three months you have your scan and then the 
week when you’re going for your results, your head starts going […] Mentally 
sometimes it screws you up a bit […] It’s like, I don’t know…an axe hanging over 
your head every three months (David).  
David’s comments indicate the increase in anxiety associated with appointments relates to the 
potential for ‘bad news’ and increased awareness of his own mortality.  
Despite the identified threats associated with appointments, all participants reported 
compliance with their medical regimes. This may reflect a perspective amongst patients that 
appointments are obligatory, and not something they have active choice over, leading to the 
subjective loss of control. Moreover, continued willingness to attend appointments despite 
identified threats may suggest that the threat of not attending, and potential repercussions of 
having less information about their CUP status, is perceived as more threatening. Thus, 
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patients choose the least aversive option, with the information provided in consultations, 
despite threatening aspects, seen as more tolerable than not knowing.   
Symptoms and side-effects. 
 Where participants were experiencing CUP-related symptoms or side-effects from 
prior treatment, these were described as aversive and disruptive of day-to-day activities. The 
below extract from Emily offers an example of this:  
I don’t think I’m going to be 100% ever again. I would like to feel that I could feel a 
little bit better than I am. I’m normally quite an energetic person […] and I find I 
can’t even peel potatoes […] I can’t even go and walk the dog...I’ve been so athletic 
all my life, so this is a great big sort of come down. 
As Emily describes the functional limitations she faces, these are interpreted in relation to 
their impact upon valued aspects of her identity. This suggests that not only has activity, and 
its adaptive coping function, been impacted by CUP, but consequently Emily’s sense of 
herself more globally. Her description of a ‘come down’ may also reflect feelings of grief 
associated with experiencing multiple, cumulative losses.  
“It’s the Unknowing”: The Enduring Uncertainty of CUP 
The uncertainty associated with CUP was recognised by participants as non-
conducive to coping. As summarised by Sarah; “anybody can cope with anything if they 
know what’s going on and why they’re doing it.” For patients with CUP, these ‘what’ and 
‘why’ conditions of knowledge for coping are unobtainable, leading to a collective sense of 
CUP being confusing, unpredictable, and thus inherently threatening. Ruth shared her 
experience: “Well you see, I don’t understand really, because I was told it might never appear 
[…].I examine myself [laughs], and I can’t see anything[...] It is very perplexing, and I still 
find it difficult to believe.” Ruth’s bewilderment, as for other participants, stems from her 
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perceived lack of understanding of CUP and an absence of evidence which inhibit her ability 
to process her experiences.  
 “What the bloody hell’s that?!” 
Numerous factors were found to influence participants’ sense of CUP being unusual 
or strange. Central to this in several accounts was the fact that prior to diagnosis participants 
had not heard of CUP. Emily’s comment exemplifies this: “this was a medical title I’d not 
heard of before, and I had assumed something could be done up to this point.” For Emily, as 
with others, a lack of prior awareness of CUP seemed to exacerbate uncertainty due to an 
absence of transferrable expectations. 
Several participants remarked on their understanding of CUP’s course as different to 
the usual trajectory of other cancers: “I’ve had two cancers but I’ve just followed a normal 
trail of […] treatments and…and expected to get better and I have done […] This is… really 
weird,…it’s not at all what one expects” (Sarah). Sarah’s experience suggests that living with 
CUP for her has been qualitatively different to her other experiences of cancer. Other 
participants, who had not previously had another form of cancer, also remarked on their sense 
that living with CUP was different to living with other cancers due to its unknowability.  
 An uncertain future. 
 Participants described the uncertainty associated with how CUP might progress to be 
one of the most challenging aspects of their experience, as conveyed by Paula:  
Well, it is a big mystery really isn’t it! [laughs] […] I think a good grasp of it now but 
it’s just the thoughts that it can be popping up anywhere […] it’s difficult to live with 
sometimes.  
Paula’s account demonstrates that despite having come to understand the pathological 
mechanisms of CUP, a sense of threat in relation to the unpredictable course of the disease 
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persists. This fear of cancer ‘popping up’ in other sites was prevalent across participant 
accounts and was linked to anxieties about the possibility of increased physical symptoms.  
A proportion of participants also reported that these fears had led to hyper-vigilance 
towards potential signs of illness progression and interpretation of possibly benign or 
unrelated experiences as highly threatening. Stephen shared a recent example of this: “the 
only thing that I think of at the moment is this hiccup business, you know, and, wonder 
whether there’s something happening here that’s…shouldn’t be.”  
 Hope. 
 Several participants described their interpretation of CUP’s uncertainties as 
opportunity to hope for an extended period of wellness or recovery. Chris expressed his 
hopes for further investigations: “It would be nice actually if they did another biopsy, and this 
is what frustrates me …because if […] they look, they might say ‘ooh it’s not there, the 
cancer’s gone!’” In some instances, these expressions of hope were in the context of a period 
of relatively symptom-free stability. For others these interpretations existed in a context of 
progressive metastases, indicating possibly a false hope facilitated by denial, particularly if 
hopes were in relation to a cure being identified. In both scenarios, however, these hopeful 
interpretations seemed to serve to reduce distress.  
“Just Get on With It”: Managing and Moving Forwards  
 A pervasive theme across participants’ accounts was that being able to carry on as 
much as possible with ordinary life was the most significant factor in feeling able to cope. 
While the ability and confidence to do this varied in relation to the context of appointments 
and symptoms, participants shared a perspective that ‘getting on’ with life served as a proxy 
measure for effective coping. An extract from David demonstrates this: 
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Just get on with it, don’t you? What option have I got? I haven’t got an option really, 
have I? I mean I could sit there and be miserable as sin, and that’s not going to help 
me is it? You know, you’ve got to pick yourself up 
In this comment, David seems to suggest a polarised conceptualisation of ‘getting on’ as 
coping versus negative emotions and inactivity which represent inability to cope. To ‘not 
cope’ is not seen as a viable choice. Conscious efforts are made to avoid inactivity and 
difficult emotions which could influence coping perceptions.   
 Maintaining normality. 
Central to the conceptualisation of ‘getting on’, participants conveyed that 
maintaining a subjective continuation of their pre-CUP normality was highly valued:  
I just carry on, don’t I? And that’s it. I love my garden, I’ve always said that 
gardening is good therapy […] people mustn’t let it get hold of them, right? Or let it 
take control of their life, basically. With some people it does, they can lock 
themselves away, they can do that, and lock themselves away up here [gestures to 
head] as well, you know? Just carry on, try to carry on as per normal, and always do 
the things you love doing (Peter).  
Peter’s description suggests that continuing to engage with everyday aspects of life enable a 
sense of control and protects against introspective withdrawal which is perceived as 
maladaptive.  
For a number of participants, ability to maintain normality was bolstered by an 
absence of physical symptoms or perceptions of themselves as ‘ill.’ This is exemplified in 
Stephen’s comment: “I never felt unwell.” For participants experiencing more physical 
symptoms, a process of adaptation was described. Sarah, for example, reported focusing on 
“everyday activities that don’t require a lot of energy,” to facilitate a continued sense of 
normalcy.  
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 The construction of a subjective continued normality also served the function of 
allowing participants to maintain a coherent sense of identity and remain connected to valued 
aspects of themselves, as demonstrated in a comment from Jean, “I’ve always been an active 
person and that so I just, you know, get on with it”. This extract demonstrates that personality 
constructs such as being ‘active’ may be perceived as fixed, despite possible challenges or 
threats posed by CUP, and this may enhance perceived coping capacity and activation of 
coping skills.   
 Another important aspect of maintaining pre-CUP normality for participants was the 
potential for their usual activities to offer distraction:  
I play guitar as well so that helps […] It’s the distraction. I mean, if you’re thinking 
about something else…alright we are capable of thinking about two things at once, 
but I’m a bit mono like that [laughs]. I would say once I’ve got my sights set on 
something, I research it and look at it and think about it and nothing else comes in 
(Graham).  
Graham description highlights the potential for valued activities to offer an alternative 
attentional focus, preventing pre-occupation with CUP which could activate a threat-response 
and appraisals of being less able to cope.  
 Acceptance.  
 Most participants voiced that having had a period of six months or longer since 
diagnosis had enabled them to foster a sense of acceptance in relation to CUP after the initial 
shock of diagnosis, as articulated by Peter: 
I try and accept things, you know what I mean, I don’t dwell on anything like that, 
I’ve kind of accepted it and did what we could do about it, to better it. They told me it 
was terminal and well basically there’s no cure for it, but they can keep it […] 
harnessed a little bit. 
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This statement from Peter reflects that acceptance is effortful, something that Peter is striving 
towards, with a view that being able to accept the realities of CUP will be adaptive and 
beneficial. There is also an element of conflict between ‘true’ acceptance and the desire to 
push away aversive thoughts seen as ‘dwelling.’  
 A number of participants shared a view that accepting CUP had become easier with 
time:  
It took a couple of years to get myself back up […]At first it was…always the first 
thought was “oh, will I be ok next week?” And now I can just put it to the back of my 
head and…forget about it […] time heals, and yeah, I certainly feel that I’ve 
overcome it (Jean). 
Several participants also expressed a belief that their age helped them to accept CUP. 
Accordingly, participants expressed a sense of gratitude: “I’m 76, it’s ok, I’ve made it, I’ve 
got here…I can be comfortable, so I’m very lucky” (Sarah). Additionally, participants 
reported that having come to accept CUP had also enabled them to adjust their priorities to 
‘make the most’ of their lives: “Little trivial things that are normal life that worry you are not 
really important, are they? You know, when you think what could happen to me. Yeah, so it 
puts a different perspective on things” (David).  
 Support. 
External support was identified as a coping resource by the majority of participants. 
Paula shared the important impact of supportive personal relationships for her: “I get good 
support as I say from my family… and friends you know, they boost you on, you know.” 
Participants reported varying levels of engagement with professional support. For some 
participants, the knowledge that they could approach their specialist nurse or providers like 
Macmillan if required, was felt to be reassuring enough for their current needs: “I know 
they’re there” (Jean). Other participants had accessed additional support from their specialist 
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nurses: “she’s made everything easy,” (Sarah) or the third sector or local hospices: “[The 
hospice] have really, really been very, very helpful” (Emily).  
Discussion 
The themes from the study elucidate experiences of coping amongst people living 
longer-term with CUP and the mechanisms of coping-related processes. The findings are 
discussed within the context of relevant literature and coping theory.  
“Fuss and Bother”: The Upheaval of Everyday Life  
 Experiences appraised as life-disruptive “fuss and bother” have been previously 
highlighted within the broader cancer patient population. Of the multiple threats associated 
with appointments, the burden upon patients’ time was perceived as a significant barrier to 
engagement with valued activity and employment of behavioural coping strategies. This 
finding is supported by research by Lövgren, Tishelman, and Hamberg (2010) who suggested 
there is a discordance between ‘clock time’ in the healthcare system and ‘embodied time’ of 
cancer patients with limited life expectancy. This was proposed to produce a misalignment of 
priorities between clinicians and patients regarding how patients’ time should be spent. 
Findings such as these have been emphasised by the ‘Last 1000 Days’ NHS Improvement 
initiative which highlights the value of patient time for those in the final 1000 days of their 
lives, as many CUP patients are likely to be (Dolan & Holt, 2017; NHS Improvement, 2016). 
This is of particular relevance for patients with CUP due to the significant amount of time 
already required for diagnostic procedures (Boyland & Davis, 2008).  
 Anxiety in relation to routine appointments was described as a challenge to coping. 
This finding is supported by a study by Sandeman and Wells (2011) which identified 
anticipatory anxiety prior to appointments to be a recurring challenge for lung cancer 
patients. As with the sample of this study, however, anxiety did not prevent attendance. 
Accordingly, this was suggested by Sandeman and Wells to be due to the potential for 
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reassurance from medical consultations to relieve more general cancer-related anxieties. As 
experiences in CUP have been previously suggested to be amplified in comparison with the 
broader cancer population (Richardson et al., 2015), it is possible that anticipatory anxiety 
before appointments is exacerbated for CUP patients due to the perceived volatility of their 
condition.  
 Perceived loss of control was a further characteristic of the “fuss and bother” of CUP, 
with some patients describing a passive role in their medical care and a sense of CUP-related 
events as uncontrollable. In other cancer patient populations, reduced perceived control has 
been linked with diminished adjustment to illness and greater levels of anxiety and 
depression (Naus, Price & Peter, 2005).  
 The appraisal of threat and disruption to daily life associated with physical symptoms 
was considerable for a proportion of participants. This is consistent with prior findings that 
physical symptoms persist for many individuals after completion of cancer treatment 
(Harrington, Hansen, Moskowitz, Todd, & Feuerstein, 2010) and have a substantial impact 
upon quality of life, psychological wellbeing, and functioning (Polanski, Jankowska-
Polanska, Rosinczuk, Chabowski, & Szymanska-Chabowska, 2016). So too have physical 
symptoms been documented as a threat to identity (Mathieson & Stam, 1995).  
 “It’s the Unknowing”: The Enduring Uncertainty of CUP 
 The finding that uncertainty remained prevalent amongst participants supports 
existing findings on the psychological aspects of CUP (Boyland & Davis, 2008; Richardson 
et al., 2015). The results of this study, however, provide evidence that this experience persists 
over time, however the appraised level of threat associated with this for many was felt to 
decrease over time as individuals felt more able to accept the uncertainties of their condition.  
 The uncertainty associated with not having heard of CUP and as such not knowing 
what to expect of the illness was described as a source of anxiety. Uncertainty as a 
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consequence of limited information is a common theme for patients with other cancers 
(Shaha, Cox, Talman, & Kelly, 2008), however, is likely to be amplified for patients with 
CUP (Richardson et al., 2015). The experience of ongoing uncertainty was also linked to 
fears about the future, a prevalent concern for the wider cancer patient population.  
Findings indicated that the uncertainty associated with CUP and related threat 
appraisals may be linked to increased vigilance to physical symptoms. While a degree of 
body vigilance is considered adaptive for initiating help-seeking behaviour during illness 
(Winstanley, Renzi, Smith, Wardle, & Whitaker, 2016), research has demonstrated an 
increased prevalence of health anxiety and related hyper-vigilance and misinterpretation of 
bodily experiences amongst cancer survivors (Jones, Hadjistavropoulos, & Gullickson, 
2014). It is possible that this experience is particularly pertinent to patients with CUP given 
an absence of information about the location of the primary cancer, perhaps leading to a 
greater propensity for misinterpretation of benign symptoms.  
 The perceived opportunity for hope in response to uncertainty identified by several 
participants is consistent with Mishel’s (1988) UIT. McClement and Cochinov (2008) have 
proposed that perceiving hope in uncertainty may be viewed as an active coping strategy. 
Findings suggested that hope for desired outcomes can enable participants to cope even 
where these hopes seem to be unlikely, suggesting that for participants with more advanced 
illness hope may be facilitated by a process of denial. Differing perspectives exist regarding 
the adaptiveness of denial in illness (Vos & Haes, 2007), however, evidence suggests, in line 
with the study findings and the propositions of Horowitz (1983), that it may offer a protective 
function in the face of distressing information, reducing perceived threat and enabling coping.  
 “Just Get on With It”: Managing and Moving Forwards 
 The theme of ‘“Just Get on With It”: Managing and Moving Forwards’ captured 
processes which enable coping. As documented in previous research with patients with 
2-22 
COPING LONGER-TERM WITH CUP 
 
advanced cancer, participants relied predominantly upon strategies to influence and manage 
their emotional responses to their CUP-related experiences, rather than problem-focused 
strategies (Thomsen, Rydahl‐Hansen, & Wagner 2010).   
 All participants described the perceived maintenance of their pre-CUP normality, or 
attempts to live as closely to this as possible, as a significant aspect of coping. Continued 
participation in valued activities was central to this, providing opportunity to sustain a 
coherent sense of self and distraction from threatening stimuli and appraisals. Unsurprisingly, 
maintenance of activity and confidence to do so have been widely recognised as important 
aspects of coping with cancer (Thomsen et al. 2010). While much of the existing literature 
suggests that avoidance coping leads to negative outcomes for cancer patients (Roesch et al., 
2005), the findings of this study indicate that cognitive avoidance via distraction is an 
adaptive, self-preserving strategy. Therefore, ‘blunting’ (Miller, 1987) strategies may have 
beneficial effects for individuals with CUP, as demonstrated in other patients with terminal 
cancer (Block, 2006). 
 The findings suggested that people living longer-term with CUP increasingly accept 
their condition and associated challenges over time. This experience, however, was neither 
universal nor static, with many participants describing conflictual positions of accepting some 
aspects of their reality and whilst rejecting or denying others. This suggests that acceptance 
for those living longer-term with CUP is an ongoing dynamic process rather than an acquired 
state. Definitions of illness acceptance commonly include references to ‘making peace’ with 
the realities of one’s situation and “willingness to be present with one's illness-related 
thoughts, feelings, and bodily sensations without judging or making unnecessary attempts to 
control them” (Secinti, Tometich, Johns, & Mosher, 2019, p.28). Acceptance has been 
framed as an adaptive cognitive coping strategy linked to lower distress and positive growth 
(Bussell and Naus, 2010). The potential link between acceptance and positive growth is 
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suggested in the findings of this study where participants reported new perspectives and 
priorities since diagnosis. The reflection from participants that older age makes accepting the 
realities of CUP easier is consistent with prior findings linking older age and acceptance of 
cancer (Politi, Enright, & Weihs, 2007).  
 Finally, participants widely attributed their ability to cope to external support, both 
from personal relationships and healthcare professionals. This is consistent with the 
systematic review by Thomsen et al. (2010) which indicated that social support provides a 
“sense of safety or inner strength” (p.3412). The importance of social support as a coping 
resource is also theorised by Schaefer and Moos (1998). 
Theoretical Implications  
The findings are compatible with both Lazarus and Folkman’s TMSC (1984) and 
Mishel’s UIT (1988). A diagrammatic model and accompanying explanation are presented in 
Appendix 2-E (p.2-54), synthesising the research outcomes with these two theoretical 
frameworks to elucidate the mechanisms of the coping process for people living longer-term 
with CUP.  
While the findings correspond in many ways with the propositions of UIT and TMSC, 
these models are unable to account in totality for the experiences of participants. Sarah’s 
comment, “I don’t know that I have actually coped. I haven’t had time to cope” captures the 
possibility that for some people living with CUP, coping may not be a significantly relevant 
or salient aspect of their experience. There are several possible explanations for this. Firstly, 
neither model was been developed with CUP patients or even cancer patients more generally. 
Rather, both models have developed through wide application across both acute and chronic 
presentations of illness, the breadth of which entail such a range of differing experiences that 
to distil the coping process to a single theoretical model will inevitably be flawed and miss 
aspects of individuals’ nuanced realities. Secondly, lay applications of the term ‘coping’ often 
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mistakenly frame coping as an outcome, rather than a process as per Lazarus and Folkman’s 
proposals. There can therefore be confusion caused by perceptions that coping is the act of 
mastering stressful situations, rather than managing or enduring to varying degrees 
throughout them. Corr and Doka (2001) discuss that for this reason referring to ‘adaptive 
strategies’ rather than coping may be helpful, although this terminology is also fraught with 
room for misinterpretation and false emphasis upon the obtainment of an 
adjusted/adapted/coping state of being. Thirdly, it may be that the emphasis upon coping or 
adjustment in illness, which have been a prevalent paradigm on dying within psychological 
and social work studies, overlooks other aspects of the end of life experience which may hold 
relevance for people with CUP. Nakashima (2003) has argued that the emphasis upon these 
concepts is the product of western socially constructed attitudes to death and dying as a 
struggle that must be mastered. This narrow view omits experiences such as emotional 
healing and spiritual growth that people may experience at the end of life. 
Answering the Research Questions 
What are the coping experiences of people who are living longer-term with CUP? 
 The findings of this study signify that coping for people living longer-term with CUP 
is a dynamic and multifactorial process. The identified themes and relationships between 
them correspond with existing coping theory (Lazarus & Folkman, 1984; Mishel, 1988), 
highlighting the centrality of the appraisal process in patient’s ability to manage and respond 
to stress associated with CUP. As outlined above, the experiences of coping for patients with 
CUP seems to be similar in many ways to those of comparable cancer patient populations. 
However, the research highlights several areas where it is possible that patients living longer-
term with CUP may face particular challenges to coping. These include: the acute sense of 
threat associated with loss of control and perceived passivity in relation to medical regimes; 
and a high volume of medical appointments; as well as the sustained uncertainty associated 
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with having a previously unheard-of illness, and therefore limited established knowledge and 
expectation, which follows an unpredictable trajectory.  
How do these patients perceive their ability to cope? 
 Most participants expressed a consensus that at the point of participation they did feel 
able to cope. This experience was not, however, static or universal, with participants 
describing times where they were more pre-occupied and distressed by CUP. Patients who 
identified with being less able to cope expressed their sense of CUP-related stress leaving 
them with insufficient resources (both internal and external) to initiate an active coping 
response.  
What influences perceptions of coping?  
Reduced perceived coping capacity was found to occur as a result of threat-appraisals 
regarding fluctuating “fuss and bother” associated with physical symptoms and appointments, 
as well as ongoing uncertainty. Identified coping strategies were acceptance, avoidance and 
distraction, hope, and support from others. 
What are patients’ experiences of coping over time?  
The findings of the study demonstrate that generally the sense of threat associated 
with CUP reduces over time, although this fluctuates in relation to current CUP-related life-
disruptive phenomena. Patients used a mixture of coping styles, using avoidant strategies to 
manage distressing stimuli, but feeling increasingly able to accept the realities of their 
circumstances over time.     
Clinical Implications and Recommendations 
 The research findings highlight several points relevant to clinical practice in CUP 
services. Firstly, clinicians should be mindful of the factors that CUP patients perceive as 
most threatening to minimise patients’ negative experiences associated with these. In line 
with the ‘last 1000 days’ initiative (Dolan & Holt, 2017; NHS Improvement, 2016), patient 
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time should be prioritised to decrease the perceived disruption caused by frequent 
appointments where possible. This may be achieved by considering patients’ opinions about 
how their time is best spent, reducing appointment frequency where possible, and minimising 
patient travel. Greater availability of phone or skype consultation for routine reviews where 
physical examinations or discussions regarding results of investigations are not required may 
be one way to facilitate this. Also, investigations should be guided by symptoms, as frequent 
scans and other investigations are unlikely to impact on patients’ outcomes (Fizazi et al., 
2015). Individualized approaches to frequency of consultations should be preferred. 
Secondly, given the increased potential for CUP patients to experience a subjective loss of 
control in relation to their medical input, discussion of patient preferences and collaborative 
decision making is paramount. Thirdly, focusing on optimal symptom management with 
appropriate access to palliative care services is essential for this patient group, for many of 
whom physical symptoms have a significant impact upon daily functioning. Fourthly, while 
uncertainty is an inherent aspect of CUP, provision of adequate information to patients may 
be important to alleviate this where possible. Especially important may be providing space 
for patient questions and information giving in routine appointments and signposting to 
relevant resources such as the CUP foundation and Macmillan’s ‘Understanding Cancer of 
Unknown Primary’ booklet (2014) which may help patients to gain an understanding of CUP 
and realise that they are not alone with this ‘unusual’ condition. Of course, based on the 
findings that patients cope via a mixture of approach and avoidant strategies, it is crucial that 
clinicians explore with patients what support or information they feel they need and can 
manage with at any time as this is likely to fluctuate throughout the patient journey. 
Information in relation to expected physical symptoms may be particularly important given 
the potential for CUP patients to be particularly sensitised to symptom experiences and 
possible misinterpretation of these. Finally, given the importance of support for coping, 
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health care professionals should be particularly aware of patients who have a less robust 
network of social and family support, who may require additional professional support to 
enable coping responses.  
 Psychological interventions aimed at supporting patients with CUP to cope with their 
illness experiences should focus upon strategies of both avoidance and acceptance, and 
achieving a balance between these processes in the context of current illness-related threats. 
While in many ways, the psychological needs of the CUP patients may be similar those of 
other patients with advanced cancers, results indicate that CUP patients view their condition 
as ‘unusual’. As such, group psychological and supportive interventions aimed at all cancer 
patients may be less appropriate for CUP patients given the potential for them to feel 
‘different’ to other participants. Clinical psychologists working in oncology settings may 
have a particular role in providing training and consultation to medical staff working with 
CUP patients to enable all professionals working in CUP services to better understand the 
coping challenges faced by CUP patients and how patients can be best supported.  
Recommendations for Future Research 
 Findings have highlighted areas where further research would be valuable. Support 
from others was highlighted as a significant factor in enabling coping. Future studies should 
explore the experiences of professionals and carers supporting individuals with CUP and how 
they cope with the uncertainties faced by those they care for. The potential for 
misinterpretation of physical symptoms amongst CUP patients was also identified. Research 
exploring this further or assessing the prevalence of health anxiety in patients with CUP 
versus other cancers may help to increase understanding of this phenomenon, although it is 
recognised that the heterogeneous and unpredictable patterns of metastases in CUP may 
present a challenge to this. While results demonstrate that patients living longer-term with 
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CUP feel more able to cope than immediately post-diagnosis, longitudinal research would 
elucidate patients’ experiences over time.  
Limitations 
 The findings of this study are subject to several limitations. Firstly, IPA methodology 
requires the recruitment of a homogeneous sample; while every effort was made to meet this 
criterion, the included participants diverged on several factors which may have influenced 
findings. The extent of metastases differed across the sample and it is possible that the 
experiences of those with less extensive disease and better response to treatment versus those 
with a more extensive and symptomatic disease may be quite different and lead to different 
experiences of coping. Likewise, the site of metastases may influence these experiences, with 
involvement of the vital organs possibly being perceived as more threatening than 
secondaries in areas of the body (e.g. lymph nodes) which are less likely to impact survival 
(Zabora et al., 2001). Another factor which may have caused participants to have had 
differing experiences was treatment type and recency (Admiraal, Reyners, & 
Hoekstra‐Weebers, 2013). Heterogeneity also presented in relation to time from diagnosis. It 
is possible that those who had longer to adjust to their diagnosis may have reported greater 
perceived coping and acceptance. Additionally, the age range of the sample spanned almost 
20 years across what may be categorised as middle- and older-age. It has been previously 
established that experience of cancer is different for individuals in these different life stages 
(Cimprich, Ronis, & Martinez‐Ramos, 2002).    
 Secondly, as all participants were White British and from the north west of England, 
findings may not reflect the experiences of people from other localities or ethnic 
backgrounds. As the age range of the sample was 58-77 years, findings may not account for 
the experiences of younger or older CUP patients. 
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 Thirdly, the employment of a convenience sampling relied upon participants opting-in 
to the study. While the study had a relatively high response rate (83%), a minority of eligible 
patients did not opt-in. It is possible that those experiencing greatest difficulty with coping 
may have been less likely to volunteer.  
 Finally, while efforts were made to incorporate patient perspectives within the design 
of the research through consultation, it is acknowledged that the scope of this to lead to 
meaningful outcomes may have been limited by the absence of any patients with CUP within 
the consulting group and the stage of the research at which this occurred. Opportunity to 
consult directly with CUP patients at an early stage of the research process could have led to 
greater potential for CUP survivors to orient the research questions to aspects of their 
experience that they view as most important.  
Conclusion 
This study explored the experiences of coping of people living longer-term with CUP. 
Coping was shown to be a dynamic and multifactorial process, with perceived stress and 
coping capacity seen to fluctuate in response to contextual phenomena. The results 
demonstrated that despite being six months or more after diagnosis and clinically stable, CUP 
continued to play a disruptive role in participants lives and to be associated with uncertainty. 
Both of these experiences were appraised as significant stressors, with the potential to elevate 
distress. Despite this, participants reported feeling increasingly able to cope over time since 
diagnosis, which was enabled through employment of emotion-focused strategies of 
avoidance, acceptance, hope, and external support systems. These findings correspond with 
Lazarus and Folkman’s TMSC (1984) and Mishel’s UIT (1988). In many ways, the 
experiences of this population are similar to those of other cancer populations, however, 
patients with CUP may face particular challenges as a result of the uncertainty entailed in 
their condition. Supportive care which takes these factors into account is essential to enable 
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patients living longer-term with CUP to cope with the multiple stressors associated with the 
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Tables and Figures 
Table 2-A: Sample Characteristics 




Site(s) of secondary 
cancer 
77 Female White British 38 Abdominal wall 
72 Female White British 67 Lymph nodes 
58 Male White British 6 Pelvis 
76 Female White British 9 Kidneys, lymph nodes, 
thoracic cavity 
74 Male White British 7 Liver 
67 Male White British 38 Lymph nodes 
77 Male White British 14 Oesophagus 
70 Male White British 18 Lymph nodes 
76 Female White British 15 Ovaries, liver 
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“Fuss and Bother”: 
The Upheaval of 
Everyday Life




“Just Get on with It”:
Managing and Moving 
Forward




“What the Bloody 
Hell’s That”
An Uncertain Future Hope
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Appendices 
Appendix 2-A: Interview Schedule 
Interview scheduve (Version 0.1, created 11/07/2018) 
 
 
• Could you tell me about what things have been like for you since your diagnosis 
of CUP? 
Prompts: response to diagnosis, now 
• What is your understanding of the diagnosis? 
Prompts: Anything not understood/unclear; had you heard of CUP before? 
• On a day-to-day basis, how do you deal with having CUP? 
• Since your diagnosis has there been times when you have felt more or less able to 
cope? 
o Has there been any things which have helped you to cope? 
Prompts: personal qualities and strengths, actions, external resources 
o Have any things made coping more challenging? 
o Are there any things that you think would help you feel more able to 
manage? 
• Has the way you’ve dealt with CUP been similar or different to how you have 
dealt with any other difficult things in your life? 
• Do you think that knowing the primary site of your cancer would make things 
different in any ways? 
Prompts: would anything be easier/more difficult 
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Appendix 2-B: Theme Development 
 Examples of manual transcript analysis. 
Comments Transcript (Sarah, p. 9) Emerging themes 
Impact of treatment on 
appearance/sense of sevf. 
More ‘revaxed’ over time. 
Time wasted/vife and 
goavs on hovd. 
 
Muvtipve investigations- 









CUP seen as ‘different’, 
compared to other 
cancers, unpredictabve. 
 
Comparison to ageing 
process- simivar 
unpredictabivity? Or part 
of normav ageing to 
experience ‘sudden 
ivvness’? 
Injustice/vack of controv. 
P: Erm, and my hair’s grown back more or vess, it’s a bit spikey but it…so I feev…I feev 





P: Fourteen months of…of not…not easy examinations and avv very upsetting knowing 




P: Erm, it’s very draining indeed. And I’ve had to worry about my husband, you know, this 
is not easy for him, we’re not used to his…we’ve never had anything…I…I have…I’ve had 




P: Treatments and…and expected to get better and I have done. This is…is…is reavvy 
weird, it…it’s not at avv what one expects…wouvd expect. I actuavvy made a comment here 
there seems to be a paravvev with surviving an ovd age because in [vaughs] ovd age you 





P: That, erm...but they avv seem to be very recognisabve [vaughs] with…with erm…erm 
treatments that can hevp and support them 
Symptoms and side-effects 
 
Easier with time 
Upheavav of daivy vife 
 
 
Burden on time 



















Loss of controv in CUP 
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Comments Transcript (David, p.3) Emerging themes 
Keeping busy distracted 
as a way of coping. 
 
Fear of time to think? 









Perception of sevf as an 
unusuav case within an 
unusuav ivvness- positivevy 
framed, feeving fortunate.  
Doctors not having the 
answers. 
Hope or deniav? Creation 
of a narrative to make 
sense of things. 
 
 
CUP as strange 
Increased anxiety- fear of 
‘bad news’ versus desire 
to ‘know’ and cvarity of 
treatment pvan 
P: And then I’ve got grandkids, and I have my own caravan but we got another one for 
the kids to use with the grandkids, but I have to tow it wherever it’s going, dump it, and 
come back, you know, then go and pick it up, so I’m avways busy. It’s the onvy way to do 





P: But, I mean, this vast resuvt I onvy had vast Thursday, I think my vast ones were, I think. 
Yeah, when she asked me about seeing you 
 
I: Yeah so it was quite recent 
 
P: And they said to me, normavvy with a cancer of unidentified primary, from what I can 
gather off what she said was, the…the primary appears quite quickvy, after you’ve been 
diagnosed as cancer with unidentified primary. And in my case I’ve gone nearvy two years 
now, so she said that’s good in itsevf, but she said “we don’t quite understand the biovogy 
of it avv” themsevves, so…and I just think “wevv if they can’t find it I haven’t got it, have I?” 






P: I’vv worry about it when I go and they tevv me they’ve found something. Strange reavvy, 
it’s just odd. I mean, I must admit once or twice I’ve been and, vike I say, a coupve of 
nights before your mind starts “are they going to find something?” and I sometimes 
think, “I wish they’d find something” then at veast I’d go and they’d say “right, we’re 






























CUP as unusuav 
Appointment anxiety 
Desire to ‘know’ 
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? Acceptance of the 
unknown aspects of the 
ivvness- no point in asking. 
CUP as ‘strange’. 
 
Making own narrative to 
make sense based on 
avaivabve information- 
Hopefuv interpretation of 











Hope that the treatment 
has ‘cured’ the primary- 




No desire to know more- 
‘good enough’ 
understanding 
P: Yes, so…I never ask questions about it. I never say, “when you say cancer of unknow 
primary, where couvd it be”, sort of thing, or “where does it tend to be?”. Obviousvy, 
because it’s unknown they don’t know. But…no. So…strange 
 
I: Yeah, and that not reavvy asking many questions- is that just because you’ve not reavvy 
wanted to know or? 
 
 
P: No, it’s just because I vook at it that I’ve had the chemo and it’s cveared the other up…it 
must have cveared the other up, you know, the unknown one, because when I have CT 
scans and that they just say it’s avv cvear. But, I suppose it wouvdn’t be cancer of unknown 
primary if they couvd [vaughs] 
 
I: yeah, if it were as simpve as that 
 
P: Yeah, yeah. But it…it does interest me that it’s cavved a cancer of unknown primary, 
and yet it’s probabvy stivv in your body, or it’s not. It’s a difficuvt one, that one, to expvain 
reavvy 
 
I: Yeah, certainvy, and again vooking at the bookvet there, it says something on it about 
coping with uncertainty doesn’t it, which I think is there for any kind of cancer but can be 
more so with Cup sometimes 
 
P: Yeah, as I say, even now with that, that it’s uncertain, I’ve stivv got in my mind that the 
chemo has cveared up the other one so it’s obviousvy gone through my body and 
wherever it was…I did have a vittve thing removed off my face here, a vittve…and that, you 
know…whether that couvd have been it? But they gave me the avv cvear off it afterwards  
 
I: Yeah. But it sounds vike that’s a good enough expvanation to give you a bit of certainty 
about it 
 
P: Yeah, yeah, yeah, that’s about the onvy…you know….yep 
Avoidance of savient information 
Acceptance of the unknown 




























Acceptance of remaining 
uncertainty 
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Examples of clustered ‘emerging themes’ to form superordinate or subordinate 
themes. 









Avoidance of information  
Avoidance of reminders 




Part of normal ageing 
Making the most of remaining time 
Getting used to it 
Easier with time 
Accepting uncertainty 
Making sense 
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  P4p9 I’ve had two cancers but I’ve just 
followed a normal trail of […] 
Treatments and…and expected to get 
better and I have done […] This 
is…is…is really weird, it…it’s not at all 
what one expects…would expect 
 
P5p14: there’s one question…how…it keeps coming 
into my mind all the time…if it’s secondary, it’s 
coming from somewhere, right? It must be cancer of 
somewhere else in the body. Now, how can’t we tell 
in this day and age where it’s coming from? This is 
the big question in my head. 




 P1p11: It’s not advertised like all the 
other cancers, you hear on the news, but 
not CUP- You don’t see any posters up 
in the surgery, there’s nothing, you 
know, but there’s plenty of posters or on 
the screen about cancer but nothing 
about CUP, but I suppose it would have 
opened my eyes a bit 
 
P6p5: Well I just say “look, they found cancer cells, 
they don’t know where they’ve originated from. 
They’ve taken them cancer cells out and I’m still 
here, and there’s no more shown up, so” and that’s the 
easiest way I can explain it […] if you don’t 
understand it, people aren’t going to understand it are 
they? 
  Never heard 
of it 
P1p9: No never, so, erm, that was a 
completely new to me  
P7p5: all I knew was some people had cancer in 
different parts of the body, you know, but I’d no idea 
what a CUP cancer was  
 
  Other’s lack 
of 
understanding 
P4p27 They argue with me, “no, no such 
thing” [laughs] it’s one of the reasons 
why I didn’t want to go back to the art 
groups because I…I don’t want to talk 
about it to anybody […] Erm, they 
won’t believe 
P8p10: the lads I think sometimes, unless they’ve 
seen my appointments, they think ‘you’re pulling my 
leg’, you know, 
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 P4p13 So it’s just lack of information 
about how I’m…how I’m developing 
P2p5: Well, it is a big mystery really isn’t it! [laughs] 
You know, I can’t pinpoint anything I think I’ve got 
a… I’ve got I think a good grasp of it now but it’s just 
the thoughts that it can be popping up anywhere sort 
of thing that’s just, it’s difficult to live with 
sometimes 
 
  Fear of 
decline 
P4p13 pain worries me, I haven’t got 
any at the moment but I don’t know how 
I would react. […] I don’t like feeling 
helpless, I don’t want to feel helpless, I 
don’t want to feel dependant 
P2p13: Yeah it’s very difficult. I know I’ve got two 
tumours and I know they were growing and I know 
that this last lot of chemo has shrunk them down but 
they’re still there and in the past 3 months they could 
have gone up in leaps and bounds for all I know, or 
they could be sitting there still just not progressing, 
hopefully [laughs] 
 
  Interpretation 
of physical 
symptoms 
P8p9: I’ve been alright since. I got a 
lump last Christmas that appeared and I 
thought “oh God, here we go […] So I 
went and had my scan, and I said while 
I’m there, “I’ve got another lump”, she 
said “oh yeah, that’s definitely s lump”, 
and then my results came back, I was 
expecting ‘this is going to be it’, and she 
said, “no, it’s clear”  
P10p4: I just had another scan. I hadn’t…my tum 
hadn’t been right or something…I do have a pretty 
sort of solid tum “but look at it this way, if there’s 
anything wrong, they can do something about it, and 
if everything’s ok, you can go away and you’ll be ok” 
and as it turned out it was ok. There is a little cyst or 
something but nothing too, you know, nothing 
untoward. she just said everything was clear, clear, 
clear. 
 
 Hope  P1p16: I like to think that I am a fighter, 
you know, just hope that it …I put it off 
and you know 
P6p10: take everything when it comes, and cross that 
bridge when it does come. And hope there’s not a big 
toll on it. 
 
  Opportunity 
for longer 
life/cure 
P4p52 another thing is if…if I’ve got rid 
of the primary, why can’t I get rid of the 
secondaries? My husband has stayed 
P5p12: what’s at the back of my mind is this drug that 
I’m on did hold it, did shrink it, so whether it’s got 
next time…that it’s there the same or not, we know it 
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with that idea 
 
can do it 
[…]  if it is coming back, basically, you know raising 
its ugly head again, we know that treatment does 
work […] And there’s a possibility that I go back on 
it. 
 
  Denial P3p35: But it would be nice actually if 
they did another biopsy, and this is what 
frustrates me, they keep 
saying…because if it is another one and 
they look, they might say “ooh it’s not 
there, the cancer’s gone!” 
P5p21: I do not think of an end. It never comes in my 
head about an end. To me there is no end. 
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Appendix 2-C: Reflective Journal Excerpts  
10/06/2019- Pre-data collection 
First two interviews scheduled for Friday. Calls made to participants to arranged- surprised 
when one lady sounded quite sprightly on the phone. I think I have been expecting that 
participants will mainly be really struggling- maybe this won’t be the case. Limited 
knowledge about what ‘clinical stability’ from the medical perspective actually means- 
(speak to xxxxx/xx xxxxxxx [field supervisors] about this).  
Assumptions going in to interview process- that patients will be quite frail/visibly unwell- 
probably based on my ideas of what a ‘typical’ patient with advanced cancer or during 
treatment might look like. This is strange really as patients on placement don’t necessarily 
look this way- influence of stereo-types from media/family. Not having met anybody with 
CUP before- feels a bit mysterious so think I’m expecting the worst- based probably on the 
literature but also attitudes of Medics in CUP network. Likewise, expecting participants will 
probably find talking about their experiences quite difficult/distressing.  
12/07/2019- Reflections After Interview 4 
Participant 4- most distressed so far, seemed that life had been placed of pause for CUP. Felt 
incredibly sad for this lovely lady who clearly has so many ambitions and goals that she 
currently doesn’t feel able to pursue. I think that after the first three this has come as a bit of a 
surprise, although probably more what I expected initially. Focus upon suicide as a ‘way 
out’- some really hard conversations- could really sympathise with her position that it 
probably would be a ‘kinder’ end- has left me thinking and feeling frustrated about UK laws 
around assisted suicide for those that do end up with little quality of life and lots of pain etc. 
Had to contact Anna re. risk concerns, actions carried out to pass concerns on to specialist 
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nurse. Feel conflicted about this- necessity of carrying out professional obligations vs the 
sense that by reducing ‘risk’ it may also reduce this lady’s access to the thing that is 
providing her with a safety net/ability to continue knowing she can remain in control of her 
own destiny.  
27/08/2019- Reflections after Interview 8 
Interview carried out with male participant in own home- genuinely surprised at how well 
this man seems to be managing with his situation- very personable/humorous, laughed easily 
about the uncertainties faced, seemed to have come to a place of accepting how things are. 
helped by? – no symptoms, secondary cancer treated, long period of wellness since treatment, 
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Appendix 2-D: Occurrences of Themes by Participant 
Superordinate theme Subordinate Theme Participants 
“Fuss and Bother”: The 
Upheaval of Everyday Life 
 Sarah, Peter, Ruth, Graham, 
Joanne 
 Multiple threats of 
appointments 
Chris, Sarah, Graham, 
Stephen, David, Ruth, Joanne 
 Symptoms and side-effects Emily, Paula, Chris, Sarah, 
Peter, Graham, Ruth, Joanne 
“It’s the Unknowing”: The 
Enduring Uncertainty of 
CUP 
 All 
 “What the bloody hell’s 
that!?” 
Emily, Sarah, Graham, 
Stephen 
 An uncertain future Emily, Paula, Chris, Sarah, 
Stephen, David, Ruth, Joanne 
 Hope Emily, Chris, Sarah, Peter 
“Just Get on With It”: 
Managing and Moving 
Forwards 
 Emily, Paula, Chris, Graham, 
Stephen, David 
 Maintaining normality All 
 Acceptance Emily, Chris, Sarah, Peter, 
Graham, Stephen, David, 
Ruth, Joanne 
 Support Emily, Paula, Chris, Sarah, 
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Appendix 2-E: Theoretical Synthesis 
Figure 2-E-1. Model of Coping Longer-Term with CUP Based Upon Study Findings and 
Existing Coping Theory 
According to Lazarus and Folkman’s TMSC, the stressor exists within the context of 
personal and situational ‘influencing factors.’ For patients living longer-term with CUP, 
situational factors including time since diagnosis and experiences of diagnosis, treatment, and 
care are likely to have contributed towards patients’ illness experiences. Findings 
demonstrated that support is a significant personal factor with potential to influence the sense 
patients make of their illness in context.  
Lazarus and Folkman theorised that these experiences are subject to two stages of 
appraisal. Findings showed that CUP experiences were initially appraised as both highly 
disruptive of patients’ everyday lives and entailing a high degree of uncertainty. These 
interpretations, in line with the model, were subject to secondary appraisal of the meaning 
these subjective experiences have to the individual. Perceived “fuss and bother” and 
uncertainty were appraised predominantly as threatening or dangerous. However, consistent 
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with Mishel’s UIT (1988), uncertainty was also appraised by some participants at the 
secondary stage as opportunity for more favourable outcomes.  
Secondary appraisals within the TMSC serve to prompt the employment of emotion-
focused and problem-focused coping strategies. Consistent with Thomsen et al.’s (2010) 
review findings, participants relied predominantly upon emotion-focused strategies to reduce 
negative emotional responses. Strategies were compiled under the theme of ‘“Just get on with 
it”: Managing and Moving Forwards’, within which patients described their behavioural and 
cognitive attempts to maintain their pre-CUP sense of self and distract themselves via 
avoidant strategies. These findings also fit with Moos and Schaefer’s (1993) concepts of 
approach and avoidance coping, with acceptance used when participants felt able to orient 
attention towards CUP and distraction used to orient away and protect from the negative 
emotional experiences associated with CUP. The concept of hope was also found to be a 
significant emotion-focused coping strategy. This was suggested to be protective regardless 
of accuracy. Findings suggested that participants drew upon different strategies at different 
times and moved back and forth between approach and avoidance coping to manage with the 
fluctuating threat associated with CUP. Data suggested that as time had passed, patients 
progressively moved towards strategies of acceptance.  
In the final stage of Lazarus and Folkman’s TMSC, coping itself is appraised, along 
with the outcomes of coping efforts forming a ‘transactional’ loop feeding back into primary 
stress appraisals. Accordingly, participants for the most-part expressed a sense of being able 
to employ coping strategies and therefore cope effectively, reducing CUP-associated distress. 
Where patients reported feeling less able to employ active coping strategies, particularly 
behavioural responses, coping was perceived as less effective, potentially creating negative 
appraisals which serve to increase the sense of perceived threat in the re-appraisal process. 
Furthermore, participants described support from personal relationships and the healthcare 
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system as facilitative of increased coping capacity and outcomes, as such this relationship is 
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Appendix 2-F: Target journal author guidelines 
1.1 EuropeanoJournaloofoCanceroCare Author Guidelines 
 
1. SUBMISSION 
2. AIMS AND SCOPE 
3. MANUSCRIPT CATEGORIES AND REQUIREMENTS 
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2. AIMS ANB SCOPE 
The EuropeanoJournaloofoCanceroCare aims to encourage comprehensive, multiprofessional 
cancer care across Europe and internationally. It publishes original research reports, literature 
reviews, commentaries, guest editorials, letters to the Editor and special features on current 
issues affecting the care of cancer patients. The Editor welcomes contributions which result from 
team working or collaboration between different health and social care providers, service users, 
patient groups and the voluntary sector in the areas of: 
 
• Primary, secondary and tertiary care for cancer patients 
• Multidisciplinary and service-user involvement in cancer care 
• Rehabilitation, supportive, palliative and end of life care for cancer patients 
• Policy, service development and healthcare evaluation in cancer care 
• Psychosocial interventions for patients and family members 
• International perspectives on cancer care 
 
The journal provides a forum for multiprofessional and service-user dialogue, and the reporting of 
original research or rigorous reviews within the field of cancer care both in Europe and 
internationally. The journal welcomes original research, reviews and correspondence from 
individuals whose first language is not English, but places great weight in its published papers on 
accuracy, fluency and clarity of expression as befits any journal published for an international 
and multiprofessional audience. 
 
 
3. MANUSCRIPT CATEGORIES ANB REQUIREMENTS 
 
Original Papers 
Original articles, which report on new research findings or conceptual analyses that make a 
significant contribution to knowledge will be considered for publication. 
WORD LIMIT: 4000 word limit, excluding references, figures, and tables). 
ABSTRACT: A structured abstract is required (200 words maximum) under the following sub-
headings: Objective; Methods; Results and Conclusion. The abstract should describe the 
purpose, study population, methodology, setting and details of the variables under study. It 
should also highlight the main results and conclusions of the study. 
MAIN TEXT: Should be structured under the following sub-headings: introduction, methods, 
results, and discussion. 




WORD LIMIT: 5000 
ABSTRACT: A structured abstract is required (200 words maximum) under the following sub-
headings: Introduction, Methods, Results, Conclusion. 
MAIN TEXT: Reviews must contain a clear exposition of the background, search strategy, 
databases, keywords and any selection/evaluation criteria used in the review where appropriate. 
It should also highlight the main results and conclusions of the study. 
RESEARCH REPORTING CHECKLIST: Please see section 5 Research Reporting Guidelines. 
 
Letters to the Editor 
WORD LIMIT: 600 
ABSTRACT: N/A 
MAIN TEXT: Letters should be succinct and must relate to an article that has been published in 
the Journal. The Editor reserves the right to shorten letters if necessary, but will be sent to the 
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authors for approval. 
RESEARCH REPORTING CHECKLIST: N/A 
 
Commentaries 
WORD LIMIT: 1500 
ABSTRACT: N/A 
MAIN TEXT: evidence-based opinion pieces involving areas of broad interest. 
RESEARCH REPORTING CHECKLIST: N/A 
 
Registered Reports 
EuropeanoJournaloofoCanceroCare welcomes Registered Reports. This is a new article type 
designed to increase the transparency and reproducibility of hypothesis-driven science. 
Registered Reports differ from the conventional research article as part of the review process is 
conducted before authors collect and analyse data. The cornerstone of the Registered Reports 
format is that a significant part of the manuscript will be assessed prior to data collection, with the 
highest quality submissions accepted in advance. Please view the full Registered Reports author 
guidelines here to help prepare your submission. 
 
 
4. PREPARING THE SUBMISSION 
 
Cover Letters 
Cover letters are not mandatory; however, they may be supplied at the author’s discretion. 
 
Parts of the Manuscript 
The manuscript should be submitted in separate files: title page; main text file; figures. 
 
Title page 
The title page should contain: 
  
i. A short informative title containing the major key words. The title should not contain 
abbreviations (see Wiley's best practice SEO tips); 
ii. A short running title of less than 40 characters; 
iii. The full names of the authors and email address and telephone number of corresponding 
author; 
iv. The author's institutional affiliations where the work was conducted, with a footnote for 
the author’s present address if different from where the work was conducted; 
v. Acknowledgments. 
vi. Conflict of Interest statement for all authors; 
vii. Funding statements 
  
Authorship 
Please refer to the journal’s authorship policy the Editorial Policies and Ethical 
Considerations section for details on eligibility for author listing. 
 
Acknowledgments 
Contributions from anyone who does not meet the criteria for authorship should be listed, with 
permission from the contributor, in an Acknowledgments section. Financial and material support 
should also be mentioned. Thanks to anonymous reviewers are not appropriate. 
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Conflict of Interest Statement 
Authors will be asked to provide a conflict of interest statement during the submission process. 
For details on what to include in this section, see the section ‘Conflict of Interest’ in the Editorial 
Policies and Ethical Considerations section below. Submitting authors should ensure they liaise 
with all co-authors to confirm agreement with the final statement. 
 
Main Text File 
As papers are double-blind peer reviewed the main text file should not include any information 
that might identify the authors. 
 
The main text file should be presented in the following order: 
  
i. Title, abstract and key words; 
ii. Main text; 
iii. References; 
iv. Tables (each table complete with title and footnotes); 
v. Figure legends; 
vi. Appendices (if relevant). 
  
Figures and supporting information should be supplied as separate files. 
 
Title 
Should be clear, descriptive, and avoid the use of metaphor, elaborate language or respondent 
quotations which are less likely to be discovered by the electronic algorithms of modern search 
engines. Titles should include words pertaining to population or sample, the method of inquiry, 
any tools or measures used and its key findings as appropriate. These words should be 
reiterated at least once in the abstract. 
 
Keywords 
Please provide six keywords. When selecting keywords, Authors should consider how readers 
will search for their articles. These words should be reiterated at least once in the abstract and or 
title. Keywords should be taken from those recommended by the US National Library of 
Medicine's Medical Subject Headings (MeSH) browser list at www.nlm.nih.gov/mesh. 
 
Main Text General Style Points 
 
• Anonymity: As papers are double-blind peer reviewed, the main text file should not 
include any information that might identify the authors. 
• Spelling: The journal uses British UK spelling; however, authors may submit using either 
UK or US spelling, as this is converted to UK spelling by the production team. 
• Footnotes: to the text are not allowed and any such material should be incorporated into 
the text as parenthetical matter. 
• Abbreviations: In general, terms should not be abbreviated unless they are used 
repeatedly and the abbreviation is helpful to the reader. Initially, use the word in full, 
followed by the abbreviation in parentheses. Thereafter use the abbreviation only. 
• Units of measurement: Measurements should be given in SI or SI-derived units. Visit 
the Bureau International des Poids et Mesures (BIPM) website at www.bipm.fr for more 
information about SI units. 
• Numbers: numbers under 10 are spelt out, except for: measurements with a unit 
(8mmol/l); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils). 
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• Trade Names: Chemical substances should be referred to by the generic name only. 
Trade names should not be used. Drugs should be referred to by their generic names. If 
proprietary drugs have been used in the study, refer to these by their generic name, 




References should be prepared according to the PublicationoManualoofotheoAmericano
PsychologicaloAssociation (6th edition). This means in text citations should follow the author-date 
method whereby the author's last name and the year of publication for the source should appear 
in the text, for example, (Jones, 1998). The complete reference list should appear alphabetically 
by name at the end of the paper. 
 
A sample of the most common entries in reference lists appears below. For more information 
about APA referencing style, please refer to the APA FAQ. Note that for journal articles, issue 
numbers are not included unless each issue in the volume begins with page one, and a DOI 
should be provided for all references where available. 
 
Journaloarticle 
Beers, S. R. , & De Bellis, M. D. (2002). Neuropsychological function in children with 





Bradley-Johnson, S. (1994). Psychoeducationaloassessmentoofostudentsowhooareovisuallyo
impairedooroblind:oInfancyothroughohighoschool (2nd ed.). Austin, TX: Pro-ed. 
 
InternetoDocument 





Tables should be self-contained and complement, not duplicate, information contained in the 
text. They should be supplied as editable files, not pasted as images. Legends should be concise 
but comprehensive – the table, legend, and footnotes must be understandable without reference 
to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, , §, ¶, should be 
used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as 
SD or SEM should be identified in the headings. 
 
Figure Legends 
Legends should be concise but comprehensive – the figure and its legend must be 
understandable without reference to the text. Include definitions of any symbols used and 
define/explain all abbreviations and units of measurement. 
 
Figures 
Although authors are encouraged to send the highest-quality figures possible, for peer-review 
purposes, a wide variety of formats, sizes, and resolutions are accepted. Click here for the basic 
figure requirements for figures submitted with manuscripts for initial peer review, as well as the 
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more detailed post-acceptance figure requirements. 
 
Figures may be reproduced in colour online free of charge. Please note, however, that it is 
preferable that line figures (e.g. graphs and charts) are supplied in black and white so that they 




Appendices will be published after the references. For submission they should be supplied as 
separate files but referred to in the text. 
 
Supporting Information 
Supporting information is information that is not essential to the article, but provides greater 
depth and background. It is hosted online and appears without editing or typesetting. It may 
include tables, figures, videos, datasets, etc. 
 
Click here for Wiley’s FAQs on supporting information. 
 
Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are 
available via a publicly available data repository, authors should include a reference to the 
location of the material within their paper. 
 
Wiley Author Resources 
Manuscript Preparation Tips: Wiley has a range of resources for authors preparing 
manuscripts for submission available here. In particular, authors may benefit from referring to 
Wiley’s best practice tips on Writing for Search Engine Optimization. 
 
Article Preparation Supports 
Wiley Editing Services offers expert help with English Language Editing, as well as translation, 
manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you 
can submit your manuscript with confidence. Also, check out our resources for Preparing Your 
Article for general guidance about writing and preparing your manuscript. 
 
5. EBITORIAL POLICIES ANB ETHICAL CONSIBERATIONS 
 
Editorial Review and Acceptance 
The acceptance criteria for all papers are the quality and originality of the research and its 
significance to journal readership. Except where otherwise stated, manuscripts are double-blind 
peer reviewed. Papers will only be sent to review if the Editor-in-Chief determines that the paper 
meets the appropriate quality and relevance requirements. 
 




An appeal against a decision on a manuscript should be filed within 28 days of notification of the 
decision. The appeal should be in the form of a letter addressed to the Editor-in-Chief and 
submitted to the EJCC editorial office. The letter should include clear and concise grounds for the 
appeal, including specific points of disagreement with the decision. The appeal will then be 
assessed by the EJCC editorial team, led by the Editor-in-Chief, and informed by the reviewer 
assessments and subsequent editorial communications. 
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Bata Storage and Bocumentation 
EuropeanoJournaloofoCanceroCare encourages authors to share the data and other artefacts 
supporting the results in the paper by archiving it in an appropriate public repository. Authors 
should include a data accessibility statement, including a link to the repository they have used, in 
order that this statement can be published alongside their paper.” If data cannot be shared for 
reasons such as ethical, privacy, or confidentiality matters, please inform the Editors in your 
cover letter on submission. 
 
Authors can consult the global registry of research data repositories re3data.org to help them 
identify registered and certified repositories relevant to their subject areas. 
 
Bata Citation 
In recognition of the significance of data as an output of research effort, Wiley has endorsed the 
FORCE11 Data Citation Principles and is implementing a mandatory data citation policy. Journal 
policies should require data to be cited in the same way as article, book, and web citations and 
authors are required to include data citations as part of their reference list. Data citation is 
appropriate for data held within institutional, subject focused, or more general data repositories. It 
is not intended to take the place of community standards such as in-line citation of GenBank 
accession codes. 
 
When citing or making claims based on data, authors must refer to the data at the relevant place 
in the manuscript text and in addition provide a formal citation in the reference list. We 





Human Studies and Subjects 
For manuscripts reporting medical studies that involve human participants, a statement 
identifying the ethics committee that approved the study and confirmation that the study 
conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal 
Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good 
Clinical Practice. It should also state clearly in the text that all persons gave their informed 
consent prior to their inclusion in the study. 
 
Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent 
human subjects being recognized (or an eye bar should be used). Images and information from 
individual participants will only be published where the authors have obtained the individual's free 
prior informed consent. Authors do not need to provide a copy of the consent form to the 
publisher; however, in signing the author license to publish, authors are required to confirm that 
consent has been obtained. Wiley has a standard patient consent form available for use. 
 
Clinical Trial Registration 
The journal requires that clinical trials are prospectively registered in a publicly accessible 
database such as http://clinicaltrials.gov/ and clinical trial registration numbers should be 
included in all papers that report their results. Clinical trials are defined as interventional studies. 
Authors are asked to include the name of the trial register and the clinical trial registration 
number at the end of the abstract. If the trial is not registered, or was registered retrospectively, 
the reasons for this should be explained. 
 
Research Reporting Guidelines 
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Accurate and complete reporting enables readers to fully appraise research, replicate it, and use 
it. Authors are encouraged to adhere to the following research reporting standards. 
 
• CONSORT checklist for reports of randomised trials and cluster randomised trials 
• TREND checklist for non-randomised controlled trials 
• PRISMA checklist for systematic reviews and meta-analyses 
• STROBE checklist for observational research 
• SRQR or CASP checklist for qualitative studies 
• SQUIRE checklist for quality improvement 
 
See the EQUATOR Network for other study types, and for guidance on selecting the appropriate 
tool for your article. 
 
Conflict of Interest 
The journal requires that all authors disclose any potential sources of conflict of interest. Any 
interest or relationship, financial or otherwise that might be perceived as influencing an author's 
objectivity is considered a potential source of conflict of interest. These must be disclosed when 
directly relevant or directly related to the work that the authors describe in their manuscript. 
Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, 
membership of a company board of directors, membership of an advisory board or committee for 
a company, and consultancy for or receipt of speaker's fees from a company. The existence of a 
conflict of interest does not preclude publication. If the authors have no conflict of interest to 
declare, they must also state this at submission. It is the responsibility of the corresponding 
author to review this policy with all authors and collectively to disclose with the submission ALL 
pertinent commercial and other relationships. 
 
Funding 
Authors should list all funding sources in the Acknowledgments section. Authors are responsible 
for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry 




The list of authors should accurately illustrate who contributed to the work and how. All those 
listed as authors should qualify for authorship according to the following criteria: 
 
1. Have made substantial contributions to conception and design, or acquisition of data, or 
analysis and interpretation of data; 
2. Been involved in drafting the manuscript or revising it critically for important intellectual 
content; 
3. Given final approval of the version to be published. Each author should have participated 
sufficiently in the work to take public responsibility for appropriate portions of the content; 
and 
4. Agreed to be accountable for all aspects of the work in ensuring that questions related to 
the accuracy or integrity of any part of the work are appropriately investigated and 
resolved. 
  
Contributions from anyone who does not meet the criteria for authorship should be listed, with 
permission from the contributor, in an Acknowledgments section (for example, to recognize 
contributions from people who provided technical help, collation of data, writing assistance, 
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acquisition of funding, or a department chairperson who provided general support). Prior to 
submitting the article all authors should agree on the order in which their names will be listed in 
the manuscript. 
 
Additional Authorship Options. Joint first or senior authorship: In the case of joint first 
authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered 
joint first author’ or ‘X and Y should be considered joint senior author.’ 
 
ORCIB 
As part of the journal’s commitment to supporting authors at every step of the publishing process, 
the journal requires the submitting author (only) to provide an ORCID iD when submitting a 




This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses 
iThenticate’s CrossCheck software to detect instances of overlapping and similar text in 
submitted manuscripts. Read Wiley'sTop 10 Publishing Ethics Tips for Authors here. Wiley’s 
Publication Ethics Guidelines can be found here. 
 
 
6. AUTHOR LICENSING 
If your paper is accepted, the author identified as the formal corresponding author will receive an 
email prompting them to log in to Author Services, where via the Wiley Author Licensing Service 
(WALS) they will be required to complete a copyright license agreement on behalf of all authors 
of the paper. 
 
Authors may choose to publish under the terms of the journal’s standard copyright agreement, 
or OnlineOpen under the terms of a Creative Commons License. 
 
General information regarding licensing and copyright is available here. To review the Creative 
Commons License options offered under OnlineOpen, please click here. (Note that certain 
funders mandate that a particular type of CC license has to be used; to check this please 
click here.) 
 
Self-Archiving definitions and policies. Note that the journal’s standard copyright agreement 
allows for self-archiving of different versions of the article under specific conditions. Please click 
here for more detailed information about self-archiving definitions and policies. 
 
Open Access fees: If you choose to publish using OnlineOpen you will be charged a fee. A list 
of Article Publication Charges for Wiley journals is available here. 
 
Funder Open Access: Please click here for more information on Wiley’s compliance with 
specific Funder Open Access Policies. 
 
 
7. PUBLICATION PROCESS AFTER ACCEPTANCE 
 
Accepted article received in production 
When an accepted article is received by Wiley’s production team, the corresponding author will 
receive an email asking them to login or register with Wiley Author Services. The author will be 
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Proofs 
Once the paper is typeset, the author will receive an email notification with the URL to download 
a PDF typeset page proof, as well as associated forms and full instructions on how to correct and 
return the file. 
 
Please note that the author is responsible for all statements made in their work, including 
changes made during the editorial process – authors should check proofs carefully. Note that 
proofs should be returned within 48 hours from receipt of first proof. 
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The journal offers rapid speed to publication via Wiley’s Early View service. Early View (Online 
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CRITICAL APPRAISAL 
This paper is intended to provide a critical appraisal of the research study entitled 
‘Patients’ experiences of coping longer-term with cancer of unknown primary’(CUP). The 
paper commences with an overview of the findings of both the literature review and research 
paper incorporated in the thesis. The remainder of the paper is split into three sections 
focusing upon: epistemological and ontological assumptions and apparent dissonance 
between sections one and two of the thesis; reflections upon the position of the researcher and 
importance of researcher reflexivity; and reflections upon the research process and the 
study’s strengths, limitations, and implications for future research.  
Overview of the Research Findings 
 The systematic review synthesised the results of 15 quantitative studies examining the 
relationship between uncertainty and psychological distress amongst younger adults with 
cancer. Findings indicated uncertainty and psychological distress are significantly associated 
for patients at differing time points in the cancer journey and with differing types and grades 
of cancer. Analyses of causality in the relationship tended to suggest that uncertainty is causal 
of distress which lends support to Mishel’s uncertainty in illness theory (1988). Findings 
indicated the potential for communication to act as an intervention for reducing uncertainty in 
order to minimise experiences of psychological distress amongst younger adults with cancer.  
 The research paper aimed to understand the coping experiences of people living 
longer-term with CUP. Interpretative phenomenological analysis was used to generate themes 
from interview data from 10 participants. Three superordinate themes were generated from 
the data. ‘“Fuss and Bother”: The Upheaval of Everyday Life’ captured the disruptive nature 
of CUP in patients’ lives and impact on ability to engage with valued activity. This was seen 
to adversely affect patients’ through negative appraisals, leading to increased anxiety, 
perceived loss of control, and challenged concepts of identity. ‘“It’s the Unknowing”: The 
Enduring Uncertainty of CUP’ brought together patients’ ongoing experiences of uncertainty, 
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highlighting that while uncertainty associated with an absence of transferrable expectations 
and anxieties about the future were perceived as highly threatening, some participants 
appraised uncertainty as opportunity and were able to generate hope in response to unknown 
aspects of CUP.  ‘“Just Get on With It”: Managing and Moving Forwards’ subsumed the 
various strategies used by participants to cope with CUP-related threats, including emotion-
focused strategies of maintaining normality through cognitive and behavioural avoidance, 
moving increasingly towards adaptive acceptance of the realities of CUP, and drawing on the 
external support of others to bolster internal resources for coping. Findings demonstrated that 
while the experiences of patients living longer-term with CUP are in many ways similar to 
those of other populations living with cancer, this population may face particular challenges, 
including high levels of threat associated with perceived passivity and loss of control in the 
face of intensive medical regimes, and living with the relentless uncertainties of having an 
illness perceived as unusual, unpredictable, and volatile. Despite these challenges, the 
majority of patients reported generally feeling able to cope, and that this had become easier 
over time since diagnosis. Findings indicate that this patient population would benefit from 
more collaborative decision making processes in relation to their medical care and how their 
time is used, opportunity to gather more information about their condition to reduce 
uncertainties where possible, and that those experiencing high levels of psychological distress 
may benefit from interventions to enhance skills of avoidance and acceptance.  
 Together, the systematic review and research paper offer an insight into the 
experiences of distress and uncertainty faced by cancer patients and the ways that these might 
be coped with. Jointly, findings demonstrate the potential for uncertainty to generate distress 
and reduce subjective coping. The findings contribute to the well-established psycho-
oncology evidence base, by providing insights into the experiences of younger cancer 
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survivors and CUP patients, two cancer-patient groups that have been previously overlooked 
respectively in systematic reviews and empirical research. 
Ontological and Epistemological Assumptions of the Thesis 
The ontological assumptions by which research is underpinned inform the 
epistemological position taken, and subsequently the methodological approach (Mack, 2010). 
The two over-arching positions in ontological theory are realism and relativism (Willig, 
2008). Realist positions assume there to be an objective reality made up of structures and 
objects with observable cause and effect relationships. Relativist positions, on the other hand, 
posit that reality is not objectively knowable and instead is constructed by the individual 
based upon personal interpretations (Mertens, 2010; Willig).  
These opposing understandings of the essential nature of reality have informed 
differing epistemological theories of and approaches to how knowledge might be attained. 
Epistemological assumptions based upon realist ideas assume that a singular reality can be 
known or ‘seen’. This stance underlies empiricist and positivist paradigms, most often 
associated with quantitative research methods which seeks to use ‘objective’ measurement to 
reveal universal ‘truths’ (Darlaston-Jones, 2007). Relativist ideas, on the other hand, have 
informed the development of epistemological paradigms such as social constructionism and 
interpretivism which are broadly allied with qualitative research methodologies, concerned 
with individual, subjective perceptions and the construction of meaning in context. 
Resultingly, qualitative and quantitative research methods can be understood to stem from 
conflictual theoretical ancestries and are frequently framed as incompatible (Howe, 1992).  
For this reason, during the conception phase of this thesis, I grappled uneasily with 
the theoretical implications of conducting a quantitative literature review and a qualitative 
research paper. While I was assured by conversations with my research supervisors that such 
an undertaking was not unusual, I had reservations about the meaning and implications of 
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mixing paradigms in this way and the potential for incongruence with my own ontological 
and epistemological views.  
Personally, I have come to take a relativist view which is consistent with critical 
realism. Critical realist theory suggests that “no one can step out of their conceptual world 
and see if reality ‘really exists’ or what it ‘essentially is,’ free of conceptual prejudging” 
(Danermark, Ekstrom, Jakobsen, & Karlsson, 2002, p. 18). This, I believe, has implications 
for both qualitative and quantitative research, however, is an issue that is rarely 
acknowledged explicitly in quantitative studies which are usually presented within a 
positivist frame, as though presenting universal truths. However, with a critical realist lens in 
place, I believe that both qualitative and quantitative research can offer much to our shared 
understanding of psychological issues. Thus, my own views also align somewhat with 
pragmatist ideas, further understanding of which has helped me through the thesis process to 
reconcile the apparent incompatibility between the systematic review and research paper.  
Pragmatism, similarly to constructionism, rejects positivist conceptions that scientific 
enquiry and a single scientific method can lead to the uncovering of ‘truths’ (Mertens, 2010). 
As the paradigm has evolved, the focus has been upon a common sense approach to research 
(Mertens), and pragmatic ideas have come to be associated with mixed methods research 
(Tashakkori & Teddlie, 2003). In transcending concerns about metaphysical concepts of 
‘truth’ and ‘reality’ which have conventionally created a barrier between research 
methodologies, pragmatism expounds a dual understanding that “there is a single ‘real world’ 
and that all individuals have their own unique interpretations of that world” (Mertens, p.36), 
consistent with critical realist ideas. Based on this, both qualitative and quantitative research 
methods are compatible with pragmatism which emphasises that the method should be 




The Researcher Position  
 Consistent with critical realist and pragmatist perspectives, Foster (2009) highlights 
the false dichotomy often used to position the researcher as an ‘insider’ or ‘outsider’ in 
relation to their subject of inquiry. While traditional positivist theory suggest that the 
researcher is separate to the research subject and able to hold an unbiased ‘outsider’ lens over 
an objective reality, Foster argues that “all research is, at least in part, a product of human 
thought and meaning-making, including that of the researcher” (p. 18). Therefore, consistent 
with pragmatic and critical realist ideas that the ‘real’ world cannot be seen without the 
individual interpretation of research participants, so too do the researcher’s interpretations 
influence the research. According to Foster’s thesis, we must acknowledge the role of 
inescapable researcher bias in the conception and design of research, regardless of the 
methodological approach, which often places them as an ‘insider’ in the research process. 
Forster outlines four conditions under which the researcher becomes an ‘insider’:  
1. experienced that which is being researched (Farnsworth, 1996), 
2. experienced that which is being researched and has a personal relationship with 
many of the participants (Sherry, 2002) 
3. been part of the community being researched (Bolak, 1995), or 
4. worked with the population under study (Bland 1987; Coglan 2000, cited in 
Sherry).  
Based upon the interpretation of the above criteria, it may be argued that all researchers in the 
field of psychology are part of the human population which they study, and even if they have 
not experienced the particular phenomenon of enquiry, are likely to have developed 
preconceptions as a result of co-existing in a society with others that have. By virtue of their 




Research credibility and rigour. 
 Due to the inextricable role of the researcher as an ‘insider’ and creator of meaning in 
IPA and other qualitative research methods, qualitative research has traditionally come under 
criticism for lacking scientific rigour (Rolfe, 2006). Noble and Smith (2015) have argued, 
however, that reduced rigour in qualitative research does not relate to methodology, but 
rather to a lack of consensus regarding the quality standards that qualitative research should 
be assessed against. They argue that concepts of reliability and validity used to assess quality 
in quantitative research are not transferrable to qualitative enquiry, and as such, posit that the 
emphasis should instead be placed upon the ‘trustworthiness’ of findings. This, they suggest, 
may be achieved via strategies which enhance the ‘truth value’, ‘consistency’, ‘neutrality’, 
and ‘applicability’ of the research.  
The ‘truth value’, according to Noble and Smith, is met through the acknowledgement 
that multiple realities exist and transparent researcher reflexivity. In order to meet this 
criterion, a reflective journal was kept throughout the research process. Excerpts from this 
journal are presented in Appendix 3-A (p.3-17). According to Vicary, Young, and Hicks 
(2017), “The use of a journal is an established tool for the recording of learning and prompts 
the process of interpretation and bracketing as a reflective mechanism” (p.563). The process 
of keeping reflective notes, especially prior to and immediately after interviews, allowed me 
to notice assumptions contemporarily. Potential biases highlighted in journal content and 
more generally were also discussed in ‘debriefing’ discussions carried out in monthly 
research supervision sessions. Based upon the output generated via these reflexive 
mechanisms, a section highlighting my own experiences and ways in which these may have 
influenced the research process and interpretation of data has also been included below.  
‘Consistency’ and ‘neutrality’ relate to the transparency of researcher decision making 
and openness about the impact of researcher’s own philosophical position. To comply with 
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these criteria, and enhance ‘auditability’, decision making and rationales were captured in the 
reflective journal and also discussed in research supervision. The use of Standards for 
Reporting Qualitative Research was also seen to support this, by ensuring that each aspect of 
the research was reported and justified in the body of the research paper. Additionally, the 
analysis and generation of themes was carried out in consultation with my field and research 
supervisors who jointly have a significant level of experience of qualitative research and 
working in settings with cancer patients.   
‘Applicability’ is framed as a qualitative research-appropriate alternative to the 
concept of generalisability, focusing upon whether findings can be applied to other ‘contexts, 
settings, or groups’. This is seen to have been achieved through rich description of the 
research setting(s) and sample. This has been achieved through thorough description of the 
study setting(s), inclusion and exclusion criteria, and sample characteristics.  
Researcher reflexivity. 
The focus on the ‘double hermeneutic’ process in IPA explicitly acknowledges the 
researcher’s role in interpreting meaning from data based on their own, often unconsciously 
held, knowledge, experience, and beliefs. As outlined above, this reflexivity is viewed as a 
fundamental tenet of ‘quality’ and ‘trustworthiness’ in qualitative research. The impact of my 
own experiences of and understandings of cancer, and position as an ‘insider’, will 
undoubtedly have influenced the findings of the empirical paper. Additionally, they have 
probably coloured the entirety of both components of the thesis, in terms of the way that 
cancer and associated experiences have been described and framed. As such, to increase 
transparency and ‘credibility’ it feels important to consider the experiences I am aware have 
shaped my conceptualisation of cancer.  
Given the prevalence of cancer, there are very few people who have not been affected 
by its unexpected appearance in their lives or the lives of their loved ones. To this I am no 
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exception. I have lost two grandparents to cancer and have witnessed many of those I care 
about lose family and friends, both young and old, as a consequence of malignant disease. I 
have also seen people survive cancer and go on with their lives. My mum, whose cancer was 
caught early by an impromptu screening appointment I will always be grateful for, is one of 
those fortunate enough to be here. From these experiences and the narratives formed around 
cancer’s presence in the lives of myself and my loved ones, I came to develop a sense of 
cancer as a frightening, destructive force which indiscriminately enters and shatters lives. 
Whilst writing this thesis I have been on a trainee placement in a clinical health 
psychology service, working directly with cancer patients. In this role, I had borne witness to 
the high levels of distress a cancer diagnosis can bring and the devastating impact it can have 
on individuals’ emotional wellbeing, relationships, social roles, and belief systems. I was 
struck by the strength, humility, humour, and determination of the people I worked with. So 
too was I touched by their sense of loss, injustice, and sorrow in the face of the threats posed 
by cancer.  
As I commenced data collection, I became aware of a contrast between those I was 
working clinically with and those I was interviewing for research purposes. Several of the 
CUP patients I was fortunate enough to speak with expressed positive experiences despite 
CUP’s presence. While this was not universal, and participants also reported distress, loss, 
and struggle, I was struck by how well some participants reported to be managing and feeling 
in their circumstances. This caused me to reflect upon the assumptions I had been 
unconsciously carrying in relation to cancer being a pervasively negative and life-shattering 
experience. I considered my professional experiences with cancer patients, recognising with 
renewed awareness that individuals referred to clinical psychology are likely to be those 
patients experiencing the highest, clinically significant levels of distress, and while these 
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experiences can affect a significant proportion of cancer patients, there are many more 
patients who do not come into contact with psychological services. 
My assumptions may have been further coloured by my knowledge, or lack thereof, 
of CUP. Prior to embarking on this research project, much like many of the participants, I had 
not heard of CUP. I was shocked upon learning more about the condition to discover how 
little modern medicine seemed to be able to offer to this patient population. Based upon the 
existing literature I had read about high levels of uncertainty and distress amongst people 
newly diagnosed with CUP, along with my existing assumptions around cancer more 
generally, when embarking on the research I believe I had fully expected study participants to 
be experiencing a high level of psychological distress and functional limitation and therefore 
difficulty with coping. I was therefore pleasantly surprised to hear just how well some of the 
study participants reported feeling both physically and psychologically and was struck on 
multiple occasions by the remarkable resilience and stoicism shown by the people I was 
fortunate enough to meet.  
Reflections on the Thesis Process 
 The following section offers an overview of the challenges and limitations associated 
with the thesis process as well as strengths and implications for future research.  
Limitations and challenges. 
Practical challenges. 
Pragmatic challenges in relation to time constraints and recruitment arose during the 
research process which had a considerable impact upon the time-scales of the project and 
hand in date. In the early stages of the empirical research process, I was fortunate to have 
opportunity to discuss potential topics and ideas with clinical oncology staff working across 
recruitment sites and learn from their perspectives. A recurring theme of these discussions 
was that individuals meeting the study’s inclusion and exclusion criteria were a clinical 
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minority and relatively rare. I recall at one network meeting that one oncologist present made 
it quite clear that he believed recruiting the target sample number would not be possible. With 
the reassurance of my supervision team, including an extremely experienced and enthusiastic 
consultant in clinical oncology, I opted to embark on the research regardless of these 
warnings. Acutely aware from the offset that recruitment may be challenging, early 
discussions with my field supervisor focused on ways to optimise recruitment opportunities. 
With this aim in mind, I attended the north-west CUP education day and had opportunity to 
present my research proposal to staff from across numerous NHS Trusts with the aim of 
recruiting staff contacts in CUP services that my supervision team did not already have links 
with via the local network. Through this process I was able to include three more recruitment 
sites (although unfortunately it transpired that one of these Trusts was not currently open to 
external research due to capacity issues). I have no doubt that taking this extra time during 
the set-up of the study was essential to the eventual success of the study. Three of the total 
ten participants came from the additional three sites, as such reaching the target sample 
number would not have been feasible without them. Nor would it have been feasible without 
developing relationships with contacts in each of the recruiting sites who I was totally 
dependent upon to identify and initially seek consent from. Of course, going through separate 
R&D processes for six Trusts was an additional and unforeseen task which demanded a 
significant amount of time. 
The process of conducting the research was in many ways dependent upon the 
structure of the DClinPsy programme. One challenge of this was a relatively short time-frame 
to complete the thesis research. A significant delay occurred at the ethics application stage, 
firstly due to supervisor absence whilst putting the application together, and secondly as a 
consequence of the ethics process itself.  While the Health Research Authority (HRA) have 
made recent system changes to make the process of gaining ethical approval for research in 
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NHS settings more streamlined and less lengthy (HRA, 2017), it remains a notoriously time-
consuming process (Whitburn, Singh, & Sooriakumaran, 2017). With hindsight, it would 
have been necessary to commence this process much earlier in order to gain relevant 
approvals, conduct recruitment and data collection, and complete the analysis and write-up of 
the project within the original estimated time frames.  
Reflecting upon these process issues, it is possible that both of the challenges with 
recruitment and timescales for ethical approval may have been overcome through a different 
recruitment strategy. Recruitment nationally via relevant organisations (e.g. The CUP 
Foundation) or social media (there are three CUP-specific Facebook pages offering 
information and support) may have allowed access to a much wider pool of potential 
participants. Due to the potential for this mode of recruitment to access patients all over the 
country, it would likely have been necessary for interviews to be carried out either over the 
telephone or via internet-based video communication software such as ‘Skype’. Voice over 
Internet Protocol (VoIP) technologies are increasingly employed as a method of data 
collection in qualitative research which have a high level of acceptability and convenience 
(Lo Iacono, Symonds, & Brown, 2016). This approach would also have negated the need for 
HRA ethical approval, with approval instead being sought via Lancaster University’s Faculty 
of Health and Medicine Research Ethics Committee, a process which anecdotally and in my 
personal experience is considerably quicker. I believe, however, that there would also have 
been some drawbacks to this approach. One possible drawback would have been an absence 
of links with patients’ clinical nurse specialists to direct any concerns or highlight any needs 
for additional support to. I also believe that the opportunity for building rapport and 
providing a ‘safe’ space to discuss very difficult subject matter is better facilitated in face-to-
face discussion than it could be over the telephone or VoIP technology due to greater 
potential for non-verbal cues to be missed (Irvine, Drew, & Sainsbury, 2012).  
3-13 
CRITICAL APPRAISAL 
Ethical challenges.  
 One of the major findings of the research paper was about the importance of patient 
time and minimising the time-burden of CUP-related appointments in order to allow patients 
to better engage with valued activities in their daily lives. Of course, this has made me reflect 
upon the request placed upon participants to give up their precious time to attend an interview 
and focus explicitly upon the more distressing aspects of their experiences. While participants 
opted-in to the study voluntarily, I have wondered about the ethical implications of this 
within the context of patient compliance and whether patients may have felt obliged to 
participate due to the research being raised by the medical professionals responsible for their 
care.  
 Also on the theme of participant time, I became aware during the research process of 
potential challenges associated with the option of having a summary of the study findings 
posted out after completion of the research. Given the uncertain trajectory of CUP and the 
possibly limited life expectancy faced by some participants, comments arose on several 
occasions from participants about the possibility that they may no longer be alive at the point 
at which summaries are posted. At no time in these discussions did participants seem overtly 
distressed, and from some these comments seemed to be made jokingly, however it made me 
consider the impact of this relatively standard research procedure. While it is common 
practice for participants to be offered feedback upon the outcomes of research they have been 
part of, I had not prior to data collection really considered the practice within the sample 
context. The focus upon the future and possible mortality raised could have been particularly 
challenging and is certainly a learning point that I will take forward.  
Strengths. 
The research focused upon the lived experience of people living ‘longer-term’ with 
CUP.  No prior research has focused upon this patient population, and as such a significant 
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strength of the research is the opportunity for the voices of these patients to be heard and 
consequently for their needs to be better understood by the services that provide their 
healthcare.  
The involvement of stakeholders, including both service-user representatives and 
medical staff working in CUP services, in the early stages of research design was also seen to 
be a strength of the research as this provided opportunity to ensure that the research would be 
both acceptable to participants and valuable to the services that work with people with CUP.  
 Implications for future research. 
 The research findings indicate a number of areas where further research is needed. As 
in other cancer populations, social support is an important coping resource for people with 
CUP. Research investigating the experiences of those providing care and support to 
individuals with CUP as yet has not been undertaken. It is possible that these individuals may 
face similar struggles with coping as a result of the uncertainty associated with the condition 
as patients themselves. Findings also highlighted the potential for misinterpretation of 
physical symptoms amongst CUP patients and research investigating these experiences 
further may be very useful as it may be that individuals with CUP are more likely to 
experience health anxiety than other cancer patients. While findings provided insights into 
the way that participants’ appraisals and sense of coping have changed over time, 
longitudinal research investigating these experiences over time would be beneficial to better 
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Appendix 3-A- Reflective Journal Excerpts  
10/06/2019- Pre-data collection 
First two interviews scheduled for Friday. Calls made to participants to arranged- surprised 
when one lady sounded quite sprightly on the phone. I think I have been expecting that 
participants will mainly be really struggling- maybe this won’t be the case. Limited 
knowledge about what ‘clinical stability’ from the medical perspective actually means- 
(speak to xxxxx/xx xxxxxxx [field supervisors] about this).  
Assumptions going in to interview process- that patients will be quite frail/visibly unwell- 
probably based on my ideas of what a ‘typical’ patient with advanced cancer or during 
treatment might look like. This is strange really as patients on placement don’t necessarily 
look this way- influence of stereo-types from media/family. Not having met anybody with 
CUP before- feels a bit mysterious so think I’m expecting the worst- based probably on the 
literature but also attitudes of Medics in CUP network. Likewise, expecting participants will 
probably find talking about their experiences quite difficult/distressing.  
12/07/2019- Reflections After Interview 4 
Participant 4- most distressed so far, seemed that life had been placed of pause for CUP. Felt 
incredibly sad for this lovely lady who clearly has so many ambitions and goals that she 
currently doesn’t feel able to pursue. I think that after the first three this has come as a bit of a 
surprise, although probably more what I expected initially. Focus upon suicide as a ‘way 
out’- some really hard conversations- could really sympathise with her position that it 
probably would be a ‘kinder’ end- has left me thinking and feeling frustrated about UK laws 
around assisted suicide for those that do end up with little quality of life and lots of pain etc. 
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Had to contact Anna re. risk concerns, actions carried out to pass concerns on to specialist 
nurse. Feel conflicted about this- necessity of carrying out professional obligations vs the 
sense that by reducing ‘risk’ it may also reduce this lady’s access to the thing that is 
providing her with a safety net/ability to continue knowing she can remain in control of her 
own destiny.  
27/08/2019- Reflections after Interview 8 
Interview carried out with male participant in own home- genuinely surprised at how well 
this man seems to be managing with his situation- very personable/humorous, laughed easily 
about the uncertainties faced, seemed to have come to a place of accepting how things are. 
helped by? – no symptoms, secondary cancer treated, long period of wellness since treatment, 
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Previous research has shown that individuals living with a diagnosis of cancer are 
likely to experience elevated emotional distress (Carlson et al., 2004; Zabora et al., 1997; 
Zabora et al., 2001). This distress in relation to cancer has been defined by The National 
Comprehensive Cancer Network (NCCN, 2013) as “a multifactorial unpleasant emotional 
experience of a psychological (cognitive, behavioural, emotional), social, and/or spiritual 
nature that may interfere with the ability to cope effectively with cancer, its physical 
symptoms and its treatments.” Within this definition, distress is conceptualised as difficulties 
with mood, anxiety, and adjustment across a continuum ranging from ‘normal’ reactions such 
as feelings of fear and sadness, to more disabling experiences including anxiety, depression, 
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and existential and spiritual crises (NCCN, 2013). The evidenced increase in distress has 
been linked to an increased prevalence of mental health difficulties amongst cancer patients. 
A meta-analysis of eight studies by Singer, Das-Munshi and Brähler (2010) found that around 
one in three people with cancer meet criteria for diagnosis of a mental health difficulty, 
indicating a greater prevalence than in the general population.  
Quality of life (QoL) has also been shown to be negatively impacted by a diagnosis of 
cancer. While inversely associated with distress, QoL includes a broader range of phenomena 
“including physical, social, cognitive, spiritual, emotional, and role functioning, as well as 
psychological difficulties and physical symptoms such as pain, nausea and vomiting, and 
fatigue” (Carlson & Bultz, 2003). Research findings have shown that following diagnosis of 
cancer, QoL is impaired in a number of areas, particularly fatigue, sleep disturbance, and 
financial concerns (Götze, Ernst, Brähler, Romer, & von Klitzing, 2015). Due to the negative 
implications of living with cancer described above, a large volume of research has been 
undertaken investigating how people cope with the life-altering changes and emotional 
distress associated with a cancer diagnosis.  
Coping has been conceptualised in numerous ways within psychology. Lazarus and 
Folkman’s (1984) definition of coping as “constantly changing cognitive and behavioural 
efforts to manage external and/or internal demands that are appraised as taxing or exceeding 
the resources of the person” has been widely accepted and applied. Based on this definition, 
Folkman & Lazarus (1980; 1985; Lazarus & Folkman, 1984) proposed that coping can be 
separated into the two distinct categories. Emotion-focused coping relates to attempts to 
attempts to manage or alter internal conflicts and emotions through strategies such as re-
appraisal.  Problem-focused coping pertains to attempts to change external factors or reduce 
conflict between the individual and the environment via strategies such as support seeking 
(Roesch, 2005). A further dimension to coping is direction of focus i.e. strategies directed 
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towards a threat are described as ‘approach coping’ (e.g. problem-solving) and strategies 
directed away from a threat are labelled as ‘avoidance coping’ (e.g. denial) (Moos & 
Schaefer, 1993).  This theoretical framework has been used widely to guide research into how 
people cope with a wide range of phenomena, including cancer. 
Previous research has demonstrated that a wide range of coping styles and strategies 
are used by people living with various cancer diagnoses, including lung cancer, breast cancer, 
and gastrointestinal cancers (Al-Azri, Al-Awisi & Al-Moundhri, 2017; Nipp et al., 2016; 
Walker, Zona & Fisher, 2006). Both emotion-focused and problem-focused approach coping 
have been found to be related to improved psychological and physical wellbeing (Roesch et 
al., 2005). Avoidance coping conversely has been linked to higher levels of distress and 
lower mood and physical functioning (McCaul et al., 1999; Roesch et al., 2005). QoL has 
also been found to be significantly associated with coping strategies, with avoidant strategies 
found to be particularly detrimental to QoL in a sample of women with breast cancer 
(Kershaw, Northouse, Kritpracha, Schafenacker, & Mood, 2004). Emotion-focused strategies 
have been found to be used more by patients with advanced cancer diagnoses (Thomsen, 
Rydahl-Hansen & Wagner, 2010). Findings from a study by Nipp et al. (2016) suggest 
coping strategies employed are related to individual illness perceptions, with increased 
perception of chronicity found to lead to increased use of passive strategies such as anxious 
preoccupation and hopelessness.  
               Perceived capacity to cope with cancer and employ coping strategies have been 
demonstrated to be negatively correlated with uncertainty (Germino et al., 1998). The use of 
emotion-focused coping strategies, however, has been found to mediate between fear of 
uncertainty and emotional distress during and after cancer treatment (Mishel & Sorenson, 
1991; Taha, Matheson & Anisman, 2012). The theme of coping with uncertainty has also 
been identified amongst patients with advanced illnesses (Kimbell, Murray, Macpherson & 
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Boyd, 2016; Tejani, Kamen, Mohile & Gramling, 2014). While the experience of uncertainty 
has been identified as a challenge to coping across a range of cancer diagnoses, it is possible 
that it may be a particular issue for individuals diagnosed with cancer of unknown primary 
(CUP).  
                  A diagnosis of CUP is given to individuals where a secondary cancer has been 
identified in the absence of an identifiable primary source (Varadhachary & Raber, 2014). 
Approximately 9000 people in the UK are diagnosed with CUP each year (Cancer Research 
UK, 2017), with figures suggesting CUP diagnoses make up 2-5% of all diagnosed cancers 
(Riihimäki, Hemminki, Sundquist, & Hemminki, 2013). The condition is associated with a 
poor prognosis, with a median survival rate of 3 months (Hemminki, Bevier, Hemminki, & 
Sundquist, 2012; van de Wouw, Janssen‐Heijnen, Coebergh, & Hillen, 2002). The majority 
of patients are very frail at the time of diagnosis and unable to undergo any anti-cancer 
treatment (cytotoxic chemotherapy). While a minority of patients (15-20%) belong to clinico-
pathological subsets with more favourable prognosis (favourable risk subsets), 80-85% of 
patients do not belong to those subsets and even if they are well enough to undergo 
chemotherapy the median survival is generally less than 1 year (Fizazi et al 2015). 
                 To date very little research has been undertaken with people living with CUP, 
however existing studies has identified that CUP amplifies difficulties encountered across 
other cancer diagnoses due to elevated levels of uncertainty (La Pushin, 2009; Richardson et 
al., 2015). This uncertainty in CUP has been related to: a high volume of investigative testing 
(Symons, James & Brooks, 2009); indefinite prognosis and lack of clarity in treatment plan 
(Ryan, Lawlor & Walshe, 2013); and lack of continuity in care (Richardson et al., 2015; 
Wagland et al. ,2017). This increased uncertainty has been linked to increased depression and 
anxiety and decreased quality of life (Hyphantis et al., 2013). Therefore, increased 
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uncertainty in CUP may make coping for individuals with this diagnosis particularly 
challenging.  
                   Only a subgroup of CUP patients are medically stable 6 months beyond their 
diagnosis. This group of patients have had a prolonged period of coping with the uncertainty 
of CUP and potential related distress, however no research found in literature searches has as 
yet focused on this particular population. As such research addressing this gap in the 
literature is warranted to inform clinical practice around how this patient group can be best 
supported to cope with any distress stemming from uncertainty about their illness, the process 
of treatment, or any other CUP-related difficulties, potentially enhancing quality of life. The 
proposed study will aim to explore the coping experiences of this particular population. 
Rationale 
The above background provides an overview of the relevant literature relating to 
coping in cancer patients and highlights the gap in this literature in relation to those living 
relatively longer-term with a diagnosis of CUP. As previous findings have highlighted that 
uncertainty has a detrimental impact on coping with cancer and that CUP is a diagnosis 
characterised by uncertainty, it is possible that for individuals with CUP, coping is even more 
challenging that it is for individuals with cancer of known primary site. As such, it is 
important to better understand the experience of individuals living for an extended period (6 
months or more) with CUP and how they cope.  
Aims 
The aim of the study is to explore the experiences of individuals coping longer-term 
with CUP. The intended outcome of the study will be to identify themes from participants’ 
data relating to how they have coped over the time since their CUP diagnosis. It is hoped that 
this knowledge will indicate what kind of coping strategies are most or least helpful for 
people living with CUP and what potential support mechanisms may be beneficial.  
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It is hoped that findings will be of use to inform services and staff how they can best support 
people living longer-term with CUP to cope throughout their time living with the condition. It 
may also help to identify what, if any, form of psychological support is perceived to be most 
helpful by this patient group.  
Research Questions 
What are the coping experiences of people who are living longer term with CUP? 
• Do these patients feel able to cope? What factors increase or decrease perceived 
coping capacity? 
• Has their sense of ‘coping’ changed throughout their illness? 
• Do patients feel that coping longer term with CUP is qualitatively different than 
coping with a cancer of known primary site? 
 
Method 
The study will use Interpretative Phenomenological Analysis (IPA), a qualitative 
approach which provides both the methodology and analytic strategy as outlined by Smith 
and Osborne (2008).   
Participants 









 A purposive sampling strategy will be used in order to identify participants who will 
meet the outlined inclusion and exclusion criteria. The medical teams in the identified CUP 
services will be responsible for identifying potential candidates for participation and during this 
process will assess whether the criteria are met. The chief investigator will also ascertain that 
each participant meets inclusion and exclusion criteria during initial phone contact prior to 
interviews taking place.  
 The aim will be to recruit up to 10-12 participants. The size of the sample has been based 
upon the IPA’s focus upon small, homogenous samples (Smith & Osborne, 2008). Typically, 
selection of sample size is based upon having enough participants to shed light upon the 
phenomenon of interest and identify convergent and divergent themes, yet not so many that the 
‘depth’ necessary for IPA is lost (Pietkiewicz & Smith, 2012). Published IPA studies typically 
have samples of between 4-15 people. The aim of 10-12 participants for this study therefore falls 
within the usual boundaries for IPA studies and is estimated to be realistic for the scope of the 
study whilst offering the possibility of reaching data saturation (i.e. that no new themes are 
likely to emerge through further interviewing) (Brocki & Wearden, 2006).  
 Should more participants that this be interested in taking part, participants will be 
selected on a first-come-first-served basis. Exceptions to this may be made if there is a 
significant gender imbalance in the existing sample, for example if males are under-represented, 
potential male participants may be chosen ahead of females who expressed their interest sooner.  
Inclusion and Exclusion Criteria 
Participants will be eligible for inclusion in the study if:  
• They have received a diagnosis of CUP 
• They received their CUP diagnosis over 6 months ago and are now deemed to be 
clinically stable by their medical team 
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• They are currently receiving treatment or being actively monitored by the CUP 







• They are aged 18 or over 
• They are able to provide informed consent to participate 
Participants will not be eligible for inclusion in the study if:  
• They are acutely unwell or nearing the end of their life 
• They do not speak English (unfortunately no funds are available for a translator as 
part of this study) 
• They are under 18 years of age 
• They lack mental capacity to provide informed consent to participate (e.g. due to a 
severe learning disability or dementia) 
Smith and Osborne (2008) posit that the sample should be homogeneous in order to 
shed light on the phenomenon of interest, in this instance coping with CUP. Therefore, the 
inclusion and exclusion criteria aim to ensure participants recruited have had a relatively 
similar journey in terms of time passed since their CUP diagnosis and current clinical 
stability.  
In order to make outcomes as useful as possible when considering the wider 
population, efforts will be made to recruit a relatively even gender mix if possible. Efforts 
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will also be made to recruit participants from across the different host NHS trusts to ensure 
results are not representative of the experience of care in individual Trusts. The decision to 
involve seven NHS trusts in order to recruit a relatively small number of participants was 
made based on advice from the field supervisor Dr xxxxxxxxxxx and other oncologists 
working in CUP services that the number of patients meeting inclusion criteria for the study 
in each Trust is likely to be very small. Therefore, seven Trusts were selected to maximise 
recruitment opportunities, however, it is possible that participants will not be recruited from 
each Trust if no patients meet the criteria or are willing to be involved in the study.   
One contact person (ordinarily a clinical nurse specialist) will be identified in each 
Trust who will act as the primary link with the chief investigator to facilitate recruitment.  
Materials  
The following materials were produced by the chief investigator:  
• Participant Information Sheet  
• Professionals’ Information Sheet  
• Consent to be contacted form  
• Consent form  
• Interview Schedule  
• Demographic Information Form  
The consent form and participant information sheet were based on templates provided 
by the Health Research Authority and on guidance provided by the Doctorate in Clinical 
Psychology Programme at Lancaster University.  
Questions for the interview schedule were developed by the chief investigator and 
guided by the research questions. Guidance provided by Smith and Osborne (2008) for the 
production of interview schedules for IPA research was followed.  
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The demographic information form was created to capture relevant demographic data. 
Data gathered are age, time since diagnosis, gender, and ethnicity. These data are important 
variables for providing an accurate report on the study sample. Options for ethnic background 
were obtained from the Office for National Statistics’ (ONS) recommendations for collection 
of ethnicity survey data in England.  
Patient and public involvement 
As part of the process of developing the research materials, the chief investigator 
consulted with members of the Patient Cancer Care Improvement (PCCI) Group. The group 
is made up of service users who have been under the care of xxxxxxxxxxxxxxxxxxxxxx for 
cancer treatment and is co-ordinated by staff from the on-site xxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxx team.  
A consultation session was held on the 12
th
 September 2018. All members of the 
group were invited to attend. Two service users attended the session along with the 
xxxxxxxxxx group co-ordinator. The service users were invited to provide feedback on the 
interview schedule, participant information sheet, consent to be contacted form, and consent 
form. Feedback was received regarding the accessibility of materials in terms of language, 
layout, font size etc., the sensitivity of and wording of the interview questions given the 
sensitive nature of the research, and the acceptability of the research from the service users’ 
perspectives.  
Based on feedback, a number of amendments were made to the materials to increase 
the likelihood that they will be easily understood by potential participants. Feedback from the 
service users was that they were in favour of the project and its intended aims to better 




Potential participants will be identified by members of their CUP medical team (e.g. 
Clinical Nurse Specialist, Consultant Oncologist, Clinical Psychologists). An information 
sheet will be provided to the professionals in each of the seven CUP services outlining the 
study and the participant inclusion and exclusion criteria.  
Once identified, potential participants will be provided with a participant information 
sheet during a routine appointment. If they are interested in taking part, they will be invited to 
fill out a ‘Consent to be contacted’ sheet with their contact details by the involved clinician, 
giving permission for the chief investigator to make contact. If the potential candidate ticks 
all the relevant boxes on this form and agrees to be contacted, their details (name and contact 
telephone number) will be provided by the Trust contact person to the chief investigator over 
the telephone. These contact details will be stored by the chief investigator on paper in the 
locked drawer in their home. Nobody else will have access to this drawer. The paper contact 
details will be shredded as soon as the interview has taken place. The original consent to be 
contacted form will be stored in the clinical records.  
The potential participant will be given the participant information sheet to take home with 
them and refer to as necessary.   
The decision for the researcher to contact participants rather than asking participants 
to call the researcher was made following recommendation from the Research and 
Development department at xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx who 
advised that in their experience this set up was preferable to service users/participants.  
Consent 
Once an individual has provided initial ‘consent to be contacted’, the chief 
investigator will contact them on the given contact number for an informal discussion. An 
interval of at least one week will be left between the individual providing consent to be 
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contacted and being called. This time is to allow the individual to thoroughly read the 
information sheet and formulate any questions they may like to ask.  
The phone call will be made on a mobile telephone provided by Lancaster University 
specifically for research purposes. The number of the mobile phone will be provided to 
potential participants in advance on the information sheet. This decision was made based 
upon the advice of the Research and Development department at xxxxxxxxxxxxxxxxxxxxxx 
who advised that in their experience, research participants often prefer not to answer the 
phone to an unfamiliar number.  
Once reached by telephone, the individual will be given the opportunity to ask any 
questions about the study. If at this stage they are happy to participate, arrangements will be 
made with them over the phone to meet. Participants will be given the choice to meet either 
in their own homes or at their local hospital site.  
At the start of the meeting, the chief investigator will go through the consent form 
with the participant, ensuring they understand each statement and answering any questions 
that arise. Participants will be reminded at this stage that there is no obligation for them to 
proceed with the interview if they are not fully comfortable and that they are free to stop the 
interview at any point. They will also be reminded that they are free to withdraw up until 2 
weeks after the interview takes place. Following this time, the anonymised transcription will 
take place and withdrawal will no longer be possible. Reassurance can be provided at this 
stage, however, that all identifying information will be removed.  
If the chief investigator has any doubts at any stage regarding the individual’s 
capacity to provide consent, the process will be paused and the individual’s clinical team will 
be consulted regarding the appropriateness of including the individual in the research. Only 
once it is clear that the individual has capacity to provide informed consent would 
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undertaking the interview be re-visited. This would be contingent upon meeting criteria for 
capacity as laid out in the Mental Capacity Act (Department of Health, 2005).  
Three copies of the consent form will be produced. The original copy will be retained 
in the patient’s file, one copy will be given to the participant, and one copy will be retained 
by the chief investigator. Where the interview takes place in participants’ homes, the consent 
form will be attached to the letter to the participant’s Clinical Nurse Specialist in order for it 
to be retained in their clinical file. The chief investigator’s copy will be scanned to make an 
electronic copy as soon as possible which will then be stored securely on the researcher’s 
personal Lancaster University storage drive. This drive is secure and password protected. The 
transfer will be made via the Lancaster University VPN.  The paper copy of the consent form 
will then be shredded by the chief investigator. The electronic version of the consent form 
will be stored for a maximum of six months after the completion of the study in line with the 
protocols of Lancaster University’s doctorate in clinical psychology programme. 
Data Collection 
Participants will be given a choice as to whether the interview is conducted at their 
local hospital site or in their own home. The decision to offer this choice was made in order 
to maximise participant comfort during the research process. If the participant chooses for the 
interview to be conducted in their own home, the researcher will follow the lone working 
policy of their employer, xxxxxxxxxxxxxxxxxxxxxx in order to minimise any risk to the 
researcher. This includes assessing any risks posed by participants or the environment and 
making the time and location of any interviews known by a selected colleague as per xcxx’s 
‘buddy system’. For any interviews with participants recruited via 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx, their local lone working policy will also be adhered 
to. This involves a similar arrangement to xxxx’s ‘buddy-system’ along with an additional 
risk assessment process and documentation needing to be completed prior to the interview. If 
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the patient chooses for the interview to be conducted at the hospital site this will be arranged 
for the most convenient time for the participant. This may be prior to a medical appointment 
to minimise travel or at another time if the participant prefers. A room for this purpose will be 
booked on the hospital site for the researcher and participant to meet. Interviews will not be 
carried out directly following a medical appointment due to the potentially emotionally 
exhausting nature of such appointments and the potential for the specific appointment 
outcomes to influence the interview content, rather than offering a more general overview of 
the participant’s experience since their diagnosis.  
Data will be collected via semi-structured interviews lasting for around 1 hour. One 
interview will be completed with each participant. This approach is deemed the ‘exemplary’ 
method for IPA, allowing for in-depth exploration along with flexibility to respond with 
additional follow up questions or prompts in response to participant answers (Smith and 
Osborne, 2008). Interviews will be carried out in person by the chief investigator. If 
necessary or more appropriate (i.e. due to fatigue) the interview may be split over more 
sessions in order to make the process manageable for individual participants. This will be 
discussed with each participant when the interview is initially arranged and should any 
participants become fatigued/unwell during the interview process and wish to continue at 
another time. Additional interviews with participants may also be carried out if any additional 
themes/questions arise from interviews conducted later in the research process which it would 
be valuable to discuss with any participants interviewed prior to generate richer data. 
Participants will be asked on the consent form whether they are willing for the chief 
investigator to contact them following their interview in these circumstances. Participants 
will be made aware they are free to decline contact of this type and that contact would only 
be made within three months of their initial interview taking place.  
Interviews will be audio recorded using a portable Dictaphone. 
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The chief investigator will also go through the Demographic Information for Study 
Participants with each participant to gather key demographic information. The participant’s 
name will not be included on this sheet. Information will be used to provide information on 
overall characteristics of the sample.  
Following the interview, the chief investigator will send a copy of the ‘Letter to 
Clinical Nurse Specialists’ to the individual’s CNS to advise of their participation in case of 
any additional support needs.  
Storage of Data 
The recording file will be transferred onto the chief investigator’s Lancaster 
University storage drive which is password protected and secured. The transfer will be made 
via Lancaster University’s VPN. This transfer from the Dictaphone to the University drive 
will be made as quickly as practicably possible due to the Dictaphone not having the option 
to encrypt or password protect the recording. Once this is completed the recording will be 
deleted from the Dictaphone. For the short period of time prior to the transfer being made the 
Dictaphone will stored as securely as possible by the chief investigator.  
Following transfer of the recording to the University Drive, the recording will be 
transcribed verbatim, following the guidance from Smith and Osborne (2008). Participants’ 
names and any other identifying information referred to (e.g. names of family members, town 
lived in) will be omitted from the transcripts to ensure participant anonymity. Once the 
recording has been transcribed it will be deleted from the Lancaster University storage drive.  
During analysis electronic copies of transcripts will be stored on the researcher’s 
personal University storage drive which is password protected and secured. Electronic 
transcripts will be stored separately to electronic consent forms so it is not possible to identify 
which transcript belongs to which participant.   
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Once the study is complete, the anonymised transcripts will be encrypted and 
transferred electronically via the secured University VPN to the Research Coordinator of the 
Doctorate in Clinical Psychology at Lancaster University where the chief investigator is a 
student. The transcripts will then be stored by the Research Director for up to ten years (in 
line with the course protocol), at which point they will be deleted by the Research Director.  
The Demographic Information for Study Participants form will be electronically 
scanned following each interview and the electronic copy will be stored on the chief 
investigator’s secure university storage drive via the university VPN. The paper copy will 
then be shredded.  
Proposed analysis 
The analytic strategy will be guided by the recommendations of Smith and Osborne 
(2008). This involves initially reading each transcript independently a number of times to 
generate initial themes. The initial themes are then organised into clusters of related themes. 
This process is then repeated for each transcript, with convergences and divergences between 
participants noted. Finally, the clusters of themes from across the participants are synthesised 
and organised hierarchically to produce main ‘superordinate’ themes and associated 
subordinate themes. In order to complete this process effectively, initial annotations and 
colour coding of themes will be done by hand. This will involve printing off copies of the 
anonymised transcripts. These copies will be stored securely in a locked drawer in the home 
of the chief investigator. Once this stage of the analysis is complete, the annotated paper 
transcripts will be scanned and the electronic copies will be securely stored on the 
researcher’s personal Lancaster University storage drive. This means of storage is password 
protected and secure. The paper copies of transcripts will then be shredded by the chief 
investigator.   
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Electronic software (Microsoft Excel) may also be used to undertake the analysis of 
themes. Any electronic documents relating to the analysis will be saved securely on the 
researcher’s password protected personal University storage drive.  
Practical concerns 
Room bookings for interviews where required will be made via staff contacts at each 
Trust site.  
Costs of printing and photocopying will be covered by Lancaster University’s 
Doctorate in Clinical Psychology programme along with mileage costs associated with the 
researcher’s travel to interviews.  
Ethical concerns 
A number of ethical issues may arise from undertaking the proposed research. The 
primary identified risk is of causing distress to participants through discussion of emotionally 
challenging topics. A risk assessment and management plan is included below.  
Assessment and Management of Risk 
Participants are made aware on the consent form that in the instance of the disclosure of risk 
confidentiality may not be maintained if other services or professionals need to be involved to 
ensure the safety of themselves or anybody else. This will be reiterated verbally at the 
beginning of the interview. 
Risks to participants 
Emotional distress:  
Due to the sensitive nature of the research topic, it is possible that participants may 
experience some emotional distress as a result of participating. If this is to occur during the 
interview, the interview and digital recorder will be paused. The participant will be given the 
chance to speak with the chief investigator if they desire and given as much time as needed 
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until their distress decreases. The option to cancel or rearrange the interview will be offered 
to the participant. If the participant is highly distressed, the chief investigator will liaise as 
soon as possible with their field supervisor regarding the patient’s welfare. The participant 
will be made aware of this. Following this, support can be offered by the clinical team as 
necessary.  
If the individual becomes distressed following the interview, a list of support 
resources is provided on the information sheet that they may find useful. This section also 
directs them to their clinical team who have a great amount of expertise in managing CUP 
and can provide emotional support. The individual will be made aware of these resources at 
the end of the interview.  
Risks to self: 
If the participant discloses any thoughts or intent to harm themselves in anyway 
immediate support will be sought by the chief investigator from their field supervisor or 
academic supervisor. If an imminent risk of harm to self is identified (e.g. threats of suicide, 
acts of self-harm), the chief investigator may contact relevant emergency services to ensure 
the person’s safety. If the risk is not imminent, discussion will take place between the 
individual, chief investigator, and the chief investigator’s supervisors to devise an appropriate 
plan of action. This may include referral to mental health crisis services, involvement of 
family members or friends with the individual’s consent, and support from the treating CUP 
service. The participant will be kept informed of who will need to know about their 




Due to the nature of the research, it is possible that participants may present as 
physically unwell at interview. To minimise this risk, participants will only be recruited 
where deemed to be medically stable by their medical team. However, it is recognised that 
this may not necessarily be static. If at interview it is evident that the participant is not 
physically well enough to engage in the interview process (e.g. fatigue, sickness, weakness 
etc.) the interview will be cancelled or postponed based on the participant’s wishes. Any 
concerns regarding deterioration or sudden changes in physical health will be passed on to the 
participant’s clinical nurse specialist to ensure any medical assistance required is made 
available. This will be discussed with the participant as appropriate. If it is apparent at 
interview that the participant is acutely unwell the researcher may contact the participant’s 
medical team to seek advice or the participant’s GP or ambulance services if they require 
immediate medical attention.  
Risk from others: 
If any risk to the participant from others is disclosed or apparent during the interview, 
the interview will be paused in order to address the risk as a priority. Again, the chief 
investigator will make contact with the research or field supervisor regarding appropriate 
action to be taken. This may include referral to safeguarding agencies, or police in instances 
of immediate risk of harm from others. The participant will be kept informed of who will 
need to know about their disclosure. The option to cancel or rearrange the interview will be 
offered to the participant. 
Risks to researcher 
Risks from others: 
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In carrying out interviews individually it is possible that the researcher may be 
vulnerable to risk of harm from participants should they become aggressive during the 
session. The likelihood of this is reduced where interviews are carried out on the hospital site 
where other professionals will be in the immediate vicinity. The risk, therefore, is greater 
when visiting individuals in their own homes. It is also possible that there may be risks in 
these instances of harm from other individuals (e.g. family members). There is also a 
potential risk on home-visits of environmental risks such as dogs. To minimise any risk the 
xxxx lone worker policy will be followed by the chief investigator. For home visits to any 
participants recruited via xxxxxxxxxxxxxxxxxxxxxxxxx, their local lone working policy will 
be followed and risk assessment documentation completed.  
Risk of emotional distress: 
Due to the nature of the research area, it is possible that the chief investigator may 
experience some emotional distress as a result of carrying out the interviews with 
participants. In this instance, supervision can be sought by the chief investigator from the 
field supervisor or academic supervisor as required. The chief investigator also has access to 
an Employee Assistance Programme via their employer xxxxxxxxxxxxxxxxxxxx should 
further emotional support be required.  
Timescale 
Data collection will commence following the necessary ethical approvals being 
granted. It is anticipated that interviews will commence in January 2019 and will be 
completed by April 2018. The project will end in May 2019 when it will be submitted to the 
Doctorate in Clinical Psychology programme for marking. Results will be fed back to 






Brocki, J. M. & Wearden, A. J. (2006). A critical evaluation of the use of 
interpretative phenomenological analysis (IPA) in health psychology. Psychology and 
Health, 21(1),87-108. doi: 10.1080/14768320500230185 
Cancer Research UK. (2017). About cancer of unknown primary. Retrieved 17 October 2018, 
from https://www.cancerresearchuk.org/about-cancer/cancer-unknown-primary-
cup/about   
Carlson, L. E., Angen, M., Cullum, J., Goodey, E., Koopmans, J., Lamont, L., ... & Bultz. B. 
D. (2004). High levels of untreated distress and fatigue in cancer patients. British 
journal of cancer, 90(12), 2297. doi: 10.1038/sj.bjc.6601887 
Carlson, L. E., & Bultz, B. D. (2003). Cancer distress screening: needs, models, and 
methods. Journal of psychosomatic research, 55(5), 403-409. doi: 10.1016/S0022-
3999(03)00514-2 
Department of Health. (2005). Mental Capacity Act. London, HMSO. Retrieved from 
https://www.legislation.gov.uk/ukpga/2005/9  
Fizazi, K., Greco, F. A., Pavlidis, N., Pentheroudakis, G., & ESMO Guidelines Working 
Group. (2015). Cancers of unknown primary site: ESMO Clinical Practice Guidelines 
for diagnosis, treatment and follow-up. Annals of oncology, 26(suppl_5), v133-138. 
Götze, H., Ernst, J., Brähler, E., Romer, G., & von Klitzing, K. (2015). Predictors of quality 
of life of cancer patients, their children, and partners. Psycho‐Oncology, 24(7), 787-
795. doi: 10.1002/pon.3725  
4-25 
ETHICS FORM 
Health Research Authority. UK policy framework for health and social care research. 
Retrieved from file:///C:/Users/hayle/Downloads/uk-policy-framework-health-social-
care-research.pdf 
Hemminki K, Bevier M, Hemminki A, & Sundquist, J. (2012). Survival in cancer of 
unknown primary site: population‐based analysis by site and histology. Annals of 
Oncology, 23, 1854–63. 
Kershaw, T., Northouse, L., Kritpracha, C., Schafenacker, A., & Mood, D. (2004). Coping 
strategies and quality of life in women with advanced breast cancer and their family 
caregivers. Psychology & Health, 19(2), 139-155. doi: 
10.1080/08870440310001652687  
National Comprehensive Cancer Network. (2013). Distress Management (Version 2). 
Retrieved from https://www.nccn.org/professionals/physician_gls/default.aspx  
National Institute for Health and Care Excellence. (2010). Metastatic malignant disease of 
unknown primary origin in adults: diagnosis and management. Retrieved 17 October 
2018, from https://www.nice.org.uk/guidance/cg104 
Office for National Statistics. Measuring equality: A guide for the collection and 




Pietkiewicz, I. & Smith, J.A. (2012) Praktyczny przewodnik interpretacyjnej analizy 
fenomenologicznej w badaniach jakościowych w psychologii. Czasopismo 
Psychologiczne, 18(2), 361-369.  
4-26 
ETHICS FORM 
Riihimäki, M., Hemminki, A., Sundquist, K., & Hemminki, K. (2013). Time trends in 
survival from cancer of unknown primary: small steps forward. European Journal of 
Cancer, 49(10), 2403-2410. doi: 10.1016/j.ejca.2013.02.022 
Singer, S., Das-Munshi, J., & Brähler, E. (2010). Prevalence of mental health conditions in 
cancer patients in acute care—a meta-analysis. Annals of Oncology, 21(5), 925-930. 
doi: 10.1093/annonc/mdp515 
Smith, J. A., & Osborn, M. (2008). Interpretative phenomenological analysis. In J. A. Smith 
(Ed.), Qualitative psychology: A practical guide to research methods (2nd ed.) (pp. 
53–80). London: Sage. 
Van de Wouw, A. J., Janssen-Heijnen, M. L. G., Coebergh, J. W. W., & Hillen, H. F. P. 
(2002). Epidemiology of unknown primary tumours; incidence and population-based 
survival of 1285 patients in Southeast Netherlands, 1984–1992. European journal of 
cancer, 38(3), 409-413 
Zabora, J. R., Blanchard, C. G., Smith, E. D., Roberts, C. S., Glajchcn, M., Sharp, J. W., ... & 
Dozier-Hall, D. (1997). Prevalence of psychological distress among cancer patients 
across the disease continuum. Journal of Psychosocial Oncology, 15(2), 73-87. doi: 
10.1300/J077v15n02_05 
Zabora, J., BrintzenhofeSzoc, K., Curbow, B., Hooker, C., & Piantadosi, S. (2001). The 
prevalence of psychological distress by cancer site. Psycho‐oncology, 10(1), 19-28. 






IRAS Form                                                                    Reference:                                                     IRAS Version 
5.11 19/NW/0096  
 
Welcome to the Integrated Research Application System  
 
IRAS Project Filter  
 
The integrated dataset required for your project will be created from the answers you give to the following questions. The 
system will generate only those questions and sections which (a) apply to your study type and (b) are required by the 
bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications. 
 
Please complete the questions in order. If you change the response to a question, please select ‘Save’ and review all the 
questions as your change may have affected subsequent questions.  
 
 
Please enter a short title for this project (maximum 70 characters)  
Coping longer-term with CUP 
 
1. Is your project research? 
 
 Yes  No  
 
 
2. Select one category from the list below: 
 
Clinical trial of an investigational medicinal product 
 
Clinical investigation or other study of a medical device 
 
Combined trial of an investigational medicinal product and an investigational medical device 
 
Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice 
 
Basic science study involving procedures with human participants 
 
Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative 
methodology 
 
Study involving qualitative methods only 
 
Study limited to working with human tissue samples (or other human biological samples) and data (specific project 
only) 
 
Study limited to working with data (specific project only) 
 




If your work does not fit any of these categories, select the option below: 
 
 Other study  
 
 
2a. Please answer the following question(s):   
a) Does the study involve the use of any ionising radiation? Yes No 
b) Will you be taking new human tissue samples (or other human biological samples)? Yes No 
c) Will you be using existing human tissue samples (or other human biological samples)? Yes No 
   
   
3. In which countries of the UK will the research sites be located?(Tickoallothatoapply)   
England   
Scotland    
 
Date: 28/01/2019 1 251064/1328269/37/297 
Appendices 





















This study does not involve the NHS  
 
 
4. Which applications do you require? 
 
 IRAS Form 
 Confidentiality Advisory Group (CAG)  





Most research projects require review by a REC within the UK Health Bepartments' Research Ethics Service. 
Is your study exempt from REC review? 
 
 Yes       No  
 
 
5. Will any research sites in this study be NHS organisations? 
 
 Yes       No  
 
 
5a. Are all the research costs and infrastructure costs (funding for the support and facilities needed to carry out 
research e.g. NHS Support costs) for this study provided by a NIHR Biomedical Research Centre, NIHR Collaboration 
for Leadership in Health Research and Care (CLAHRC), NIHR Patient Safety Translational Research Centre or 
Medtech and In Vitro Biagnostic Cooperative in all study sites? 
 
Please see information button for further details. 
 
 Yes       No 
 
Please see information button for further details.  
 
5b. Bo you wish to make an application for the study to be considered for NIHR Clinical Research Network 
(CRN) Support and inclusion in the NIHR Clinical Research Network Portfolio? 
 
Please see information button for further details. 
 










 6. Bo you plan to include any participants who are children? 
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Yes No   
    
      
7. Bo you plan at any stage of the project to undertake intrusive research involving adults lacking capacity to 
consent for themselves? 
 








8. Bo you plan to include any participants who are prisoners or young offenders in the custody of HM Prison Service 
or who are offenders supervised by the probation service in England or Wales? 
 




9. Is the study or any part of it being undertaken as an educational project? 
 
 Yes       No 
 
Please describe briefly the involvement of the student(s):  
The chief investigator is a trainee clinical psychologist undertaking this project in partial fulfilment of a doctorate in 
clinical psychology (DClinPsy) at Lancaster University. 
 
While the HRA's UK policy framework for health and social care research (2017, file:///C:/Users/hayle/Downloads/uk-
policy-framework-health-socia l-care-research.pdf) states that ordinarily students should not take the role of chief 
investigator, exceptions to this rule may be made "for an experienced care practitioner or manager undertaking an 
educational qualification for continuing professional development or a doctoral-level study while employed by a health 
or social care provider or a university, or for a researcher undertaking a doctoral-level study in receipt of a fellowship" 
(p.17). The student in question meets these requirements for the role of chief investigator.  
 
 
9a. Is the project being undertaken in part fulfilment of a PhB or other doctorate? 
 
 Yes       No  
 
 
10. Will this research be financially supported by the United States Bepartment of Health and Human Services or any 
of its divisions, agencies or programs? 
 
 Yes       No  
 
 
11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of the 
project (including identification of potential participants)? 
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Integrated Research Application System  
Application Form for Research involving qualitative methods only  
 





The Chief Investigator should complete this form. Guidance on the questions is available wherever you see this symbol 
displayed. We recommend reading the guidance first. The complete guidance and a glossary are available by selecting 
Help. 
 





Short title and version number: (maximum 70 characters - this will be inserted as header on all forms) 







REC Name:  
Liverpool East 
 
REC Reference Number: Submission date: 
19/NW/0096 28/01/2019 
  
    
PART A: Core study information  
 
1. ABMINISTRATIVE BETAILS  
 
A1. Full title of the research: 
 
Patients’ experiences of coping longer-term with cancer of unknown primary  
 
 
A2-1. Educational projects 
 





Title Forename/Initials Surname  














Give details of the educational course or degree for which this research is being undertaken: 
 
Name and level of course/ degree:  
Doctorate in Clinical Psychology (DClinPsy) 
 
 














Name and contact details of academic supervisor(s): 
 
Academic supervisor 1 
 
 
 Title Forename/Initials Surname 
 Dr Anna Daiches 
Address Department of Health Research 
 Faculty of Health and Medicine 
 Lancaster University  
Post Code LA1 4YG  
E-mail a.daiches@lancaster.ac.uk 
Telephone 01524 594406  
Fax    
Academic supervisor 2   
 Title Forename/Initials Surname 
 Dr Anna Duxbury 
Address Department of Health Research 
 Faculty of Health and Medicine 
 Lancaster University  
Post Code LA1 4YG  
E-mail a.duxbury@lancaster.ac.uk 
Telephone 01524 592 974  
Fax    
    
 




 Student(s) Academic supervisor(s)  
 
 
Student 1  Ms Hayley Slater 
   
 
 
Dr Anna   Daiches      
 
  Dr Anna Duxbury  
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 Title Forename/Initials Surname  
 Dr Anna Daiches  
Post Clinical Director   
Qualifications MA, D Clin Psych   
ORCID ID     
Employer Lancashire Care NHS Foundation Trust  
Work Address Department of Health Research  
 Faculty of Health and Medicine  
 Lancaster University   
Post Code LA1 4YG   
Work E-mail a.daiches@lancaster.ac.uk  
* Personal E-mail a.daiches@lancaster.ac.uk  
Work Telephone 00000000000   
* Personal Telephone/Mobile 01524594406   











 Title Forename/Initials Surname 
 Ms Becky Gordon 
Address Research Services  
 B14 Furness College  
 Lancaster University  
Post Code LA1 4YT  
E-mail ethics@lancaster.ac.uk  
Telephone 01524592981  
Fax    
    
      
A5-1. Research reference numbers. Pleaseogiveoanyorelevantoreferencesoforoyourostudy: 
 



























Additional reference number(s):   
Ref.Number Description Reference Number 

















A5-2. Is this application linked to a previous study or another current application? 
 






2. OVERVIEW OF THE RESEARCH  
 
To provide all the information required by review bodies and research information systems, we ask a number of 
specific questions. This section invites you to give an overview using language comprehensible to lay reviewers 
and members of the public. Please read the guidance notes for advice on this section.  
 





This study will seek to explore the experiences of coping of individuals who are living 'longer-term' with cancer of 
unknown primary (CUP) i.e. being maintained/stabilised on treatment over 6-months post-diagnosis. This group of 
patients represent a relatively small sub-group as, unfortunately, a CUP diagnosis is often received in the later stages of 
illness with a poor prognosis. Research with populations experiencing other cancer diagnoses has highlighted that a 
range of coping strategies are employed with direct impacts on psychological distress. Uncertainty has been identified as 
a factor which increases distress for those with cancer. Relatively little is known about the experiences of those 
diagnosed with CUP, which is a condition entailing a great deal of uncertainty in relation to prognosis, treatment, and 
illness progression and no research so far has focused specifically upon patients who are stable on treatment so far 
beyond their diagnosis, and as such have been living with CUP for a prolonged period. Therefore the current study will 
investigate coping experiences within this population. Data will be gathered via interviews with patients.  
 
 









Purpose and Design:  
To understand the coping experiences of people living longer-term with CUP, it is necessary to gather first-hand 
accounts from patients themselves. As such, a qualitative methodological approach was most fitting for this aim and will 
allow the generation of rich, detailed data from participants through semi-structured interview conversations. The nature 
of the research topic (CUP) and interview process may inevitably lead to some conversations with participants that are 
emotive in nature. There is potential for this to cause distress to participants. Should this occur the participants will be 
given the option to pause or stop the interview. Participants will be offered time to talk to the chief investigator and 
discuss possible support options. The chief investigator is a trainee clinical psychologist who regularly has difficult and 
emotionally laden conversations of this nature with clients in their clinical work. Resources for further support are listed 
on the participant information sheet should they be required in the event of distress. If there are concerns for the 
participant’s emotional well-being, the chief investigator will liaise with the field supervisor,  
Dr  (Principal Clinical Psychologist) who is an experienced clinical psychologist working in cancer services 
to discuss what support may be appropriate. Should any participant indicate any thoughts or intentions of harming 
themselves in any way as a result of distress, confidentiality will be broken (as outlined on the consent form) in order to 
ensure the relevant services are involved to provide the participant with support. 
 
Service users from the Patient Cancer Care Improvement Group at were consulted 
regarding the content of the recruitment materials and interview questions regarding how distress could be minimised for 
participants through use of sensitive language. Feedback from the group members was that they were in favour of the 
project as a means to better understand and potentially provide recommendations to improve the experiences of 
 










Potential participants will be identified by a member of medical staff from their CUP team. The CUP team will be made 
aware of the inclusion and exclusion criteria for the study so that appropriate participants can be identified. This 
information is outlined in the 'Professionals' information sheet'. 
 
Potential participants will receive a copy of the participant information sheet and, if they are interested in participating, will 
be invited to fill in a ‘consent to be contacted form’ with their contact details (name and telephone number). Their contact 
details will then be passed on to the Chief Investigator by the CUP team. A period of 1 week will be left between the 
participant giving their permission to be contacted and contact being made to allow participants time to review the 
information sheet and consider any questions they may like to ask. Following this time period, the chief investigator will 
telephone the participant to informally discuss the study and answer any questions. If at this stage the participant is still 
willing to be part of the study a meeting for the interview will be arranged. Immediately before the interview the chief 
investigator will go through the consent form with the participant to ensure their understanding of each item. They will 
then be asked whether they are happy to proceed and sign the consent form. The participant will be reminded that they 
are under no obligation to participate and that the medical care they receive will not be impacted by their taking part. 
They will be reminded that they are free to withdraw at any time without giving reason up until two weeks following 
interview at which point the data will have been anonymously transcribed for inclusion in the analysis. 
 
Risks, burdens, and benefits:  
There are no direct benefits associated with participation in the study. It is hoped that findings from the study will 
inform best practice for how services can support people living longer-term with CUP. 
 
As discussed above, there is a possibility that interviews may involve the discussion of emotional content which may 
be distressing for participants. Measures will be taken to minimise and manage any distress that arises, including: 
informing participants we can pause or terminate the interview at any time and signposting participants to resources 
(included in the participant information sheet) for further support if indicated. The Chief Investigator may also liaise  
with the field supervisor, Dr (Principal Clinical Psychologist) around what specific local support may be available or any 
onward referrals that may be beneficial. The Patient Cancer Care Improvement Group at   
provided consultation on the phrasing of interview questions in order to minimise the distress and 
wording may cause. Participants are made aware on the consent form that their clinical nurse specialist will be routinely 
made aware of their participation in the study in case of any further support being needed. Clinical nurse specialists will 
be alerted to their patient's participation by the 'letter to clinical nurse specialists' which will be sent out following the 
interview. 
 
Should any risk to or from self or others be disclosed by participants during interviews the interview process may be 
paused or terminated to allow the arising issues to be appropriately managed. Participants will be made aware by the 
consent form, participant information sheet, and verbally that should any risks be identified their confidentiality may be 
breached in order for appropriate actions to be taken to ensure the safety of those involved in the disclosure. There may 
be some risk to the chief investigator associated with conducting interviews in patients’ own homes. As 
such the  ‘Lone Working’ Policy guidelines will be followed. In the instance of  
home visits to any participants recruited via , local lone working guidelines and risk assessment procedures will also be 
followed. 
 
It is hoped that by focusing upon a sample population who are deemed to be clinically stable, the research will avoid 
placing undue burden upon those who are acutely or severely physically unwell who may find participation particularly 
challenging. However, due to their diagnosis, it is possible that participants may be experiencing fatigue or become 
unwell during interview. In these instances the interview will be terminated and, with participant consent, may be 
continued at another time. The chief investigator will discuss with participants when arranging interviews whether they 
would prefer to conduct the interview over two sessions to minimise the risk of fatigue or symptom exacerbation. 
 
Confidentiality:  
The “Caldicott Principles” and Data Protection Act (1998) have been considered when designing this research project. 
No personal patient information will be available to the chief investigator until the patient gives their consent to be 
contacted and shows interest in participating in the study. At this stage, personal data gathered by the chief investigator 
will be kept to the minimum required, namely a name and contact telephone number. Should the individual wish for their 
interview to be conducted at their home address this information will be gathered over the telephone and stored with 
their ‘consent to be contacted form’. This data will be stored securely in a locked drawer in the chief investigator’s home 
and will be shredded as soon as the interview has taken place. 
 
The interview will be audio recorded. The recording will be transferred as soon as practically possible to the chief 
investigator’s secure storage space on the Lancaster University Network which is password protected. It will then be 
transcribed anonymously, using a pseudonym. Any identifying information (e.g. names of family members or home 
town) will be redacted to protect anonymity. The participant will be referred to only by the pseudonym throughout the 
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analysis and write-up of the project. Once the interview is transcribed the recording will be deleted from the Lancaster 
University storage drive. The transcripts will be saved electronically in the drive. Upon submission of the project, 
transcripts will be securely electronically transferred to Lancaster University’s Doctorate in Clinical Psychology who will 
retain them for up to ten years as per their assessment policy. Consent forms will be scanned to create an electronic 
copy, once this is completed the paper copy will be shredded. The electronic version will be stored on the Lancaster 
University server for a maximum of six months following project completion, in line with Lancaster University Doctorate in 
Clinical Psychology guidance. 
 
Participants will be informed prior to the interview, both in writing (on consent form) and verbally, that their confidentiality 
may be breached if there are any concerns about risk to them or others. In this scenario the chief investigator would 
consult with their field supervisor regarding the best course of action, considering the participant’s wishes where 
possible. The clinical nurse specialist of each participant will be made aware of their participation in the study by the 
'clinical nurse specialist letter' which will be sent following the interview. This is to make the clinical nurse specialists 
aware of the possibility further support may be needed by participants following their interview. 
 
Conflict of Interest:  
There are no issues in relation to conflict of interest. 
 
Feedback to Participants:  
Participants will be asked to provide their postal address on their consent form should they wish to receive a summary of 
results from the study following completion. 
 
Grievances:  
Contact details for the chief investigator’s supervisors is included in the participant information sheet should any 
participants wish to make a complaint regarding any aspect of the research process.  
 
 
3. PURPOSE ANB BESIGN OF THE RESEARCH  
 
A7. Select the appropriate methodology description for this research. Pleaseotickoallothatoapply: 
 






















Questionnaire, interview or observation study 
 
Randomised controlled trial 
 





A10. What is the principal research question/objective? Pleaseoputothisoinolanguageocomprehensibleotooaolayoperson. 
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• Do these patients feel able to cope? What factors increase or decrease perceived coping capacity?  
• Has their sense of ‘coping’ changed throughout their illness?  





A12. What is the scientific justification for the research? Pleaseoputothisoinolanguageocomprehensibleotooaolayoperson. 
 
Research has demonstrated that people diagnosed with all forms of cancer may experience increased levels of 
emotional distress (Carlson et al., 2004; Zabora et al., 2001) and mental health difficulties (Singer, Das-Munshi and 
Brähler, 2010). 
 
CUP is a relatively under-researched area given that it is one of the most lethal forms of cancer (Hemminki, Bevier, 
Hemminki, & Sundquist, 2012; van de Wouw, Janssen‐Heijnen, Coebergh, & Hillen, 2002). A diagnosis of CUP is 
given when a secondary cancer is found without an identifiable primary source (Varadhachary & Raber, 2014). Due to 
this, the condition is often characterised by uncertainty in relation to cause, prognosis, and treatment (Ryan, Lawlor & 
Walshe, 2013; Symons, James & Brooks, 2009). This uncertainty has been shown to amplify the difficulties 
encountered across other cancer diagnoses for patients with CUP (La Pushin, 2009; Richardson et al., 2015). 
 
Understandably, these emotional difficulties encountered as a result of living with cancer may impact on the individual’s 
perceived coping capacity. Coping can be defined as “constantly changing cognitive and behavioural efforts to manage 
external and/or internal demands that are appraised as taxing or exceeding the resources of the person” (Lazarus & 
Folkman, 1984). Previous studies have demonstrated that people living with cancer employ a wide range of coping styles 
and strategies (Al-Azri, Al-Awisi & Al-Moundhri, 2017; Nipp et al., 2016), which may positively or negatively impact 
psychological wellbeing (Roesch et al., 2005). As yet, little research has been undertaken to investigate the coping 
experiences of people with CUP. However, findings showing that increased uncertainty negatively impacts upon ability to 
implement coping strategies (Germino et al., 1998) allows us to infer that ‘coping’ may be a particular challenge for 
people living with CUP. 
 
While unfortunately a diagnosis of CUP often indicates poor prognosis and limited life expectancy (Greco et al., 2010), a 
subset of patients are medically stable over six months following diagnosis (Riihimäki, Hemminki, Sundquist, & 
Hemminki, 2013). This group of patients, therefore, has an extended period of living with and coping with CUP, and 
potentially the associated uncertainty and emotional distress. No research has previously been undertaken which 
focuses on the experiences of coping for this patient population and, therefore, it is believed that this research is 
warranted. It is hoped the study will increase understanding of patients’ experiences and therefore how services can 
best support them throughout their time living with CUP.  
 
 




The research will be qualitative in nature and will use interpretative phenomenological analysis (IPA) as the guiding 
approach and analytic strategy. This methodological approach was selected due to the focus on understanding the 








 Seven Trusts were identified as, despite the 
relatively small sample size, it is anticipated that the number of people meeting inclusion criteria in each Trust may be 
very low, due to the nature of CUP. Relevant clinical staff will be provided with information about the study and the 
inclusion/exclusion criteria in order to identify appropriate candidates via the 'Professional's Information Sheet'. 
 
Participants will need to have been diagnosed with CUP over six months before the interview and will need to be 
assessed to be ‘medically stable’ by their clinical team. These patients treated by CUP services come from the 80-85% 
of those diagnosed who do not belong to favourable risk subsets, for whom the median survival time is generally less 
than 1 year (Fizazi et al 2015). 
 
Participants will need to be 18 years of age or older and have capacity to provide informed consent to participate. 
Unfortunately, patients that cannot speak English will not be able to participate as there are no funds available within 
the scope of this research to provide translation services. 
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A sample size of 10-12 participants will be recruited in line with the recommendations for an IPA study (Smith & 
Osborne, 2008). 
 
Recruitment and consent: 
 
Recruitment will commence once the necessary ethical approval has been granted. Patients identified as meeting the 
inclusion criteria will be provided with a participant information sheet by a member of their clinical team. If they are 
interested in participating, they will be asked to provide their name and contact number on the ‘consent to be contacted’ 
form. A period of one week will be left in between the participant providing these details and the chief investigator making 
contact to allow time to re-read the information sheet and generate any questions. Following this period, the chief 
investigator will contact the potential participant by telephone for an informal discussion about the study and to answer 
any questions. If at this stage the potential participant is still interested in participating, an interview will be scheduled. the 
participant will be given a choice between meeting in their own home or at their hospital site. 
 
Immediately prior to the interview, the chief investigator will go through the consent form with the participant to ensure 
understanding of each item. It will be reiterated that the participant is under no obligation to complete the interview and 
that they are free to withdraw at any time until two weeks after the interview without giving any reason. The participant 




Each participant will partake in one interview lasting for approximately one hour. Participants will be given the option to 
split the interview across multiple sessions if required in order to reduce risk of fatigue/exacerbation of any symptoms of 
physical illness. 
 
The interview will be semi-structured, having topics related to the research questions, but also allowing for flexibility to 
explore any salient points made in more depth and make the interview more conversational and participant-led. The 
semi-structured interview is considered the best tool for gathering data for an IPA study (Smith & Osborne, 2008). 
 
Before the interview commences participants will be reminded about the limits of confidentiality should there be any 
concerns for wellbeing and of their right to withdraw, as stated above. They will also be advised the interview may be 
paused at any time should they feel distressed or emotional. Participants will be signposted to the resources provided on 
the participant information sheet should they feel in need of further support. 
 
Interviews will be audio recorded which patients are made aware of via the participant information sheet and consent 
form. 
 
Participants will be asked to fill out their postal address on the consent form if they would like to receive a summary of 
the study results following completion of the project. 
 
At the face to face interview, the chief investigator will also go through a brief demographic information questionnaire 
(Demographic Information Form) to gather the participant's age, time since CUP diagnosis, gender, and ethnicity. This 
will take no longer than five minutes and participants will be free to decline to give the information. 
 
The recruitment materials and interview schedule were developed with consultation from service users from the 
Patient Cancer Care Improvement group. 
 
Patients will be asked on the consent form whether they would be willing to partake in a follow up interview should any 
additional themes or questions arise later in the research process which may help to generate richer data. This contact 
would occur within three months of the initial interview. Patients will be made aware that they are free to decline to 
consent to this.  
 
 
A14-1. In which aspects of the research process have you actively involved, or will you involve, patients, service 
users, and/or their carers, or members of the public? 
 
Design of the research 
 
Management of the research 
 
Undertaking the research 
 
Analysis of results 
 
Dissemination of findings 
 
None of the above 
 
 









Service users from the Patient Cancer Care Improvement group which is facilitated by  at 
 were invited to consult on the study's recruitment materials and interview questions. The 
whole group was invited and two service users were able to attend. Feedback was provided regarding the language 
and terminology used, how 'reader-friendly' recruitment materials were, and whether interview questions were 
perceived as appropriate and sensitively phrased in order to minimise the likelihood of distress. Feedback from service 
users was favourable and the group members supported the study as an opportunity to better understand patient 
experiences and potentially provide recommendations which may lead to improvements for CUP patients. 
 
All participants will be given the option to receive a summary of the study results following project completion.  
 
 
4. RISKS ANB ETHICAL ISSUES  
 
RESEARCH PARTICIPANTS  
 
A15. What is the sample group or cohort to be studied in this research? 
 






















Inflammatory and Immune System 
 














Renal and Urogenital 
 









Gender: Male and female participants 
Lower age limit:  18 Years 
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A17-1. Please list the principal inclusion criteria (list the most important, max 5000 characters). 
 
Participants will be included based upon the following criteria:  
- Diagnosis of CUP  
- Clinically stable 6 months or more following diagnosis  
- Receiving treatment or being actively monitored by Trust care teams  
- 18 years or older  
 
 
A17-2. Please list the principal exclusion criteria (list the most important, max 5000 characters). 
 
- Participants will be excluded if for any reason they are not able to engage with the research process or give informed 
consent to participate e.g. not speaking English, significant learning disability or cognitive impairment  
 
 
RESEARCH PROCEBURES, RISKS ANB BENEFITS  
 
A18. Give details of all non-clinical intervention(s) or procedure(s) that will be received by participants as part of 
the research protocol. Theseoincludeoseekingoconsent,ointerviews,onon-clinicaloobservationsoandouseoofoquestionnaires. 
 
Please complete the columns for each intervention/procedure as follows: 
 
1. Total number of interventions/procedures to be received by each participant as part of the research protocol. 
 
2. If this intervention/procedure would be routinely given to participants as part of their care outside the research, 
how many of the total would be routine? 
 
3. Average time taken per intervention/procedure (minutes, hours or days) 
 
4. Details of who will conduct the intervention/procedure, and where it will take place. 
 
Intervention or procedure 
 
Consent gained from participant by clinical staff to be 




1 2 3 4 
1 0 5 Clinical staff team- likely to be 
  minutes clinical nurse specialists or 
   consultant oncologists. 
   Conversation to take place during 
   routine contact. 
 
 Phone contact from chief investigator to answer any questions 1 0 15 Hayley Slater, Chief Investigator. 
 and, if agreed with participant, schedule interview slot.   minutes Phone contact. 
 In person consent seeking immediately prior to interview. 1 0 5 Hayley Slater, Chief Investigator. 
 Opportunity to answer any questions.   minutes Interviews will take place at 
     hospital site or participants own 
     home depending on preference. 
 Interview (one one-off interview, may be split across 2 1- 0 1 hour Hayley Slater, Chief Investigator. 
 sessions if this best meets participant needs to minimise 2   Will take place at hospital site or 
 fatigue, physical symptoms etc.)    participants' own home depending 
     on preference. 
 Follow up interview (in the event of any new themes/questions 1- 0 1 hour Hayley Slater, Chief Investigator. 
 arising later in research process). As above, if the participant 2   Will take place at hospital site or 
 is experiencing fatigue etc. interview may be over 2 sessions.    participants' own home depending 
     on preference. 
       
       
         
A21. How long do you expect each participant to be in the study in total? 
 
Approximately 1 hour in a one-off interview. This may be split over 2 sessions lasting 20-30 minutes each in order to 
minimise fatigue for participants if appropriate. 
 
Patients will be asked on the consent form and whether they would be willing to be contacted to partake in a follow-up 
interview should any new themes or questions arise later in the research process. This follow up interview would again 
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Participants will be asked questions about their experiences of CUP and how they have coped since their diagnosis. 
This is inevitably a highly sensitive area and there is a possibility that discussing these topics may be emotionally 
challenging or difficult for participants. Steps that have and will be taken to minimise the likelihood and severity of 
participant distress include: 
 
- Consulting with service users regarding choice of language and interview questions to use language that is 
sensitive and least distressing  
- Making participants aware prior to the interview that we can break and pause the interview at any point. They will also 
be made aware that at any point the interview can be terminated if preferred and they may withdrawn from the study 
any time until 2 weeks following the interview when transcription occurs. In the event that a participant wishes to 
withdraw from the study part way through an interview, their will not be included in the study.  
- Participants will have time as required during or following the interview to talk through any issues that are raised 
with the chief investigator.  
- Options for further support will be discussed with each participant. These are outlined on the participant information 
sheet and will be re-referred to at interview. If the participant is highly distressed, the chief investigator will consult with 
their field supervisor regarding what support may be available and any onward referrals for psychological support as 
indicated and desired by the participant. If there are any concerns for the participant's safety this will be immediately 
discussed with the field supervisor and acted on accordingly. 
 
Measures will also be taken to promote participants' physical comfort and reduce risk of fatigue/exacerbation of physical 
symptoms. To do so participants will be given the option of completing the approximately 60 minute interview over 2 
shorter sessions.  
 
 
A23. Will interviews/ questionnaires or group discussions include topics that might be sensitive, embarrassing 
or upsetting, or is it possible that criminal or other disclosures requiring action could occur during the study? 
 




Yes, that topic of the research (CUP) is such that discussing their experience may be upsetting or distressing for 
participants. To manage this, participants will be made aware that interviews can be paused or terminated at any 
time. If upset or distressed, participants will have opportunity to talk with the chief investigator about any concerns. 
Resources for support will be provided for each participant on the participant information sheet. If the participant is 
highly distressed or feels in need of further support, the chief investigator will contact their filed supervisor to seek 
advice and consider possible support options or onward referrals, considering the participant's preferences. 
 
If any disclosures are to occur during the interview process, the chief investigator will contact their field supervisor for 
support regarding next steps. If the disclosure is of an urgent/emergency nature the chief investigator will contact 
emergency services as appropriate. All participants will be made aware prior to interview that confidentiality will be 
breached if there are any concerns for their safety or the safety of anybody else.  
 
 
A24. What is the potential for benefit to research participants? 
 
There are no direct benefits associated with participation in the study. Patients may find it helpful to talk openly about 
their experiences.  
 
 
A26. What are the potential risks for the researchers themselves? (ifoany) 
 
It is possible that the content of interview discussions may be upsetting for the chief investigator. If this is the case 
support will be sought from the field and clinical supervisors as required. 
 
There may be risks to the chief investigator associated with lone working when conducting interviews in participants'  
own homes. To minimise this risk the Lone working Policy of  the chief investigator's 
employer, will be followed. This will mean that risks will be assessed by the chief investigator on arrival and interview will 
be immediately terminated if there are any concerns for safety. A 'buddy' system will also be put in place, with the chief 
investigator arranging with a peer for the peer to monitor their safety. The peer will be made aware 
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of the location of the interview and expected duration. The chief investigator will contact the 'buddy' once the interview is 
complete and log their safety. If this contact is not made, the buddy will follow procedures to ensure that the chief 
investigator is safe and raise the alarm if there are any concerns. 
 
In instances of home visits to any patients recruited via  Trust's local Lone 
Working Policy Guidelines will be followed in addition to established Procedures.  
The advice given in both sets of guidelines are roughly similar, however, for home visits to patients of  an 
additional risk assessment form will be completed prior to any visits taking place.  
 
 
RECRUITMENT ANB INFORMEB CONSENT  
 
In this section we ask you to describe the recruitment procedures for the study. Please give separate details 
for different study groups where appropriate.  
 
A27-1. How will potential participants, records or samples be identified? Who will carry this out and what 




Potential participants will be identified by clinical staff (e.g. clinical nurse specialists, medical oncologists) working in the 
CUP services where recruitment will take place. Relevant staff will be provided with a 'professionals' information sheet' 
listing inclusion and exclusion criteria along with information about the study to aid staff in selecting eligible participants. 
 
 
Potential participants (i.e. meeting inclusion/exclusion criteria) will be asked during routine contact by the staff member 
whether they are willing to be contacted by the chief investigator to discuss the study, ask any questions, and, if willing, 
arrange an interview slot. The chief investigator will confirm that criteria are met during the preliminary telephone 
conversation prior to interview. Informed consent will be gathered by the researcher immediately prior to the interview 
taking place. 
 
The chief investigator will not have any access to any personal information prior to participants providing details on the 
'consent to be contacted form'. This form will ask for the participant's name and contact telephone number.  
 
 
A27-2. Will the identification of potential participants involve reviewing or screening the identifiable 
personal information of patients, service users or any other person? 
 






A28. Will any participants be recruited by publicity through posters, leaflets, adverts or websites? 
 
 Yes       No  
 
 
A29. How and by whom will potential participants first be approached? 
 
By a clinical nurse specialist or other member of the individual's direct healthcare team. Clinical staff in the CUP teams 
will be provided with a 'professionals' information sheet' providing information about the study and outlining the inclusion 
and exclusion criteria in order to identify eligible patients. Patients will be approached by clinical staff during routine 
contact. They will be provided with the 'participant information sheet' and have chance to discuss the study with the 
member of staff. If they are interested in participating, they will be asked to complete the 'consent to be contacted' sheet 
in order for their details to be passed to the chief investigator. 
 
Once these details are collected, a period of one week will be left in order to give patients time to read over the 
provided information and consider any questions. Following this, the chief investigator will contact potential participants 
on the provided telephone number. This telephone call will provide time to discuss the study and answer any questions. 
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The chief investigator will have no access to any personal records or information for any patients prior to participants 
agreeing to be contacted by the chief investigator.  
 
 
A30-1. Will you obtain informed consent from or on behalf of research participants? 
 










Informed consent will be obtained from all study participants. 
 
Patients meeting the study's inclusion and exclusion criteria will be identified by direct healthcare staff. They will be 
provided with a 'participant information sheet' during routine clinical contact. If they are interested in finding out more or 
participating, they will be asked by the member of clinical staff to complete a 'consent to be contacted' sheet, giving 
their name and contact number. 
 
A time period of one week will then be left prior to contact to give patients time to re-read the 'participant information 
sheet' and consider and questions they may like to ask. 
 
Following the one week period, the chief investigator will make contact with the potential participant to informally 
discuss the study and answer any questions. If at this stage the patient is happy to participate in the study, an 
interview slot will be arranged. 
 
Immediately prior to the interview, the participant will be given time to ask any further questions. The chief investigator 
will go through the consent form with the participant, ensuring that the participant has a full understanding of each item 
on the form that they are consenting to. Participants will be reminded that they are under no obligation to participate int 
he study and that their participation has no impact on the medical care they receive. Participants will also be made 
aware that they are able to stop the interview or withdraw from the study without giving reason up until 2 weeks after the 
interview has taken place. At this stage their interviews will be transcribed and anonymised and they will be unable to 
withdraw, although every effort will be made to ensure all personal and identifiable information is removed. 
 
 
As per the Mental Capacity Act (2005), all participants will be assumed to have capacity to provide informed consent. 
The chief investigator will be responsible for assessing during contact whether the individual has capacity to consent. 
The chief investigator is a trainee clinical psychologist with experience of seeking consent from a range of service users 
in clinical practice. If there is any reason to doubt that a participant does not have capacity to provide informed consent 
then the following steps will be taken:  
- Discussion with the clinical team regarding their understanding of the individual's capacity and reason for putting 
them forward for the study  
- Consideration of whether the individual is able to understand, weigh up, retain given information, and communicate 
their decision in line with the principles of the Mental Capacity Act (2005). This will be discussed by the chief 
investigator with their clinical and field supervisors to ensure appropriate assessment has been carried out with 
reasonable adjustments made to support understanding.  
- If, based on the above criteria, the individual is not able to provide informed consent then they will be excluded from 
the study. 
 
- All recruitment materials have been written in plain language with feedback given by service users during a 








A30-2. Will you record informed consent (or advice from consultees) in writing? 
 
 Yes       No 
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A31. How long will you allow potential participants to decide whether or not to take part? 
 
One week will be left between potential participants agreeing to be contacted by the researcher and the researcher 
making telephone contact to allow time to read the information sheet. During the telephone contact potential 
participants will have opportunity to ask questions and, with their agreement a time slot for interview will be allocated at 
least another 24 hours later to allow more time for the potential participant to consider the given information and 
change their mind. Informed consent will be sought (written and verbal) immediately before interviews taking place. 
 
If during the telephone call participants are still unsure about whether they would like to participate, they will be 
advised that they may continue to consider their answer and may contact the chief investigator on their research 
mobile phone if they have any further questions or decide they would like to participate. 
 
Recruitment will begin once the relevant ethical approvals have been granted. The window for recruitment will have no 
fixed time limit and will end either once the target number of participants have been recruited or due to time constraints 
relating to the scheduled submission of the project. Participants will be recruited on a first come first served basis. 
Exceptions to this may be made only in the interest of maintaining gender balance within the sample, for example if there 
is a greater proportion of females recruited, a male participant may be selected ahead of further female participants if 
there are more participants interested than the sample limit of 12.  
 
 
A33-1. What arrangements have been made for persons who might not adequately understand verbal explanations or 
written information given in English, or who have special communication needs?(e.g.otranslation,ouseoofointerpreters) 
 
Unfortunately there are no funds available as part of this project for interpreter services and as such participants who do 
not speak English will be excluded. The process of translation may also impact the interpretative analytic process used 
in IPA and therefore is best avoided. 
 
Consultation from a service user group was sought for feedback on participant materials to ensure that language and 
layout are understandable for patients.  
 
 
A35. What steps would you take if a participant, who has given informed consent, loses capacity to consent during 
the study? Tickooneooptionoonly. 
 
The participant and all identifiable data or tissue collected would be withdrawn from the study. Data or tissue which 
 
is not identifiable to the research team may be retained. 
 
The participant would be withdrawn from the study. Identifiable data or tissue already collected with consent would 
 
be retained and used in the study. No further data or tissue would be collected or any other research procedures carried 
out on or in relation to the participant. 
 
The participant would continue to be included in the study. 
 
Not applicable – informed consent will not be sought from any participants in this research. 
 





If in between the initial permission to contact stage and the interview taking place there is reason to believe the individual 
may have come to lack capacity to consent or take part in the study they would be excluded from the study. 
 
If the participant has capacity to consent immediately prior to interview and throughout the interview process but later 
comes to lack capacity, their data would still be included in the study. 
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In this section, personal data means any data relating to a participant who could potentially be identified. It 
includes pseudonymised data capable of being linked to a participant through a unique code number.  
 
Storage and use of personal data during the study 
 
A36. Will you be undertaking any of the following activities at any stage (including in the identification of 
potential participants)?(Tickoasoappropriate) 
 
Access to medical records by those outside the direct healthcare team 
 
Access to social care records by those outside the direct social care team 
 
Electronic transfer by magnetic or optical media, email or computer networks 
 
Sharing of personal data with other organisations 
 
Export of personal data outside the EEA 
 
Use of personal addresses, postcodes, faxes, emails or telephone numbers 
 
Publication of direct quotations from respondents 
 
Publication of data that might allow identification of individuals 
 
Use of audio/visual recording devices 
 
Storage of personal data on any of the following: 
 




Social Care Service computers 
 











Consent to be contacted form: The consent to be contacted form will be filled out by patients at the hospital site and 
retained in their clinical records. The participant's name and telephone number from the form will be provided via 
telephone to the chief investigator by the clinical staff. The chief investigator will keep the participant's name and phone 
number on a paper log sheet which will be kept in a locked drawer in the chief investigator's home. Nobody other than the 
chief investigator will have access to this drawer. Once the interview has taken place these details will be immediately 
shredded. 
 
Consent form: The consent form will be completed immediately before the interview takes place. One copy of this form 
will be retained by the chief investigator, one copy will be retained by the patient, and one copy will be kept in the clinical 
file. Following the interview, the chief investigator will upload their copy to create an electronic document. The paper 
copy will then be shredded. The electronic copy of the consent form will be stored on the chief investigator's personal 
storage area on the Lancaster University server which is password protected and secure. The electronic consent form 
will be stored for a maximum of six months following completion of the study in line with Lancaster University's doctorate 
in clinical psychology data storage procedures. In the instance that an interview takes place in a participant's home, the 
file copy of the consent form will be attached to the letter to the clinical nurse specialist in order for it to be kept in their 
clinical record. This will be sent as soon as practically possible. Until this time, the consent form will be stored securely 
bu the chief investigator in a locked drawer. 
 
Interview audio recording: The audio recording of each interview will be uploaded as a file to the chief investigator's 
university storage area which is password protected and secure. This will be done as soon as practically possible 
following the interview. The recording will then be deleted from the Dictaphone. The recording file will be deleted once 
the interview has been transcribed by the chief investigator. 
 
Interview transcript: The interview will be transcribed electronically by the chief investigator. The transcription will be 
anonymised and all personal or identifiable information will be redacted. The transcription will be stored electronically in 
the chief investigator's university storage area which is password protected and secure. The file will be saved separately 
to the consent forms so the two cannot be linked. During the analysis stage, paper copies of the 
 




IRAS Form Reference: IRAS Version 5.11 
19/NW/0096  
 
transcription will be made in order for themes to be highlighted. These paper copies will be stored in a locked drawer in 
the chief investigator's home. Only the chief investigator has access to this drawer. Once this stage of the transcription 
is completed, the annotated transcripts will be scanned to create electronic files which will be uploaded to the chief 
investigator's university storage area which is password protected and secure. The paper copies will then be shredded. 
 
Once the study is complete, the electronic transcripts will be transferred electronically via the Lancaster University VPN 
to the research coordinator of the doctorate in clinical psychology at Lancaster University. They will then be deleted from 
the chief investigator's university storage area. The files will be stored for a maximum of ten years by the research 
director, in line with the course protocol. They will then be deleted by the research director. 
 
Demographic Information Form: This form will be scanned as an electronic copy as soon as practically possible 
following the interview. The electronic document will be stored in the chief investigator's secure, password-protected 
university storage drive. The hard copy will then be shredded. This document will be stored for a maximum of six 
months following completion of the study in line with Lancaster University's doctorate in clinical psychology data 
storage procedures.  
 
 
A37. Please describe the physical security arrangements for storage of personal data during the study? 
 
As stated in A36, electronic files (consent form, interview audio recordings, and interview transcripts) will be stored in 
the chief investigator's personal storage area on the Lancaster University server which is password protected and 
secure. As the audio recording device that will be used to encrypt interviews is not encrypted, audio files will be 
transferred to the secure storage space as quickly as practically possible then the recording will be deleted from the 
recording device. In the meantime the recording device will be stored securely by the chief investigator. 
 
Paper documents (transcripts and participant contact details) will be stored for the minimum possible time in a locked 
drawer in the chief investigator's home.Nobody else has access to this drawer.  
 
 
A38. How will you ensure the confidentiality of personal data?Pleaseoprovideoaogeneralostatementoofotheopolicyo
and proceduresoforoensuringoconfidentiality,oe.g.oanonymisationooropseudonymisationoofodata. 
 
Participant data will be handled in line with the NHS Code of Confidentiality (2003) and Lancaster University's doctorate 
in clinical psychology data storage policy (http://www.lancaster.ac.uk/shm/study/doctoral_study/dclinpsy/onl 
inehandbook/ethics_and_data_storage_advice/) 
 
Interview data will by anonymously transcribed using a pseudonym, following which original recordings will be 
deleted. 
 
Participant information will be stored securely, held for the minimal necessary time, and securely disposed of (e.g. by 
shredding or deletion).  
 
 
A40. Who will have access to participants' personal data during the study? Whereoaccessoisobyoindividualsooutsideo
the directocareoteam,opleaseojustifyoandosayowhetheroconsentowillobeosought. 
 
Personal data may be accessed by direct care staff during the recruitment process to verify whether patients meet the 
study inclusion and exclusion criteria. 
 
The chief investigator will have access to patient's names and telephone numbers (once consent provided on the 
'consent to be contacted' sheet) and then to data provided by the participant during interview (interview data and 
demographic information form). 
 
The chief investigator's field and research supervisors may have access to the anonymised transcripts to support the 
process of data analysis.  
 
 
Storage and use of data after the end of the study  
 
A41. Where will the data generated by the study be analysed and by whom? 
 
The data will be analysed by the chief investigator at their home address. Guidance will be obtained from the research 
supervisor and field supervisor in relation to analysis. 
 
Paper copies of transcripts and participant contact details will be stored in a locked drawer in the chief investigator's 
home to which only the chief investigator has access. Electronic copies of materials for the analysis will be stored 
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 Title Forename/Initials Surname 
 Dr Bill Sellwood 
Post Professor, Programme Director, Doctorate in Clinical Psychology, Lancaster University 
Qualifications PhD   
Work Address Division of Health Research 
 Furness College, Lancaster University 
 Lancaster  
Post Code LA1 4YG  
Work Email b.sellwood@lancaster.ac.uk 
Work Telephone 01524593998  
Fax    
    
      
A43. How long will personal data be stored or accessed after the study has ended? 
 
Less than 3 months 
 
3 – 6 months 
 
6 – 12 months 
 
12 months – 3 years 
 












A45. Please give details of the long term arrangements for storage of research data after the study has 
ended.Say whereodataowillobeostored,owhoowillohaveoaccessoandotheoarrangementsotooensureosecurity. 
 
Once the research has ended the interview transcripts will be encrypted and securely transferred by the chief 
investigator to the Lancaster University Doctorate in Clinical Psychology Research Coordinator. The chief investogator 
will send a separate email to the research coordinator with the password for the encrypted files, the end date of the 
study, and when files should be deleted. They will be stored for up to ten years as per the course's policy. Following this 
time they will be deleted by the Research Director. The course will store the files in a password-protected space on the 
University server.  
 
 
INCENTIVES ANB PAYMENTS  
 
A46. Will research participants receive any payments, reimbursement of expenses or any other benefits or 
incentives for taking part in this research? 
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A47. Will individual researchers receive any personal payment over and above normal salary, or any other benefits 
or incentives, for taking part in this research? 
 




A48. Boes the Chief Investigator or any other investigator/collaborator have any direct personal involvement (e.g. 
financial, share holding, personal relationship etc.) in the organisations sponsoring or funding the research that 
may give rise to a possible conflict of interest? 
 




NOTIFICATION OF OTHER PROFESSIONALS  
 
A49-1. Will you inform the participants’ General Practitioners (and/or any other health or care professional 
responsible for their care) that they are taking part in the study? 
 




A49-2. Will you seek permission from the research participants to inform their GP or other health/ care professional? 
 




PUBLICATION ANB BISSEMINATION  
 
A50. Will the research be registered on a public database? 
 
 Yes       No 
 
Pleaseogiveodetails,oorojustifyoifonotoregisteringotheoresearch.  
The study has been registered with The National Cancer Research Institute (NCRI) as a piece of research which 
addresses one of the current 'Top 26 living with and beyond cancer research questions'. No registry reference number is 









A51. How do you intend to report and disseminate the results of the study?Tickoasoappropriate: 
 










Submission to regulatory authorities 
 
Access to raw data and right to publish freely by all investigators in study or by Independent Steering Committee 
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on behalf of all investigators 
 
No plans to report or disseminate the results 
 





A52. If you will be using identifiable personal data, how will you ensure that anonymity will be maintained 
when publishing the results? 
 
Pseudonyms will be used for participants and no clearly identifying details will be included. Any personal details that 
may identify the participant that are disclosed during the interview will be redacted to maintain anonymity. These may 
include hometown, names of friends or relatives, names of clinical staff, specifics of occupation etc.  
 
 
A53. Will you inform participants of the results? 
 
 Yes       No 
 
Pleaseogiveodetailsoofohowoyouowilloinformoparticipantsoorojustifyoifonotodoingoso.  
Patients will be asked on the consent form if the would like to receive a summary of results once the project is 
completed. If they would like to receive the results they will be asked to provide a postal address on the consent form.  
 
 
5. Scientific and Statistical Review  
 
A54. How has the scientific quality of the research been assessed?Tickoasoappropriate: 
 
Independent external review 
 
Review within a company 
 
Review within a multi−centre research group 
 
Review within the Chief Investigator's institution or host organisation 
 
Review within the research team 
 






The research project has been developed under the supervision of the chief investigator's research supervisor at 
Lancaster University and field supervisor who is a clinical psychologist working in cancer services. The research will also 








A59. What is the sample size for the research? Howomanyoparticipants/samples/dataorecordsodooyouoplanotoostudyoin 
total?oIfothereoisomoreothanooneogroup,opleaseogiveofurtherodetailsobelow. 
 
Total UK sample size: 12
 
Total international sample size (including UK): 0 
 
Total in European Economic Area: 0
 
Furtherodetails:  
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A60. How was the sample size decided upon? Ifoaoformalosampleosizeocalculationowasoused,oindicateohowothisowasodone, 
givingosufficientoinformationotoojustifyoandoreproduceotheocalculation. 
 
This sample size is the largest recommended size for a study using IPA methodology (Smith and Osborne, 2008). The 
sample will be selected purposely to recruit a sample whose experience is relevant to the research questions.  
 
 
A62. Please describe the methods of analysis (statistical or other appropriate methods, e.g. for qualitative research) 
by which the data will be evaluated to meet the study objectives. 
 
 
Interpretative phenomenological analysis will be used to analyse qualitative data. This will involve manual analysis to 
generate hierarchical themes across the data.  
 
 
6. MANAGEMENT OF THE RESEARCH  
 






Title Forename/Initials Surname 
 





















Title Forename/Initials Surname 
 
Post Medical Oncology Consultant (Second field supervisor) 
 
Qualifications MD   
Employer    
Work Address    
Post Code    
Telephone    
Fax    
Mobile    
Work Email    
 Title Forename/Initials Surname 
 Dr Craig Murray 
Post Senior Lecturer  
Qualifications PhD   
Employer Lancaster University  
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Work Address Department of Health Research 
 




Post Code LA1 4YG 
 






Work Email c.murray@lancaster.ac.uk 
 
 
Title Forename/Initials Surname 
 


















Work Email  
 
 


















Medical device industry 
 
 Local Authority 
 










Name of organisation Lancaster University 
 
Given name Becky 
 
Family name Gordon 
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Post code LA1 4YT 
 















Funding secured from one or more funders 
 
External funding application to one or more funders in progress 
 








Project that is part of a programme grant 
 
Project that is part of a Centre grant 
 
Project that is part of a fellowship/ personal award/ research training award 
 Other 
 




A66. Has responsibility for any specific research activities or procedures been delegated to a subcontractor 
(other than a co-sponsor listed in A64-1) ? Pleaseogiveodetailsoofosubcontractorsoifoapplicable. 
 
 Yes       No  
 
 
A67. Has this or a similar application been previously rejected by a Research Ethics Committee in the UK or 
another country? 
 







































A69-1. How long do you expect the study to last in the UK? 
 
Planned start date: 03/01/2019 
 




Years: 0 Months: 7 Days: 28  
 
 




 Multicentre  
 
 










Other countries in European Economic Area 
 
Total UK sites in study 7 
 
Boes this trial involve countries outside the EU?  
 Yes       No  
 
 
A72. Which organisations in the UK will host the research?Pleaseoindicateotheotypeoofoorganisationobyotickingotheoboxoand 
giveoapproximateonumbersoifoknown: 
 
NHS organisations in England 7
 
NHS organisations in Wales 
 
NHS organisations in Scotland 
 
HSC organisations in Northern Ireland 
 
GP practices in England 
 
GP practices in Wales 
 
GP practices in Scotland 
 
GP practices in Northern Ireland 
 
Joint health and social care agencies (eg 
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Educational establishments  
 
Independent research units  
 




Total UK sites in study: 7 
  
    
A73-1. Will potential participants be identified through any organisations other than the research sites listed above? 
 




A74. What arrangements are in place for monitoring and auditing the conduct of the research? 
 
The chief investigator will be supervised by the research supervisor and field supervisor which will include monthly 
supervisory contact. A research contract has been agreed between the three parties agreeing arrangements for 
monitoring and audit  
 
 
A76. Insurance/ indemnity to meet potential legal liabilities  
 
Note: in this question to NHS indemnity schemes include equivalent schemes provided by Health and Social 
Care (HSC) in Northern Ireland  
 
A76-1. What arrangements will be made for insurance and/or indemnity to meet the potential legal liability of the 






NHS indemnity scheme will apply (NHS sponsors only) 
 
Other insurance or indemnity arrangements will apply (give details below) 
 




A76-2. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of the 







NHS indemnity scheme will apply (protocol authors with NHS contracts only) 
 
Other insurance or indemnity arrangements will apply (give details below) 
 




 A76-3. What arrangements will be made for insurance and/ or indemnity to meet the potential legal liability of 
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NHS indemnity scheme or professional indemnity will apply (participants recruited at NHS sites only) 
 






A78. Could the research lead to the development of a new product/process or the generation of intellectual property? 
 



































































Please enter details of the host organisations (Local Authority, NHS or other) in the UK that will be responsible for 














































































































































































































































































































































    
 
  name   
 
  Family 
Slater    





 Address Qualification   
 
  (MD...)   
 
  Country   
 
 Post Code    
 
 Country    
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PART B: Beclarations  
 
B1. Beclaration by Chief Investigator 
 
1. The information in this form is accurate to the best of my knowledge and belief and I take full responsibility for it. 
 
 
2. I undertake to fulfil the responsibilities of the chief investigator for this study as set out in the UK Policy 
Framework for Health and Social Care Research. 
 
3. I undertake to abide by the ethical principles underlying the Declaration of Helsinki and good practice 
guidelines on the proper conduct of research. 
 
4. If the research is approved I undertake to adhere to the study protocol, the terms of the full application as 
approved and any conditions set out by review bodies in giving approval. 
 
5. I undertake to notify review bodies of substantial amendments to the protocol or the terms of the approved 
application, and to seek a favourable opinion from the main REC before implementing the amendment. 
 
6. I undertake to submit annual progress reports setting out the progress of the research, as required by review 
bodies. 
 
7. I am aware of my responsibility to be up to date and comply with the requirements of the law and relevant 
guidelines relating to security and confidentiality of patient or other personal data, including the need to register 
when necessary with the appropriate Data Protection Officer. I understand that I am not permitted to disclose 
identifiable data to third parties unless the disclosure has the consent of the data subject or, in the case of patient 
data in England and Wales, the disclosure is covered by the terms of an approval under Section 251 of the NHS 
Act 2006. 
 
8. I understand that research records/data may be subject to inspection by review bodies for audit purposes if 
required. 
 
9. I understand that any personal data in this application will be held by review bodies and their operational 
managers and that this will be managed according to the principles established in the Data Protection Act 
2018. 
 
10. I understand that the information contained in this application, any supporting documentation and all 
correspondence with review bodies or their operational managers relating to the application: 
 
Will be held by the REC (where applicable) until at least 3 years after the end of the study; and by NHS 
R&D offices (where the research requires NHS management permission) in accordance with the NHS 
Code of Practice on Records Management.  
May be disclosed to the operational managers of review bodies, or the appointing authority for the REC 
(where applicable), in order to check that the application has been processed correctly or to investigate 
any complaint.  
May be seen by auditors appointed to undertake accreditation of RECs (where applicable).  
Will be subject to the provisions of the Freedom of Information Acts and may be disclosed in response to 
requests made under the Acts except where statutory exemptions apply. May be sent by email to REC 
members. 
 
11. I understand that information relating to this research, including the contact details on this application, may be 
held on national research information systems, and that this will be managed according to the principles 
established in the Data Protection Act 2018. 
 
12. Where the research is reviewed by a REC within the UK Health Departments Research Ethics Service, I 
understand that the summary of this study will be published on the website of the Health Research Authority 
(HRA) together with the contact point for enquiries named below. Publication will take place no earlier than 3 
months after the issue of the ethics committee’s final opinion or the withdrawal of the application. 
 
 































I would be content for members of other RECs to have access to the information in the application in confidence   




This section was signed electronically by Dr Anna Daiches on 28/03/2019 12:35. 
 
Job Title/Post: Clinical Director 
Organisation: Lancaster University 
Email: a.daiches@lancaster.ac.uk 
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I confirm that: 
 
1. This research proposal has been discussed with the Chief Investigator and agreement in principle to 
sponsor the research is in place. 
 
2. An appropriate process of scientific critique has demonstrated that this research proposal is worthwhile and of 
high scientific quality. 
 
3. Any necessary indemnity or insurance arrangements, as described in question A76, will be in place before 
this research starts. Insurance or indemnity policies will be renewed for the duration of the study where 
necessary. 
 
4. Arrangements will be in place before the study starts for the research team to access resources and support to 
deliver the research as proposed. 
 
5. Arrangements to allocate responsibilities for the management, monitoring and reporting of the research will be 
in place before the research starts. 
 
6. The responsibilities of sponsors set out in the UK Policy Framework for Health and Social Care Research will be 
fulfilled in relation to this research. 
 
Please note: Theodeclarationsobelowodoonotoformopart ofotheoapplicationoforoapprovaloabove.oTheyowillonotobe 
consideredobyotheoResearchoEthicsoCommittee.o
o
7. Where the research is reviewed by a REC within the UK Health Departments Research Ethics Service, I 
understand that the summary of this study will be published on the website of the National Research Ethics 
Service (NRES), together with the contact point for enquiries named in this application. Publication will take 
place no earlier than 3 months after issue of the ethics committee's final opinion or the withdrawal of the 
application. 
 
8. Specifically, for submissions to the Research Ethics Committees (RECs) I declare that any and all clinical trials 
approved by the HRA since 30th September 2013 (as defined on IRAS categories as clinical trials of 
medicines, devices, combination of medicines and devices or other clinical trials) have been registered on a 
publically accessible register in compliance with the HRA registration requirements for the UK, or that any 





This section was signed electronically by An authorised approver at ethics@lancaster.ac.uk on 29/03/2019 17:32. 
 
Job Title/Post: Head of Research Quality and Policy 
Organisation: Lancaster University 
Email: b.gordon@lancaster.ac.uk 
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B3. Beclaration for student projects by academic supervisor(s) 
 
1. I have read and approved both the research proposal and this application. I am satisfied that the scientific content of 
the research is satisfactory for an educational qualification at this level. 
 
2. I undertake to fulfil the responsibilities of the supervisor for this study as set out in the UK Policy Framework for 
Health and Social Care Research. 
 
3. I take responsibility for ensuring that this study is conducted in accordance with the ethical principles underlying 
the Declaration of Helsinki and good practice guidelines on the proper conduct of research, in conjunction with 
clinical supervisors as appropriate. 
 
4. I take responsibility for ensuring that the applicant is up to date and complies with the requirements of the law and 
relevant guidelines relating to security and confidentiality of patient and other personal data, in conjunction with clinical 
supervisors as appropriate. 
 
Academic supervisor 1 
 
This section was signed electronically by Dr Anna Duxbury on 31/03/2019 14:02. 
 
Job Title/Post: Clinical Psychologist/ Clinical Tutor 
 




Academic supervisor 2 
 
This section was signed electronically by Dr Anna Daiches on 28/03/2019 12:37. 
 
 Job Title/Post: Clinical Director 
 Organisation: Lancaster University 
 Email: a.daiches@lancaster.ac.uk 
    
    



























Date: 28/01/2019 35 251064/1328269/37/297 
ETHICS FORM 
10 May 2019 
 
Dr Anna Daiches 
Clinical Director  
Lancashire Care NHS Foundation Trust
Department of Health Research 
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Thank you for your correspondence of 10 May 2019, respo
further information on the above research and submitting revised documentation
 
The further information has been considered on behalf of the Committee by the Chair, together 
with the lead reviewer. 
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the date 

















Please note: This is the  
favourable opinion of the 
REC only and does not allow
you to start your study at NHS
sites in England until you 
receive HRA Approval 
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information, or wish to make a request to postpone publication, please 
contact hra.studyregistration@nhs.net outlining the reasons for your 
request. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below. 
 
Conditions of the favourable opinion 
 
The REC favourable opinion is subject to the following conditions being met prior to the 
start of the study. 
 
Management permission must be obtained from each host organisation prior to the start of 











Whereo ao NHSo organisation’so roleo ino theo studyo iso limitedo too identifyingo ando referringo










Registration of Clinical Trials 
 
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database within 6 weeks of recruitment of the first 
participant (for medical device studies, within the timeline determined by the current 
registration and publication trees). 
 
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment. We will audit the registration details as part 
of the annual progress reporting process. 
 
To ensure transparency in research, we strongly recommend that all research is registered 






If a sponsor wishes to request a deferral for study registration within the required timeframe, 
they should contact hra.studyregistration@nhs.net. The expectation is that all clinical trials will 
be registered, however, in exceptional circumstances non registration may be permissible with 
prior agreement from the HRA. Guidance on where to register is provided on the HRA website. 
 
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable). 
 




The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 








Evidence of Sponsor insurance or indemnity (non NHS Sponsors 0.1 24 January 2019 
only) [Employer indemnity insurance]     
GP/consultant information sheets or letters [Professionals 0.1 07 December 2018
Information Sheet]     
Interview schedules or topic guides for participants [Interview 0.1 11 July 2018 
Schedule]     
IRAS Application Form [IRAS_Form_10052019]  10 May 2019 
    
Letter from sponsor [Letter from sponsor] 0.1 24 January 2019 
    
Non-validated questionnaire [Demographic Information Sheet] 0.1 07 December 2018
    
Non-validated questionnaire [Demographic Information sheet] 0.2 11 March 2019 
    
Other [Lone working- xxxxxxxx]  13 January 2019 
    
Other [Risk assessment- xxxxxxxx]  13 January 2019 
    
Other [Lone Working- xxxxxxxx]  13 January 2019 
    
Other [Employer professional negligence insurance] 0.1 24 January 2019 
    
Other [Letter to Clinical Nurse Specialist] 0.2 11 March 2019 
    
Other [Re-submission cover letter]  28 March 2019 
    
Participant consent form [Participant Consent Form] 0.2 11 March 2019 
    
Participant consent form [Consent to be contacted] 0.2 11 March 2019 
    
Participant information sheet (PIS) [PIS] 0.3 11 March 2019 
    
Research protocol or project proposal [Protocol] 0.1 28 July 2018 
    
Summary CV for Chief Investigator (CI) [CI CV]  11 March 2019 
    
Summary CV for student [Student CV]  13 January 2019 
    
Summary CV for supervisor (student research) [Supervisor CV]  13 January 2019 
    
Summary CV for supervisor (student research) [Anna Duxbury CV] 0.1 11 February 2019 
     
 










The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 




The attached document “Afteroethicaloreviewo–oguidanceofororesearchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
• Notifying substantial amendments  
• Adding new sites and investigators  
• Notification of serious breaches of the protocol  
• Progress and safety reports  
• Notifying the end of the study 
 
The HRA website also provides guidance on these topics, which is updated in the light of 





The Health Research Authority is continually striving to provide a high quality service to all  
applicants and sponsors. You are invited to give your view of the service you have received and  
the application procedure. If you wish to make your views known please use the feedback form 





We are pleased to welcome researchers and research staff to our HRA Learning Events and 
online learning opportunities– see details at: 
https://www.hra.nhs.uk/planning-and-improving-research/learning/  
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With the Committee’s best wishes for the success of this project. 
 








Study title: Patients’ experiences of coping longer-term with cancer  
of unknown primary  
IRAS project IB: 251064  
REC reference: 19/NW/0096  
Sponsor Lancaster University 
 
 
I am pleased to confirm that HRA and Health and Care Research Wales (HCRW) Approval has been given for the above referenced study, 
on the basis described in the application form, protocol, supporting documentation and any clarifications received. You should not expect to 
receive anything further relating to this application. 
 
Please now work with participating NHS organisations to confirm capacity and capability, in line with the instructions provided in the 
“Information to support study set up” section towards the end of this letter. 
 
How should I work with participating NHS/HSC organisations in Northern Ireland and Scotland?  
HRA and HCRW Approval does not apply to NHS/HSC organisations within Northern Ireland and Scotland. 
 
If you indicated in your IRAS form that you do have participating organisations in either of these devolved administrations, the final document 
set and the study wide governance report (including this letter) have been sent to the coordinating centre of each participating nation. The 
relevant national coordinating function/s will contact you as appropriate. 




















Dr Anna Daiches  
Clinical Director  
Lancashire Care NHS Foundation Trust  
Department of Health Research  
Faculty of Health and Medicine  
Lancaster University  
LA1 4YG 
 
10 May 2019 
 
Dear Dr Daiches  
 
HRA and Health and Care  
















Please see IRAS Help for information on working with NHS/HSC organisations in Northern Ireland and Scotland. 
 
How should I work with participating non-NHS organisations? 
 
HRA and HCRW Approval does not apply to non-NHS organisations. You should work with your non-NHS organisations to obtain local 
agreement in accordance with their procedures. 
 
What are my notification responsibilities during the study? 
 
The document “AfteroEthicaloReview – guidanceo foro sponsorsoando investigators”, issued with your REC favourable opinion, gives detailed 
guidance on reporting expectations for studies, including: 
 
• Registration of research  
• Notifying amendments  
• Notifying the end of the study 
 
The HRA website also provides guidance on these topics, and is updated in the light of changes in reporting expectations or procedures. 
 
Who should I contact for further information? 
 
Please do not hesitate to contact me for assistance with this application. My contact details are below. 
 
 


























List of Bocuments 
 
 
The final document set assessed and approved by HRA and HCRW Approval is listed below. 
 
 
Document Version Date 
 
 
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 0.1 24 January 2019 
 
only) [Employer indemnity insurance]    
 
GP/consultant information sheets or letters [Professionals 0.1 07 December 2018 
 
Information Sheet]    
 
HRA Schedule of Events [SoE] 1 15 February 2019 
 
    
 
HRA Statement of Activities [SoA] 1 15 February 2019 
 
    
 
Interview schedules or topic guides for participants [Interview 0.1 11 July 2018 
 
Schedule]    
 
IRAS Application Form [IRAS_Form_10052019]  10 May 2019 
 
    
 
Letter from sponsor [Letter from sponsor] 0.1 24 January 2019 
 
    
 
Non-validated questionnaire [Demographic Information Sheet] 0.1 07 December 2018 
 
    
 
Non-validated questionnaire [Demographic Information sheet] 0.2 11 March 2019 
 
    
 
Other [Lone working- xxxxxxxx]  13 January 2019 
 
    
 
Other [Risk assessment- xxxxxxxx]  13 January 2019 
 
    
 
Other [Lone Working- xxxxxxxx]  13 January 2019 
 
    
 
Other [Employer professional negligence insurance] 0.1 24 January 2019 
 
    
 
Other [Letter to Clinical Nurse Specialist] 0.2 11 March 2019 
 
    
 
Other [Re-submission cover letter]  28 March 2019 
 
    
 
Participant consent form [Participant Consent Form] 0.2 11 March 2019 
 
    
 
Participant consent form [Consent to be contacted] 0.2 11 March 2019 
 
    
 
Participant information sheet (PIS) [PIS] 0.3 11 March 2019 
 
    
 
Research protocol or project proposal [Protocol] 0.1 28 July 2018 
 
    
 
Summary CV for Chief Investigator (CI) [CI CV]  11 March 2019 
 
    
 
Summary CV for student [Student CV]  13 January 2019 
 





IRAS project IB 251064 
  
 
Information to support study set up 
 
The below provides all parties with information to support the arranging and confirming of capacity and capability with participating NHS 
organisations in England and Wales. This is intended to be an accurate reflection of the study at the time of issue of this letter. 
 
Types of Expectations related to Agreement to be Funding Oversight HR Good Practice Resource 
participating confirmation of used arrangements expectations Pack expectations 
NHS capacity and capability     
organisation      
      
This is a non- Research activities A Statement of No application for A Local For research team members 
commercial should not commence at Activities has been external funding Collaborator is that do not have existing 
study with participating NHS submitted and the has been made. expected to be in contractual relationships with 
multiple organisations in England sponsor is not As per the place at the the participating organisation, 
participating or Wales prior to their requesting and Statement of participating Letters of Access should be in 
NHS formal confirmation of does not expect Activities, no organisation. place if the activities undertaken 
organisations. capacity and capability any other site funding will be As per the at the NHS site involve contact 
There is one site to deliver the study. agreement to be provided to the Statement of with patients (e.g. to take 
type involved in  used. participating Activities, the consent), on the basis of 
the study.   organisation. sponsor will not Research Passports (if 
    provide additional University employed) or NHS to 
    training. NHS confirmation of pre- 
     engagement checks letters (if 
     NHS employed). The pre- 
     engagement checks should 
     include standard DBS checks 
     and Occupational Health 
     Clearance. No specific pre- 
     engagement checks are 
     required to have taken place if 
     the members of the research 
















patients’ data.  
 
 




The applicant has stated that they do not intend to apply to the CRN Portfolio. 
ETHICS FORM 
11 March 2019 
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The Research Ethics Committee reviewed the above application at the 




The Committee is unable to give an ethical opinion on the basis of the information and 
documentation received so far. Before confirming its 
that you provide the further information set out below.
 
Authority to consider your response and to confirm the Committee’s final opinion 
has been delegated to the Chair and Dr Supriya Kapas.
 
Further information or clarification required
 
1. Amend the IRAS form to change the Academic Supervisor to Chief 
Investigator, entering details of the Academic Supervisor and re
authorising the IRAS form. 
2. In the Informed Consent Form, 
a. Include the below point in relation to audits, “I und
relevant sections of my medical notes and data collected during the 
study may be looked at by doctors from the research group, from 
regulatory authorities or from the NHS Trust, where it is relevant to 
my taking part in this research. I give p
to have access to my records.”
























































b. Make clear that points, 7, 8 and 9 are optional by indicating each as  
(Optional).  
3. Either correct the Consent to Contact form to ensure consistency of version 
numbers and dates with corresponding documents or make this part of the form 
blank, to be added when the form is completed.  
4. Correct the recipient of the GP letter and:  
a. Correct tense to ensure clarity.  
5. Remove patient identifiable information from the demographic information sheet. 
 
If you would find it helpful to discuss any of the matters raised above or seek further 
clarification from a member of the Committee, you are welcome to contact Gemma 
Warren. 
 
When submitting a response to the Committee, the requested information should be 
electronically submitted from IRAS. Please refer to the guidance in IRAS for instructions on how 
to submit a response to provisional opinion electronically. 
 
Please submit revised documentation where appropriate underlining or otherwise highlighting 
the changes which have been made and giving revised version numbers and dates. You do not 
have to make any changes to the REC application form unless you have been specifically 
requested to do so by the REC. 
 
The Committee will confirm the final ethical opinion within a maximum of 60 days from the date 
of initial receipt of the application, excluding the time taken by you to respond fully to the above 
points. A response should be submitted by no later than 10 April 2019. 
 
Extract of the meeting minutes 
 
Care and protection of research participants; respect for potential and enrolled 
participants’ welfare and dignity 
 
The Committee picked up on the assessor’s comments on the storage of identifiable data 








The Committee was satisfied. 
 
The Committee wished to clarify that the number provided in order to contact the 



































Informed consent process and the adequacy and completeness of 
participant information 
 
The Committee noted that points 7, 8 and 9 were optional and should be demarcated 
as such. 
 
The Committee noted that there was no consistency between consent to contact version 
numbers and dates. The Committee suggested leaving these blank to add corresponding 
version numbers and dates when they are used. 
 
The Committee asked that information regarding the possibility of audits conducted for 
regulatory purposes was advised in the Participant Information Sheet. 
 
Suitability of the applicant and supporting staff 
 
The Committee agreed that the Academic Supervisor should take the role of the Chief 






The Committee agreed that they would much prefer an academic supervisor take the 
role of Chief Investigator to ensure proper supervision. 
 
Other general comments 
 
The Committee noted that the GP letter should be addressed to the Clinical Nurse 
Specialist as they were to be the recipient of this letter and tense was changed to 
ensure clarity. 
 
The Committee noted that the IRAS form referred to the creation of intellectual property 
and the Committee wished to clarify whether Ms Slater thought that Intellectual property 





The Committee confirmed that this did not constitute intellectual property and that this 
question in the IRAS form no longer applied. 
 
The Committee noted that the demographic information sheet had identifiable patient 
information and asked that this was removed. 
 
Please contact the REC Manager if you feel that the above summary is not an 












The documents reviewed at the meeting were: 
 
Document Version Date 
 
 
Evidence of Sponsor insurance or indemnity (non NHS Sponsors 0.1 24 January 2019 
 
only) [Employer indemnity insurance]    
 
GP/consultant information sheets or letters [Professionals 0.1 07 December 2018 
 
Information Sheet]    
 
GP/consultant information sheets or letters 0.1 06 December 2018 
 
    
 
Interview schedules or topic guides for participants [Interview 0.1 11 July 2018 
 
Schedule]    
 
IRAS Application Form [IRAS_Form_28012019]  28 January 2019 
 
    
 
IRAS Checklist XML [Checklist_12022019]  12 February 2019 
 
    
 
Letter from sponsor [Letter from sponsor] 0.1 24 January 2019 
 
    
 
Non-validated questionnaire [Demographic Information Sheet] 0.1 07 December 2018 
 
    
 
Other [Lone working-xxxxxxx]  13 January 2019 
 
    
 
Other [Risk assessment- xxxxxxxxx]  13 January 2019 
 
    
 
Other [Lone Working- xxxxx]  13 January 2019 
 
    
 
Other [Employer professional negligence insurance] 0.1 24 January 2019 
 
    
 
Participant consent form [Consent form] 0.1 01 December 2018 
 
    
 
Participant consent form [Consent to contact] 0.1 07 December 2018 
 
    
 
Participant information sheet (PIS) [PIS] 0.1 11 July 2018 
 
    
 
Research protocol or project proposal [Protocol] 0.1 28 July 2018 
 
    
 
Summary CV for Chief Investigator (CI) [CI CV]  13 January 2019 
 
    
 
Summary CV for student [Student CV]  13 January 2019 
 
    
 
Summary CV for supervisor (student research) [Supervisor CV]  13 January 2019 
 
    
 
Summary CV for supervisor (student research) [Anna Duxbury CV] 0.1 11 February 2019 
 




Membership of the Committee 
 
The members of the Committee who were present at the meeting are listed on the attached 
sheet 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
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Appendix 4-E: Re-Submission of Ethics Application Covering Letter 








 March 2019 
 
Dear RES Committee North West – Liverpoov East members, 
 
 Re: IRAS Project ID: 251064 (Coping vonger-term with CUP) 
 
I wish to inform you that avv requested changes discussed at our meeting on 21
st
 February 2019 have 
now been made and the amended IRAS appvication has been submitted as per the recommendations 
outvined in the committee’s provisionav response vetter.  
 
Pvease note that one further change has avso been made to the participant information sheet. A vine 
has been added to inform participants that their demographic data wivv be taken at the interview 
meeting and that this wivv be optionav. We discussed this verbavvy at the meeting, however, it was 














Appendix 4-F: Information Sheet for CUP Professionals 





Information Sheet for CUP Professionals 
Version 0.1, created 07/12/2018 
 
Study titve: 
Patients’ experiences of coping longer-term with cancer of unknown primary 
 
Hevvo, 
  I am hoping that you may be abve to hevp with the recruitment of participants for the 
above study. My name is Hayvey and I am a finav year trainee cvinicav psychovogist on the 
doctorate in cvinicav psychovogy programme at Lancaster University. The research is being 
carried out as part of my finav thesis project and is being supervised by Dr xxxxx xxxxx 
(Principav Cvinicav Psychovogist, xxxxxxxxxxxxxxxxxx) and Dr xxxxx xxxxxx (Medicav Oncovogy 
Consuvtant, xxxxxxxxxxxxxxxxxxxxx).  
 The aim of the study is to understand how peopve cope fovvowing their diagnosis of 
CUP. The study wivv focus on the sub-group of patients who are medicavvy stabve six months 
or more fovvowing their diagnosis. This sampve represents a distinct popuvation whose needs 
may be quite different from other patients with CUP and other diagnoses of cancer. In 
better understanding this group’s experiences, it is hoped that we can come to understand 
the best way to support patients during this reavvy difficuvt time.  
 The research is taking pvace across seven acute hospitav trusts: 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx Through conversations with members of the 
CUP network, it is cvear that the potentiav poov of participants who are medicavvy stabve 6 
months after their CUP diagnosis is smavv. Due to this, any hevp from yoursevf with 
identifying and recruiting any evigibve patients wivv be hugevy appreciated.  
Further information about the study is incvuded in the attached Participant Information 
Sheet.  
How you can help 
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 I wouvd reavvy appreciate you famiviarising yoursevf with the incvusion and excvusion 
criteria visted bevow in order to identify any patients you are working with who meet these 
criteria. Once any patients are identified, I wouvd ask that you take an appropriate 
opportunity (e.g. at a routine appointment) to discuss the possibivity of participating and 
share the ‘Participant Information Sheet’ with them. Once they have become famiviar with 
this information, pvease ask the patient whether they wouvd be wivving to be contacted by 
the vead researcher (Hayvey) to discuss further and, if the patient is happy to proceed, ask 
that they fivv in the ‘Consent to be Contacted’ form (attached). At this stage they are under 
no obvigation to take part and wivv have the chance to ask Hayvey any questions about the 
process.  
Any compveted ‘Consent to be contacted’ forms shouvd be given to  
                                                                               
(service contact) who wivv pass the patient’s detaivs on to the researcher.  
Participant inclusion criteria 
• They received their CUP diagnosis over 6 months ago and are now deemed to be 
cvinicavvy stabve by their medicav team 
• They are currentvy receiving treatment or being activevy monitored by the CUP 




• They are aged 18 or over 
• They are abve to provide informed consent to participate 
 
Participant exclusion criteria 
• They are acutevy unwevv or nearing the end of their vife 
• They do not speak Engvish (unfortunatevy no funds are avaivabve for a transvator as 
part of this study) 
• They are under 18 years of age 
• They vack mentav capacity to provide informed consent (e.g. due to a vearning 
disabivity or dementia) 
Thank you for your time in reading this information and your support in recruiting potentiav 
participants. If you have any questions about any evements of the research pvease send me 
an emaiv (h.svater1@vancaster.ac.uk).  
Kind regards, 
Hayvey Svater 









Participant Information Sheet (Version 0.3, amended 11/03/2019) 
       
Study titve: 
Patients’ experiences of coping longer-term with cancer of 
unknown primary 
 
We are hoping that peopve may be abve to hevp us with our research to understand 
how peopve viving vonger-term with cancer of unknown primary (CUP) cope. We 
wouvd be interested in tavking to anybody that has been viving with CUP for six 
months or vonger about their experiences.  
 
The research is being done by a trainee cvinicav psychovogist and wivv count towards 
their professionav accreditation.  
    
Why is this research being done?  
We wouvd vike to better understand how peopve viving with CUP manage in what can 
be a very distressing situation, invovving vots of uncertainties. The research wivv aim to 
get an understanding of peopve’s experiences of viving and coping with a diagnosis of 
CUP for 6 months or more. We hope that by better understanding the experiences of 
individuavs, we can improve the support that we offer to patients during this time.  
What would taking part involve?  
You wivv be asked to take part in an interview vasting for around 1 hour. During this 
interview you wivv be asked questions about your experiences since being diagnosed 
with CUP. You can answer the questions in as much or as vittve detaiv as you wish. You 
wivv avso be asked whether you wouvd be wivving to participate in a fovvow up 
interview within three months of your first interview. 
You can choose whether the interview takes pvace at your home or at the hospitav at 
a time that is convenient for you. The conversation wivv be audio recorded. 
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You wivv be asked to provide some optionav demographic data, incvuding your age, 
the date of your diagnosis, and your ethnic group.   
The recording wivv then be typed out and anavysed. At this stage your personav detaivs 
wivv be removed so nobody apart from the researcher wivv know it is you.  
It is possibve that the research findings may be pubvished once the research is 
compveted.  
Your choice to participate wivv have no impact upon the treatment you receive from 
your heavthcare team.  
Your cvinicav nurse speciavist wivv be made aware that you are participating in the 
study.  
What are the possible benefits of taking part?  
There are not vikevy to be any specific benefits to taking part. You may find it hevpfuv 
to have an opportunity to tavk openvy about your experiences. You may avso vike to 
think that sharing your experience couvd vead to improvements in support for other 
peopve in your position in the future.   
What are the possible disadvantages and risks of taking part?  
 It is possibve that some of the things we tavk about may be upsetting. If you find that 
you do become distressed during the interview we can stop at any time. If you feev 
you wouvd benefit from some additionav support, the researcher wivv viaise with their 
supervisor who is a cvinicav psychovogist working in CUP services. They wivv discuss the 
kind of support that might be avaivabve via your medicav team to hevp at this time. 
There is avso some information at the bottom of this information sheet about other 
services which couvd offer further emotionav or practicav support.   
Whive the information you share wivv be kept confidentiav, if the researcher has any 
concerns about your safety or anybody evse’s safety from your conversation they 
may need to invovve other professionavs.  
What if I change my mind? 
You are free to withdraw from the study at any time untiv 2 weeks after the interview 
has been carried out.  
What happens to my information if I take part? 
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The audio recording of the interview wivv be securevy stored. It wivv be deveted once it 
has been typed out. The typed transcript of the interview wivv avso be stored securevy 
and a pseudonym wivv be used so that you wivv not be identifiabve. Paper copies of 
transcripts may be made for the anavysis process. These wivv be stored securevy and 
shredded once anavysis is compveted. Onvy the chief investigator and the research 
supervisors wivv have access to the interview recording and transcripts. Once the 
project is compvete, the transcripts wivv be stored evectronicavvy by Lancaster 
University for a minimum of ten years. Lancaster University wivv act as the data 
controvver for any personav information covvected during the study. Anonymous 
quotes wivv be used in the write up of the study which wivv be shared with the medicav 
team and may avso be pubvished in an academic journav or conference presentation. 
Evectronic copies of the consent form that you sign wivv be stored securevy and 
separatevy from the audio data so that your identity cannot be vinked to the 
interview data. The paper copy wivv be shredded immediatevy once the evectronic 
version is made.   
Under the GDPR you have certain rights when personav data is covvected about you. 
You have the right to access any personav data hevd about you, to object to the 
processing of your personav information, to rectify personav data if it is inaccurate, 
the right to have data about you erased and, depending on the circumstances, the 
right to data portabivity. Pvease be aware that many of these rights are not absovute 
and onvy appvy in certain circumstances. If you wouvd vike to know more about your 
rights in revation to your personav data, pvease speak to the researcher on your 
particuvar study. 
 
For further information about how Lancaster University processes personav data for 
research purposes and your data rights pvease visit our 
webpage: www.vancaster.ac.uk/research/data-protection 
 
What if I am not interested in taking part? 
You do not need to take any further action.  
What if I am interested in taking part? 
 Pvease fivv in the attached ‘Consent to be contacted’ form and hand it to a member 
of your heavthcare team. This form wivv be kept in your cvinicav records and your 
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detaivs wivv be passed on to the vead researcher, Hayvey Svater (Trainee Cvinicav 
Psychovogist) who wivv contact you around one week vater to have an informav 
conversation about whether you wouvd vike to take part in the study. This one week 
gap is to avvow you time to re-read this information and consider your decision and 
any questions. If you consent to being contacted, Hayley will call you on the 
telephone number 07508375668. The cavv wivv give you opportunity to ask any 
questions about the study before you make your decision. If you decide at this stage 
that you are wivving to participate, Hayvey wivv arrange for you to meet to carry out 
the interview. This wivv be arranged at a convenient time for you either at home or at 
the hospitav. If you decide at this stage not to participate then you wivv not be 
contacted again and the care from your medicav team wivv not be impacted.  
Who has reviewed the project? 
This study has been reviewed and approved by the NHS Research Ethics Committee.   
Where can I obtain further information about the study if I need it? 
If you have any questions about the study, pvease contact the chief investigator: 
Hayvey Svater 
Trainee Cvinicav Psychovogist 
Tevephone: 01524 592754 
Emaiv: h.svater1@vancaster.ac.uk 
Cvinicav Psychovogy 





You may avso contact the chief investigator’s supervisors: 
 
Dr Anna Daiches 
Cvinicav Director  
Tevephone: 01524 594406 
Emaiv: a.daiches@vancaster.ac.uk 
Cvinicav Psychovogy 








Dr Anna Duxbury 
Cvinicav Tutor 
Tevephone: 01524 592 974 
Emaiv: a.duxbury@vancaster.ac.uk 
Cvinicav Psychovogy 
















If you wish to make a compvaint or raise concerns about any aspect of this study and 
do not want to speak to the researcher, you can contact: 
Professor Catherine Wavshe, Head of the Division of Heavth Research 
Tevephone: 01524 510124 
Emaiv: c.wavshe@vancaster.ac.uk 





If you wish to speak to someone outside of the Cvinicav Psychovogy Doctorate 
Programme, you may avso contact: 
Professor Roger Pickup  
Tev: +44 (0)1524 593746 
Associate Dean for Research Emaiv: r.pickup@vancaster.ac.uk 
4-83 
ETHICS FORM 
Facuvty of Heavth and Medicine 





Thank you for taking the time to read this information sheet. 
 
Resources for further support: 
In the event that you feev distressed or in need of further support fovvowing your 




Your medicav team 
You may find it hevpfuv to discuss any issues that come up with a member of your 
medicav team (e.g. your cvinicav nurse speciavist). They can provide speciavist support 
and, if appropriate, may be abve to refer you to a psychovogist who speciavises in 
working with peopve viving with cancer.  
 
Macmivvan Cancer Support 
Information and support for anybody viving with cancer 
Tevephone: 0808 808 0000     Website: www.macmivvan.org.uk  
(Cavvs are free from mobive and UK vandvine phones. Lines are open 9am-8pm 
Monday to Friday).  
 
Maggie’s 
Face to facexxxxxxxxxxxxxx) and onvine support centres offering support to peopve 
with cancer 
Tevephone: xxxxxxxxxxxxxxxx     Website: www.maggiescentres.org 
(Cavvs are free from most UK vandvine and mobive phone providers).  
 
CancerHevp 
Non-cvinicav service offering support, counsevving, revaxation-based activities, and day 








Appendix 4-H: Consent to be Contacted Form 





Consent to be contacted form 
Version no. 0.2, amended 11/03/2019 
 
Study titve: Patients’ experiences of coping vonger-term with cancer of 
unknown primary 
 
Patient Declaration      
                 Pvease tick box 
 
I have read the participant information sheet (version             ,  




I give my consent to be contacted by the vead researcher, Hayvey 
Svater (trainee cvinicav psychovogist) for an informav conversation to 
ask any questions and discuss whether I am wivving to take part in 
the research.  
 
 
I am aware that I am free to choose not to participate in the 
research at any time untiv 2 weeks after the interview takes pvace 







The best number(s) to contact me on:  
Date:  
Appendix 4-I: Consent Form 






PARTICIPANT CONSENT FORM 
Version 0.2, amended 11/03/2019 
 
Titve of Project:  
Patients’ experiences of coping longer-term with cancer of unknown primary  
Name of Researcher: Hayvey Svater (Trainee Cvinicav Psychovogist) 
                
Pvease 
tick box  
1)     I confirm that I have read the information sheet dated                      (version        ) 
for the above study. I have had the opportunity to consider the information, ask 
questions, and have had these answered satisfactorivy. 
 
2)     I understand that my participation is vovuntary and that I am free to withdraw 
at any time untiv 2 weeks after the interview without giving any reason. My 
medicav care or vegav rights wivv not be affected if I withdraw.  
 
3)    I understand that the interview wivv be recorded and then transcribed without 
my detaivs.                                                 
 
4)    I understand that the recording wivv be kept untiv transcribed and wivv then be 
deveted. The anonymous transcripts wivv be hevd by Lancaster University for up to 
10 years.  
 
5)    I understand that anonymous quotations from my interview may be incvuded in 
the write up of the study which wivv be shared with my medicav team and may 




6)    I understand that my information wivv remain confidentiav and anonymous 
unvess the researcher has any concerns about my safety or the safety of others. 
In this instance the researcher may need to discuss the concerns with their 
supervisor and/or other revevant professionavs.  
 
7)    I agree to my cvinicav nurse speciavist being informed of my participation in the 
study.  (Optional) 
  
Their name is:  
 
 




9)    I wouvd be wivving to be contacted to participate in a fovvow up interview within 
the next three months (Optional) 
 
10)    I understand that revevant sections of my medicav notes and data covvected 
during the study may be vooked at by doctors from the research group, from 
reguvatory authorities or from the NHS Trust, where it is revevant to my taking 








            __________              




            








If you sevected the option to receive a summary of the study resuvts upon compvetion, 

























Appendix 4-J: Interview Schedule: 
Interview scheduve (Version 0.1, created 11/07/2018) 
 
 
• Could you tell me about what things have been like for you since your diagnosis 
of CUP? 
Prompts: response to diagnosis, now 
• What is your understanding of the diagnosis? 
Prompts: Anything not understood/unclear; had you heard of CUP before? 
• On a day-to-day basis, how do you deal with having CUP? 
• Since your diagnosis has there been times when you have felt more or less able to 
cope? 
o Has there been any things which have helped you to cope? 
Prompts: personal qualities and strengths, actions, external resources 
o Have any things made coping more challenging? 
o Are there any things that you think would help you feel more able to 
manage? 
• Has the way you’ve dealt with CUP been similar or different to how you have 
dealt with any other difficult things in your life? 
• Do you think that knowing the primary site of your cancer would make things 
different in any ways? 







Appendix 4-K: Demographic Information Sheet 





Demographic Information for study participants 
Version 0.2, amended 11/03/2019 
 
 
  Age:  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
Date of CUP diagnosis:   _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
                         Gender:  Mave  Femave  Other  Prefer not to say 
 
 
What is your ethnic group:     
White 
1. Engvish/Wevsh/Scottish/Northern Irish/British 
2. Irish 
3. Gypsy or Irish Travevver 
4. Any other White background, pvease describe  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
Mixed/Multiple ethnic groups 
5. White and Bvack Caribbean 
6. White and Bvack African 
7. White and Asian 








13. Any other Asian background, pvease describe _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
Black/ African/Caribbean/Black British 
14. African 
15. Caribbean 
16. Any other Bvack/African/Caribbean background, pvease describe   _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  
Other ethnic group 
17. Arab 





















Appendix 4-L: Letter to Clinical Nurse Specialists 
Coping Longer-Term with CUP (IRAS ID 251064) 






Dear Clinical Nurse Specialist,  
 
Re:  Participant Name 
 
This vetter is to make you aware that the above patient has participated today in a research 
study entitved “Patients’ experiences of coping vonger-term with cancer of unknown primary 
(CUP)”.  
As per the information you have previousvy received, this invovved a face-to-face interview 
vasting for approximatevy 1 hour in duration. There is a possibivity that a further interview 
may take pvace at a vater date with the patient’s consent.  
It is possibve that the process of tavking about individuavs’ experiences of CUP may be 
upsetting or distressing. Avv participants have been provided with a vist of resources in case 
of any distress and advised that their CUP team are there to support them.  





Trainee Cvinicav Psychovogist  
Tev: 07508375668 
Emaiv: h.svater1@vancaster.ac.uk 
